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PArt i
GEnErAL intrODuCtiOn

 CHAPtEr 1
GEnErAL intrODuCtiOn

General introduction 11
COntExt
Palliative care was defined by the World Health Organisation (WHO) in 20021 and 
by the European Association for Palliative Care (EAPC) in 19982. Although those 
definitions mainly overlap, some differences can be addressed. For one thing, 
the WHO definition includes patients at an earlier stage in their illness trajectory. 
Second, the EAPC definition adds two important implications: palliative care has 
an explicit interdisciplinary approach and it is provided wherever the patient is 
cared for, either at home or in the hospital. It should be noted, however, that 
other terms are also used in literature to define the care for patients at the end 
of life, such as hospice care, terminal care, end-of-life care and supportive care. 
Definition of palliative care proposed by the WHO (2002)
Palliative care is an approach that improves the quality of life of 
patients and their families facing the problems associated with life-
threatening illness, through the prevention and relief of suffering by 
means of early identification and impeccable assessment and treat-
ment of pain and other problems, physical, psychosocial and spiritual.
Definition of palliative care proposed by the EAPC (1998)
Palliative care is the active, total care of the patient whose disease is 
not responsive to curative treatment. Control of pain, of other symp-
toms, and of social, psychological and spiritual problems is para-
mount. Palliative care is interdisciplinary in its approach and encom-
passes the patient, the family and the community in its scope. In a 
sense, palliative care is to offer the most basic concept of care – that 
of providing for the needs of the patient wherever he or she is cared 
for, either at home or in the hospital. Palliative care affirms life and 
regards dying as a normal process; it neither hastens nor postpones 
death. It sets out to preserve the best possible quality of life until 
death.
In 2013 approximately 141,000 persons died in the Netherlands, at a mean 
age of 75 years for males and 80 years for females. Almost one third of them 
died from the consequences of cancer, mainly cancer of the digestive organs or 
the respiratory organs3. Moreover, advanced cancer is the main diagnosis for 
the majority of patients in a hospice4. However, of all palliative patients, only a 
relatively small number, estimated on less than 25%5, is admitted to a hospice, 
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and reasons for admission include the complexity of their problems, lack of family 
caregivers or giving family caregivers some respite, or the patient’s preference.
AssEssMEnt Of PAin
Pain is highly prevalent in palliative patients; 45 to 70% of patients with incurable 
cancer, either admitted to a hospice or staying elsewhere, suffer from moderate 
to severe pain6-9. The prevalence of pain even increases as death approaches10. 
To control pain, 45 to 59% of patients need the highest-step drugs of the WHO 
pain ladder, i.e. opioids7, 9, 11. However, even when opioids are administered, pain 
is still prevalent or not relieved adequately in 43 to 50% of patients9, 11. These 
three aspects of pain in end-of-life patients - high prevalence, frequent use of 
opioids and a considerable portion of patients with unrelieved pain - indicate the 
need for accurate pain assessment to recognize pain and to guide pain treatment 
as death comes near.
Self-report of pain is typically considered the ‘gold standard’ for assessment12. 
However, terminally ill patients may not be able to self-report pain or to express 
it in another way due to their advanced illness state or cognitive failure, which 
is often seen prior to death13-15. It would seem obvious that assessment with 
observational scales is needed for non-communicative end-of-life patients. The 
EAPC reported about pain assessment in palliative care in 2002 and stated that, 
at that time, no valid assessment of pain in cognitively impaired was applicable16. 
Even today the number of validated observational scales for pain to use in 
palliative care facilities is still very limited17. To our knowledge, only one pain 
assessment tool for palliative patients whom are unable to self-report pain has 
been developed and tested: the Multidimensional Objective Pain Assessment Tool 
(MOPAT)17. It showed good internal consistency and sensitivity to change after a 
pain-reducing intervention, but has a major disadvantage in that blood pressure 
and heart rate measurements are included, which seem not sensitive for pain 
alone18-21. Further, these measurements are often stopped at the end of life, as 
recommended in the Liverpool Care Pathway for the dying patients22. 
Over the years our research group has developed and validated pain observa-
tions scales for  three different patient groups who are unable to express their 
pain; very young children (the COMFORT-behavior scale)23-25, patients with intel-
lectual disabilities (Child Behavior Checklist)26 and non-communicative elderly 
(Rotterdam Elderly Pain Observation Scale; REPOS)27. The REPOS was developed 
and validated in a nursing home27.
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PALLiAtivE sEDAtiOn
The national guideline developed by the Royal Dutch Medical Association (KNMG, 
2009) defines palliative sedation as follows: ‘the deliberate lowering of a patient’s 
level of consciousness in the last stages of life’28. It may be administered in two 
distinct ways: either continuous sedation until the moment of death or inter-
mittent, which is temporary sedation. Continuous sedation is administered to 
patients who are expected to die within 1 to 2 weeks and who suffer unbearably 
from one or more intractable or refractory symptoms. A symptom is considered 
refractory if the conventional treatment is ineffective or if unacceptable side ef-
fects are present while symptoms remain uncontrolled.
The prevalence of palliative sedation until death varies widely in literature; 
the highest prevalences mentioned are 64% and 69% of patients29, 30. In the 
Netherlands, the prevalence ranges from 8.2% of all deaths in 200531 to 43% of 
patients in a specialized palliative care unit in a cancer hospital over the period 
2001 to 200532. The three most common refractory symptoms that determined 
the indication to start palliative sedation are delirium, dyspnoea and pain32, 33. 
Midazolam is the most often administered drug to achieve palliative sedation, 
both national and international32, 33.
The Dutch national guideline proposes that palliative sedation should be ap-
plied proportionately; to the extent that it alleviates the patient’s suffering28. 
So, it is the degree of symptom control rather than the depth of sedation that 
determines the adequacy of palliative sedation. According to this description, the 
effect of palliative sedation should be assessed by symptom control. However, in 
literature there is no consensus on how the effect of palliative sedation should 
be assessed; either by symptom control or by sedation depth or maybe both 
simultaneously34, 35. In addition, there is no validated observational assessment 
scale or device available for this purpose in sedated end-of-life patients. 
Sedation can be guided by either an observational scale or a device that 
measures a form of brain activity. The bispectral index (BIS) monitor, an elec-
trophysiological device derived from non-invasive EEG monitoring, is being used 
in clinical practice in anaesthesia and on intensive care units36-38. The use of BIS 
monitoring in palliative care has been reported in only two studies; one case 
study and one pilot study with 12 patients39, 40. These studies concluded that BIS 
monitoring is acceptable for patients, family and care-givers, but validation of 
BIS monitoring in palliative care was beyond the scope of these studies.
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PHArMACOLOGy
Two main areas of pharmacology are pharmacokinetics and pharmacodynamics. 
Pharmacokinetics (PK) describes how the body handles the drug through the 
mechanisms of absorption, distribution, metabolism and elimination and deter-
mines the time course of drug action. Pharmacodynamics (PD) is described in 
terms of how the drug affects the body and determines the pharmacological 
responses, including both desired and adverse effects41, 42. Only few pharmaco-
logical PK/PD studies concerned palliative care43-45. The topic reported mostly on 
within the context of pharmacology in palliative care is drug interactions44, 46-49. 
Moreover, these papers are mainly theoretically based and the actual description 
of the palliative clinical practice is lacking.
Pharmacokinetic properties of drugs may be affected by factors such as the 
route of administration, drug dose and frequency of dosing. The actual prescrip-
tion of drugs in palliative care is described in a few studies performed in palliative 
care units50-52 and outpatient palliative facilities53-56. However, these studies do not 
describe the most prescribed drugs with their doses and route of administration. 
In addition, the pharmacokinetics of drugs may be affected by factors such as 
body composition (cachexia or obesity), liver and kidney function. These factors 
are likely to change if death approaches, since then a gradual decline in physical 
health and functional status is seen57, 58. This decline includes, among other clini-
cal manifestations, dehydration, weight loss and cachexia, liver impairment and 
kidney failure59-61. The clinical signs of the decline towards death may be reflected 
in laboratory results and this might have consequences for the pharmacokinetics 
and consequently for the effect of drugs in the end-of-life patient.
rEsEArCH sEttinG
The work presented in this thesis was performed in Regional Palliative Care Cen-
tre, Laurens Cadenza, in Rotterdam, the Netherlands. This is the largest ‘hospice’ 
in the Netherlands, with 20 beds for end-of-life care and symptom management. 
Annually 200 to 250 patients are admitted, of whom most suffer from advanced 
cancer. A multidisciplinary team of health care professionals, including specialised 
nurses and elderly care physicians specialised in palliative care, is available 24 
hours per day. Also, many volunteers perform supporting tasks.
General introduction 15
rEsEArCH quEstiOns Of tHis tHEsis
The following research questions were addressed:
1. Is the Rotterdam Elderly Pain Observation Scale (REPOS) a reliable and valid 
tool for pain assessment in non-communicative or unresponsive end-of-life 
patients?
2. Is Bispectral Index (BIS) monitoring a feasible and valid tool for assessing the 
depth of sedation in terminally ill patients?
3. What drugs are administered, and at what dose and route of administration, 
from admission to day of death in patients admitted to a palliative care centre?
4. Are laboratory parameters of patients at the end of life disturbed such that it 
may have consequences for the pharmacokinetics of drugs often used in those 
patients?
5. What are the pharmacokinetics of morphine and its two major metabolites 
in terminally ill patients and what are the clinically relevant parameters for 
individualized dosing based on a population PK model approach?
OutLinE Of tHis tHEsis
Chapter 2 concerns a validation study of the REPOS for pain assessment in non-
communicative or unresponsive end-of-life patients. 
Chapter 3 determines the feasibility and validity of BIS monitoring to assess the 
depth of sedation in terminally ill patients in a hospice setting.
Chapter 4 describes doses and routes of administration of the most frequently 
used drugs at admission and at day of death in patients admitted to a palliative 
care centre.
Chapter 5 evaluates laboratory parameters of hospice patients in the week be-
fore death and discusses the changes in laboratory results, and their potential 
relevance for the pharmacokinetics of drugs. 
Chapter 6 describes a population pharmacokinetic analysis of morphine and its 
two major metabolites (morphine-3-glucuronide and morphine-6-glucuoride) in 
terminally ill patients and presents clinically relevant parameters for individual-
ized dosing.
Chapter 7 provides a general discussion of the results of the studies presented in 
this thesis as well as directives for future research.
Chapter 8 summarizes the results of the studies described in this thesis, both in 
English and in Dutch.
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AbstrACt 
background: In palliative care, administration of opioids is often indispensable 
for pain treatment. Pain assessment may help recognize pain and guide treat-
ment in non-communicative palliative patients. In the Netherlands the Rotterdam 
Elderly Pain Observation Scale (REPOS) is recommended to this aim, but not 
yet validated. Therefore the objective of this study was to validate the REPOS in 
non-communicative or unconscious end-of-life patients.
Methods: In this observational study, the primary researcher applied the REPOS, 
both the researcher and a nurse applied the Numeric Rating Scale (NRS). If 
possible, the patient in question applied the NRS as well. The NRS scores were 
compared with the REPOS scores to determine concurrent validity. REPOS scores 
obtained before and after a pain-reducing intervention were analysed to establish 
the scale’s sensitivity to change.
results: A total of 183 REPOS observations in 100 patients were analysed. 
Almost 90% of patients had an advanced malignancy; observations were done a 
median of 3 days (IQR 1 to 13) before death. Internal consistency of the REPOS 
was 0.73. The Pearson product moment correlation coefficient ranged from 0.64 
to 0.73 between REPOS and NRS scores. REPOS scores declined with median 2 
points (IQR 1 to 4) after a pain-reducing intervention (p<0.001). Optimal sensi-
tivity (0.81) and specificity (0.62) were found at cut-off score 3. 
Conclusions: This study demonstrates that the REPOS is reliable and valid for 
pain assessment in non-communicative end-of-life patients. This scale may be of 
additional value to relieve suffering, including pain, in palliative care.
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bACkGrOunD
Several studies reported that 45% to 70% of patients with incurable cancer, 
either admitted to a hospice or staying elsewhere, suffer moderate to severe 
pain1-3. Forty-five per cent of them need the highest-step drugs of the WHOs pain 
ladder, i.e. opioids, to relieve their pain2, 4. The high prevalence of pain and the 
frequent use of opioids make clear that accurate pain assessment in palliative 
care is needed to recognize pain and to guide pain treatment.
Patients’ self-report of pain is considered the ‘gold standard’ for pain as-
sessment5. However, in the terminal phase of life, patients may not be able to 
self-report pain. To illustrate this, 68% to 83% of patients had cognitive failure 
prior to death6, 7 and 90% to 98% of patients were drowsy or unresponsive in 
those last days8-10. Proxy pain assessment by a nurse was needed, therefore, 
in 90% of patients in a palliative care unit at the day of death9. Assessment of 
suffering, including pain, is challenging anyway in the terminal phase, especially 
when sedation is needed11. 
Proxy assessment often results in underestimation of the patient’s pain and 
subsequent risk of under treatment12, 13. Application of a validated observation 
scale could be more effective in non-communicative patients as the observer is 
required to pay attention to well-defined behaviour that could indicate pain.
We, therefore, previously developed the Rotterdam Elderly Pain Observation 
Scale (REPOS), published in 200814. In Dutch national palliative guidelines it is 
recommended for specific non-communicative patient groups15, such as persons 
with dementia and intellectual disability. It proved a valid tool to measure pain 
in the nursing home population, including those who could not communicate14.
The Multidimensional Objective Pain Assessment Tool (MOPAT) published in 
2011 was developed for hospice patients who are unable to self-report pain. It 
was tested in a small sample of 28 alert patients and 30 non-communicative 
patients and showed good internal consistency and sensitivity to change after a 
pain-reducing intervention16. A disadvantage of the MOPAT, however, is that blood 
pressure and heart rate measurements are needed, and these measurements are 
often stopped at the end of life, as recommended in the Liverpool Care Pathway 
for the dying patients17. Also these measurements are not valid to assess chronic 
pain conditions.
In the Netherlands, the REPOS is increasingly adopted in nursing homes and 
institutions for intellectually disabled or non-communicative patients 18. Hospice 
patients may have other characteristics, however. They often suffer from ad-
vanced cancer and are mostly bedridden. Self-report is not possible due to their 
illness state (comatose, delirium or adverse effects of medication), in contrast to 
28 CHAPTER 2
nursing home patients who more often have dementia. In addition, end-of-life 
patients are in another emotional state and may be extremely anxious, facing 
death. All these aspects may influence experiences or expressions of pain19.
MEtHODs
Aim
The aim of this study was to establish whether the REPOS is a reliable and valid 
tool for pain assessment in non-communicative or unresponsive end-of-life pa-
tients.
Design, participants and setting
This observational study was performed in Laurens Cadenza in Rotterdam, the 
Netherlands. This is the largest palliative care centre in the Netherlands, with 
20 beds for end-of-life care and symptom management; 200 to 250 patients are 
admitted annually. A multidisciplinary team of health care professionals, includ-
ing specialised nurses and elderly care physicians specialised in palliative care, 
is available 24 hours per day. In addition, many volunteers perform supporting 
tasks. 
This study was approved by the Medical Ethics Review Board of the Erasmus 
University Medical Center and the institution’s local board of directors, and was 
performed in accordance with the principles of the Declaration of Helsinki and 
its later amendments. Pain assessment is standard care, and therefore informed 
consent was not required.
Assessment tools
The Rotterdam Elderly Pain Observations Scale (REPOS) consists of 10 behav-
ioural items (see Supplement), which the observer scores as present or absent, 
after having observed the patient for two minutes14. To optimize inter-observer 
reliability, a definition chart and an intervention decision tree are provided as 
well. To ascertain sufficient interrater reliability of a REPOS observation, nurses 
receive training including at least 10 bedside paired observations with an experi-
enced REPOS observer20, 21. A previous validation study in nursing home residents 
revealed a significant difference between painful and rest situations and a large 
correlation with the PAINAD (r= .75) indicating good construct validity. For 
nursing home residents both the sensitivity (.85) and the specificity (.83) were 
optimal at a cut-off score of 314. However, as behaviour might be the result of 
other emotions than pain, the observer in addition estimates the pain intensity on 
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a Numeric Rating Scale (NRS) from 0 (no pain) to 10 (worst possible pain). Thus, 
assigning an ‘NRS-observer’ score is a standard part of the REPOS observation 
and assigning a NRS-observer is part of the training18. A REPOS score of 3 or 
higher and a NRS-observer score of 4 or higher suggests moderate to severe pain 
and requires an intervention14, 22. The NRS is considered a valid tool to assess 
cancer pain intensity23, 24.
Procedure
Data were collected during three phases. First, from March to October 2010, the 
first researcher (A.M.) trained nurses in Laurens Cadenza to assess pain with 
the REPOS, since at that time symptom measurement was not standard of care. 
To ascertain sufficient interrater reliability, the primary researcher performed 
at least 10 bedside observations simultaneously with an experienced REPOS 
observer. Sufficient interrater reliability is defined as Cohen’s kappa>0.65. As Co-
hen’s kappa for the primary researcher was established as 0.76, she could serve 
as a REPOS observer in this study. November-December 2010, NRS and REPOS 
assessments were implemented in daily practice for all non-communicative or 
unresponsive patients. 
During the second phase, from January 2011 to May 2012, the first researcher 
or a trained nurse assigned a REPOS score and an NRS-observer score in daily 
practice as standard of care.
In the third phase, from February to June 2013, the second researcher (A.B.) 
was called in when a patient received a pain-reducing intervention and assigned 
a REPOS score just before and at least one hour after this intervention. These 
pre- and post-intervention data were used for the sensitivity-to-change analysis.
To determine internal consistency, concurrent validity and the optimal cut-
off score, only REPOS observations made by the experienced REPOS observer 
(first researcher) in phase one are selected; REPOS observations by the first 
researcher or trained ward nurses in phase two; and observations by the second 
researcher in phase three. For the sensitivity-to-change analysis only the pre- 
and post-intervention data form phase three were used.
The caregiving nurse assigned a NRS score (NRS-proxy) in non-communi-
cative or unresponsive patients, and communicative patients rated their pain 
themselves (NRS-patient).
Other variables
Demographic characteristics (age, gender, diagnoses, and duration of admission) 
were extracted from the electronic medical records; the primary diagnoses and 
the number of comorbidities were evaluated. The primary diagnoses refer to the 
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WHO’s International Classification of Diseases (ICD-10 classification) coding for 
the patient’s terminal illness.
Analgesics prescribed at the time observation were recorded and classified 
according to the WHO three-step pain ladder as non-opioids, NSAIDs and opi-
oids25, 26. The highest WHO step prescribed for a patient over all the observations 
is given in the patient characteristics.
Data analysis
Only the end-of-life assessments were included for analysis; data from patients 
who had been discharged and data obtained earlier than three months before 
death were excluded. 
Data are presented as mean (standard deviation; SD) in case of normally 
distributed variables and as median (interquartile range = IQR or minimum-
maximum range = range) in case of non-normally distributed variables. 
To determine interrater reliability, for the first and second researcher and for 
all trained nurses who assigned REPOS scores, Cohen’s kappa was applied and 
defined as good if > 0.6527.
Cronbach’s alpha coefficient served to examine the internal consistency of 
the REPOS items. Pearson product moment correlation coefficient was applied 
to determine concurrent validity of the REPOS with the NRS scores. This validity 
coefficient should exceed 0.3028. The Wilcoxon signed rank test served to esti-
mate sensitivity to change after a pain intervention. The optimal cut-off value for 
REPOS score was determined as the best combination of sensitivity and specific-
ity comparing the REPOS total scores with NRS proxy as reference.
Data analyses were performed using IBM SPSS Statistics 20. A p-value of < 
0.05 (two-sided) was deemed statistically significant.
rEsuLts
Patient characteristics
Over the three study phases, REPOS scores were assigned to 103 patients. Data 
from three patients were not considered end-of-life assessments; only data of the 
remaining 100 patients were included in the analysis. For those included patients, 
the first (or only) observation was done a median of 3 days (IQR 1 to 13) before 
death. The median age was 77 years (IQR 67 to 85), 65% were female, and the 
median duration of admission was 28 days (IQR 9 to 51). Advanced malignancy, 
mainly of digestive and respiratory organs, was the main reason for admission 
(89% of patients). Most patients (73%) were receiving the highest WHO-step: 
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opioids around the clock. Opioids were prescribed on an as needed basis in 6% 
of patients (rescue medication when breakthrough pain was present) and 11% 
received no analgesics. Patient characteristics are shown in Table 1.
rEPOs scores and nrs scores
All trained nurses achieved good interrater reliability with the researcher after 6 
to 10 paired observations (Cohen’s kappa values ranged from 0.70 to 0.78). A 
total of 183 REPOS observations in the 100 included patients were done.
Table 1. Patient characteristics
Characteristics N=100
Gender in %
Male / female 35 / 65 
Age in years; Median (IQR) 77 (67 to 85)
Duration of admission in days; Median (IQR) 28 (9 to 51)
Assessment days before death; Median (IQR) 3 (1 to 13)
Primary diagnosis in N (%)
Neoplasms 89 
Digestive organs 26 (29) 
Respiratory and intra-thoracic organs 17 (19) 
Female genital organs 9 (10) 
Breast 7 (8) 
Eye, brain and other parts of central nervous system 7 (8) 
Lymphoid, hematopoietic and related tissue  7 (8)
Ill –defined, secondary and unspecified sites 7 (8)
Other  9 (10)
Disease of nervous system 4 (acquired brain injury; Parkinson’s 
disease; systemic atrophy)
Infectious and parasitic disease 3 (pneumonia and frailty)
Other 4 (CVA; lung disease, kidney failure, 
invalidity)
Analgesics in %
Opioids around the clock 73 
None 11 
Non-opioids around the clock 8 
Opioids as needed 6 
Non-opioids as need 1 
NSAID around the clock 1 
IQR, interquartile range
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In 46% of patients, two or more pain observations were done. 34% of obser-
vations were made in the situation of washing and dressing in, 30% in posture 
change, 21% in rest, 9% during a transfer, and in 6% in other situations. 
The median REPOS score was 2 (IQR 1 to 5); the median NRS scores (NRS-
observer, NRS-proxy and NRS-patient) ranged from 2 to 6. REPOS scores indica-
tive of pain (3 to 10) were assigned in 55% (101/183) of observations. Pain was 
rated moderate to severe (NRS 4 to 10) in 30% to 67% of NRS scores (Table 2). 
All 10 REPOS items were scored more frequently when NRS was 4 to 10, when 
comparing them to no pain and mild pain cases. The items tense face, raising 
upper lip and closing eyes scored most frequently in the presence of moderate to 
severe pain, while the items fearful look and panicky were scored least (Figure 1).
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Figure 1. Percentage of scored REPOS items for no-mild pain and for moderate-to-
severe pain
Table 2. Pain assessments results
Median score (IQR)
Moderate to severe pain (NRS 4 to 10)
Number of observations (%)
REPOS score (N=183) 3 (1 to 5) 101 (55)
NRS-observer (N=182) 2 (0 to 4) 54 (30)
NRS-proxy (N=107) 3 (1 to 6) 47 (44)
NRS-patient (N=24) 6 (2 to 7) 16 (67)
REPOS, Rotterdam Elderly Pain Observation Scale; NRS, Numeric Rating Scale; IQR, interquartile 
range
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internal consistency
The Cronbach’s alpha coefficient for internal consistency of the REPOS was 0.73. 
The item-total correlations ranged from 0.18 to 0.69, and were below 0.30 for 4 
items (panicky, fearful look, moaning and moving body parts).
Concurrent validity
The REPOS score was correlated to the NRS-observer, NRS-proxy and NRS-patient 
separately. The Pearson product moment correlation coefficient ranged from 0.64 
(95% CI 0.51 to 0.74) to 0.80 (95% CI 0.72 to 0.86) (Table 3).
Deleting the 4 items with low correlations for internal consistency had hardly 
any effect on the Pearson coefficients, which then ranged from 0.62 (95% CI 0.49 
to 0.73) to 0.80 (95% CI 0.72 to 0.86).
sensitivity to change
Twenty-three pairs of before-and-after scores were included for the sensitivity-
to-change analysis. Twenty-one concerned a pharmacological pain-reducing 
intervention; in 17 cases (81%) administration of an opioid. The other 2 pairs 
concerned non-pharmacological interventions, namely taking a rest when moving 
is painful and changing posture to relieve pressure sores
The median REPOS score declined significantly from 4 (IQR 3 to 6) to 1 (IQR 
1 to 3) with a median reduction of 2 points (IQR 1 to 4) after a pain-reducing 
Table 3. Correlation between REPOS score and the various NRS scores 
rEPOs score NRS-observer nrs-proxy nrs-patient
rEPOs 
score
Number of 
observations
R
95% CI
183
-
-
182
0.73
0.65 to 0.79
107
0.64
0.51 to 0.74
24
0.66
0.35 to 0.84
nrs-
observer
Number of 
observations
R
95% CI
182
-
-
107
0.80
0.72 to 0.86
24
0.77
0.53 to 0.90
nrs-
proxy
Number of 
observations
R
95% CI
107
-
-
24
0.72
0.45 to 0.87
nrs-
patient
Number of 
observations
R
95% CI
24
-
-
REPOS, Rotterdam Elderly Pain Observation Scale; NRS, Numeric Rating Scale; R, Pearson correla-
tion; CI, Confidence Interval
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intervention, both pharmacological and non-pharmacological. This change was 
statistically signifi cant (p<0.001). The percentage of REPOS scores indicating no 
pain (score 0 to 2) increased from 9% (2/23) to 70% (16/23).
Cut-off score
In 107 observations, both a REPOS score and a NRS-proxy score were available. 
At the cut-off REPOS score of 3, sensitivity was 0.81 and specifi city was 0.62. The 
ROC curve, with an AUC of 0.80 (95% CI 0.71 to 0.88), is displayed in Figure 2. 
1 - Specificity
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Figure 2. ROC curve of the optimal sensitivity and specifi city for the REPOS score
The full line represents sensitivity and specifi city of de REPOS score. The dotted line represents the 
line for which sensitivity and specifi city are equal. A horizontal and a vertical grey line are added to 
show the optimal cut-off value of the REPOS score
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The positive predictive value was 0.62 and the negative predictive value was 
0.80. 
In 21% (23/107) of observations the REPOS score was indicative for pain 
(score 3-10) whereas the NRS-proxy score was below 4; suggesting false-positive 
outcomes of the REPOS. In contrast, in 8% (9/107) of observations the REPOS 
score did not indicate pain (score 0-2) whereas the NRS-proxy score did (score 
4-10), suggesting false-negative outcomes.
DisCussiOn 
The fi ndings from this study show that the REPOS is a reliable and valid tool to 
assess pain in non-communicative end-of-life patients. In addition, good sensitiv-
ity to change was demonstrated. 
A variety of observational pain scales have been developed for other set-
tings where non-communicative patients are treated, including intensive care 
units29 and nursing homes30. Only one, the MOPAT16, has been validated for non-
communicative end-of-life patients, albeit preliminary and without establishing a 
cut-off score. The MOPAT was published (2011) after start of our study (2010). 
We therefore could not use it, although it would have been interesting to compare 
the two scales. One disadvantage of the MOPAT, however, is that changes in 
heart rate and blood pressure are included. We question the usefulness of these 
items, as a person’s physiology may change at the end of life, regardless of the 
presence of pain. Also, these measurements are often stopped at the end of life, 
as recommended in the Liverpool Care Pathway for the dying patients17. In addi-
tion, the behavioural items are scored on a 4-points scale (none, mild, moderate 
or severe), which might be subject to individual interpretation. In contrast, the 
well-defi ned items of the REPOS are scored for presence or absence. This may 
result in a more objective assessment.
The overall internal consistency of the REPOS in the present study was ad-
equate as judged from the Cronbach’s alpha coeffi cient of 0.7331. Although the 
item-total correlations of 4 items (panicky, fearful look, moaning and moving 
body parts) were below 0.30, we chose to retain those items. These low values 
could be related to the less frequent occurrence of those behaviours. For example, 
the ability to fully react with all body parts is often diminished in the end-of-life 
stage. In terms of concurrent validation, a 6-items REPOS from which those 4 
items were removed did not perform better than the original 10-items REPOS. 
A major reason for retaining these items is that the scale would be applicable in 
other settings with non-communicative patients as well.
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With respect to concurrent validity, a high correlation (0.73) was found – not 
surprisingly – between REPOS and NRS scores assigned by the same person. 
The correlation between REPOS and the gold standard (NRS-patient) was only 
moderate31, as is seen in other pain scale studies too32, 33. This moderate correla-
tion is perhaps explained by patient characteristics. Patients who are unable to 
report pain with the NRS seem to be more nonverbally responsive32, 34. For these 
patients a behavioural score would be a better reflection of their pain than a 
proxy NRS only.
It is not unlikely that the REPOS score and the NRS-proxy score differ to 
some extent. A high REPOS score combined with a lower NRS-proxy score, or a 
so-called false positive score, is typically seen in patients who show ‘emotional’ 
behaviour not related to pain, but based on anger, fear or agitation35, 36. The op-
posite, a false-negative score, may occur when the attending nurse has observed 
behaviour not included in the REPOS score, such as muscle tension. Alternatively, 
the nurse’s NRS score reflects knowledge of relevant characteristics, such as 
history or medication use, illness and other patient specific characteristics12, 13, 37.
This study showed that the cutoff score of 3 or higher is applicable for non-
communicative end of life patients. Application of a ‘one-fits-all’ cutoff score is 
debated, however38, 39. A reason suggested by Chan et al is that different underly-
ing conditions cause different types of damage to the brain, and consequently 
different responsiveness to pain39. Based on these arguments one could plead for 
an individualized cutoff score, which has been recommended for other vulnerable 
patients groups, i.e. young children40. However, this approach asks more from 
the caregivers: a dynamic approach with evaluation and adjustment at regular 
times and when indicated. As daily pain assessment itself was shown to be prob-
lematic41, one can wonder if an individualized approach is feasible in a daily care 
situation42, 43. 
A strength of the present study is that most observations were done within the 
last two weeks of life and therefore including even those patients near the time of 
death. In the previous validation study of the REPOS14, only a small proportion of 
the population was at the end of life. In addition, communicative patients rated 
their pain themselves, which enabled comparison between the REPOS and the 
gold standard of self-report. Also, the sample size in the present study was 100 
patients, which far exceeds the minimal number of 50 patients44, 45. 
Some limitations of this study have to be addressed, however. First, this is a 
single-centre study and therefore extrapolating the findings to other settings, like 
palliative home care or community based palliative care, should be done care-
fully. Nevertheless, it seems unlikely that pain behaviour would be different in a 
different palliative environment. Second, the sensitivity-to-change analysis con-
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cerned only a relatively small sample. However, this limitation is encountered in 
many other psychometric studies, seeing that researchers often are not available 
when patients receive additional analgesia and also because nurses may tend to 
forego reassessment after a pain-reducing intervention46. The comparable MOPAT 
study16 overall also included fewer patients than planned, also in part for logisti-
cal reasons. The fact that the observer knew whether the patient received pain 
medication or not, could be considered a weakness of the sensitivity-to-change 
analysis. In the ideal situation, observers blinded for this condition apply the 
REPOS when watching video recordings made before and after an intervention. 
However, it was felt undesirable to ask relatives’ approval for video recordings of 
their loved ones in the dying phase for research purposes. Still, knowing that the 
REPOS is sensitive enough to measure small changes after an intervention means 
that it is suitable for pharmacodynamic studies, which are urgently needed in this 
palliative patient group11. Lastly, in the present study the REPOS was compared 
with NRS scores, however a comparison with another behaviour pain scale would 
have strengthened the reliability and validity testing47. At the time this study with 
the REPOS score was started (2010), the MOPAT score or another behaviour pain 
scale were not validated for the palliative population. In future studies different 
observational scales could be compared and should than preferably be assigned 
by different observers.
COnCLusiOns
In conclusion, the REPOS seems to meet the criteria for the use of pain mea-
surement tools in palliative care of the Expert Working Group of the European 
Association of Palliative Care (EAPC)48. That is, ease of administration, validity, 
sensitivity to treatment effect, validation study in palliative care, and multilingual 
validity (it is available in Dutch and English). In addition, next to the Dutch 
national palliative guidelines15, the use of the REPOS for pain assessment in 
non-communicative patients is recommended in a report on quality indicators 
in palliative care, published by the Netherlands Institute for Health Services 
Research49. We have demonstrated that the REPOS is a valid tool for the as-
sessment of pain in non-communicative end-of-life patients. We recommend its 
use on a daily basis for every non-communicative palliative patient. After a brief 
training course every professional palliative caregiver will be able to use it in daily 
practice. A REPOS instruction sheet and an educational CD-ROM and e-module 
(both in Dutch or English) are available to guide implementation and training18.
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suPPLEMEntAry fiLEs
Rotterdam Elderly Pain Observation Scale (REPOS)
Please observe for 2 minutes, and tick the box if the specific behavior was present during the 
observation. Next, summate all ticked behaviors to obtain the REPOS total score.
REPOS TOTAL SCORE
NAME CLIENT
NAME OBSERVER
SITUATION
(ADL, transfer, walking, physical therapy,
rest, wound care, e.g.)
PAIN MEDICATION
(type, dosing and time of last administration)
DATE/TIME
Moving body parts
see REPOS decision tree
1st observation
Eyes (almost) squeezed
Raising upper lip
Grimace
Frightened, fearful look
Tense face
Panicky, panics attack
Moaning / groaning
Sounds of restlessness / 
verbal expressions
Breath holding / 
faltering respiration
2nd observation 3rd observation
see REPOS decision tree see REPOS decision tree
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Supplement 1. Rotterdam Elderly Pain Observation Scale (REPOS) score form
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No pain Repeat REPOS after intervention
No pain
Please give a pain rating 
                 Range 0 -10
*action A
Pain medication, in consultation with staff nurse / 
physician
Comforting interventions, such as
• Attention / Distraction
• Massage
• Heat / Cold
• Change in posture
• Sedatives
REPOS score2 or lower
*action B
4 
or higher
3 
or lower
Think out possible causes, such as:
- Pain medication taken?
- Good posture when seated or lying down?
- Full bladder / catheter well positioned?
- Fearful / sad / angry / hungry / thirsty?
Take action yourself, or consult physiotherapist / ergono-
mist / physician
Pain?
3 
or higher
Pain! Action A* and / or action B*
NAME CLIENT
NAME OBSERVER
REPOS score
ACTION
DATE/TIME
1st observation 2nd observation 3rd observation 
PAIN RATING
REPOS decision tree
Please enter the REPOS score and pain rating in the schedule below, as well as the action taken. 
The pain rating ranges from 0 (no pain) to 10 (worst imaginable pain).
Supplement 2. Rotterdam Elderly Pain Observation Scale (REPOS) decision tree 
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Rotterdam Elderly Pain Observation Scale (REPOS)
Instruction chart
Tense face
One or more facial muscles are being tightened (are not relaxed).
This is NOT scored when client is talking.
Eyes (almost) squeezed
Eyes tightly shut or squeezed.
Do NOT score if client shows blinking eyes or eyes shut without squeezing.
Raising upper lip  
The upper lip is being pulled up, shortening the distance between upper lip and nose; nasio-labal 
furrows deepened, nostrils raised and enlarged.
Grimace 
Scored as present only when the following three facial expressions occur together:
1) Eyebrows drawn together and downward, with the skin fold between the eyebrows bulged out.
2) Eyes tightly shut or squeezed.
3) Nasio-labal furrows deeper than normal and drawn up sideways.
Frightened, fearful look
Large, widely opened eyes, and inner sides of eyebrows slightly raised and drawn together. 
Moving body parts
Each movement indicative of resistance or protecting a (painful) body part. Included are movements 
such as changing one’s position in a chair so as to relieve one’s bottom, and grasping the head.
Do NOT score when the movement or action is functional, e.g. pushing one’s hair out of one’s face, or 
raising arms to take off clothes.
Panicky, panics attack 
An extreme manifestation of anxiety showing in random nervous body movements or fierce resistance.
This may co-occur with: 
•  Frightened expression characterized by large, widely opened eyes, and inner sides of eyebrows   
   slightly raised and drawn together; and/or
•  Intense screams or verbal expressions of pain, such as ‘ouch’ or “you’re hurting me’.
Moaning/groaning
Monotonous and whining sound.
Sounds of restlessness/verbal expressions
Sudden or persisting intense screams or verbal expressions of pain, such as ‘ouch’ or “you’re hurting me’.
Breath holding/faltering respiration
Briefly interrupted breathing, gasping.
Definitions of the behaviors
Each item in the REPOS represents specific behavior or a certain reaction. The REPOS does not score intensity of 
behavior, but rather occurrence, yes or no. An item is only scored as present if the behavior in question was clearly 
visible. Scoring is not useful if the client is in relaxed sleep.
Supplement 3. Rotterdam Elderly Pain Observation Scale (REPOS) instruction chart
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AbstrACt
Context: If regular therapies cannot relieve symptoms sufficiently in the last 
days of life, continuous palliative sedation may serve to reduce consciousness. 
Sedation level can be measured with EEG monitoring with the bispectral index 
(BIS) monitor. 
Objective: To determine the feasibility and validity of BIS monitoring in termi-
nally ill patients.
Methods: In this prospective study, BIS registrations were performed in uncon-
scious end-of-life patients admitted to a palliative care centre. Validated scores 
were used to measure level of sedation (Ramsay score), pain (NRS or REPOS), 
delirium (DOS score) and overall comfort (NRS). Validity and sensitivity to change 
of BIS values were considered and the effects of medication and the time till 
death on BIS values were evaluated in a linear mixed model analysis.
results: Fifty-eight patients were included for analysis. BIS monitoring was ac-
ceptable to patients, relatives and medical staff. BIS values were moderately cor-
related with Ramsay scores (0.46), but were highly variable for deeply sedated 
patients. BIS values changed significantly before and after a midazolam dose 
(p<0.001). Midazolam treatment resulted on average in a statistically significant 
reduction of the BIS values (-4.5, 95% CI -7.0 to -2.0) whereas morphine and 
haloperidol did not. 
Conclusion: This is one of the first validation study in which BIS monitoring 
in end-of-life patients is described. BIS monitoring is feasible in unconscious 
terminally ill patients. However, based on our results, the wide range of BIS 
values in deeply sedated and comfortable patients seems to hamper its use in 
daily clinical practice.
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intrODuCtiOn
In some patients in the terminal phase of life, regular medication may fail to 
provide adequate symptom relief. Then, continuous palliative sedation may be 
an option of last resort. However, it cannot be excluded that patients suddenly 
awaken1; this occurred in 39% and 49%, respectively, of patients in two separate 
studies2, 3. During palliative sedation, it is important to monitor the patient’s 
comfort4-6. However, a valid assessment tool within this context is not available7. 
Patients’ self-report of comfort is typically considered the ‘gold standard’8, 9. 
However, in the terminal phase of life, patients may not be able to self-report 
their symptoms, due to cognitive failure prior to death10, 11 or due to being un-
responsive in those last days12-14. It would seem obvious that assessment with 
observational scales or physiological devices is needed for non-communicative 
end-of-life patients15. Most observational sedation scales (e.g. Ramsay score), 
however, have not been validated for palliative care facilities15, 16. Moreover, 
there is no general consensus on how the effect of palliative sedation should 
be assessed; either by symptom control or by sedation depth, neither which 
observational assessment should be used15, 16. 
Monitoring palliative sedation is still based on observational scales only. A 
main problem with these scales is that they consider unresponsiveness equal to 
unawareness, the correctness of which has been questioned15, 17. We aimed to 
explore whether an electrophysiological device, the bispectral index (BIS) moni-
tor, would prove a clinically relevant parameter that measures unawareness and 
may help improve the care for end-of-life patients.
During general anaesthesia, the level of sedation can be continuously moni-
tored using the BIS monitor:  a continuous electrophysiological measure, derived 
from non-invasive EEG monitoring. The values displayed on the BIS monitor 
serve to guide sedation therapy18-20. BIS monitoring during palliative sedation 
may be valuable, since distressed behaviour is often diminished in the end-of-life 
stage. Therefore patients could mistakenly be considered to be comfortable when 
using only behavioural assessment15, 21.
So far, the use of BIS monitoring in palliative care has been reported in only 
two studies with small sample sizes (respectively, one and 12 patients)22, 23. 
These studies concluded that BIS monitoring is acceptable for patients, family 
and care-givers and can be used to monitor sedation level as well as the effect 
of medication. However, these descriptive studies were not aimed at validation of 
BIS monitoring in the palliative care setting. Therefore, in this study we applied 
BIS monitoring in combination with validated pain, sedation and delirium assess-
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ments, and aimed to determine whether BIS monitoring is feasible and valid for 
use in a hospice setting.
MEtHODs
Design and setting
This prospective observational pilot study was performed during various periods 
over the years 2008 to 2012, for almost 3 years in total, in Laurens Cadenza, the 
largest palliative care centre in the Netherlands, with 20 beds for terminal care 
and symptom management. Annually 200 to 250 patients are admitted.
Participants
Patients admitted for palliative care during the study period were eligible to par-
ticipate, except those who were unable to provide consent and those admitted 
for a short period, for instance to find the most effective pain medication. The 
timing of information provision about the study was decided in consultation with 
the responsible health professionals. If possible, the patient was informed in 
the presence of a relative. They were given at least 24 hours to consider their 
decision. Written consent was obtained from participants. Later, the patient and/
or the family were asked renewed consent for BIS monitoring.
This study was approved by the Medical Ethics Review Board of the Erasmus 
University Medical Centre and the institution’s local board of directors of Laurens 
Cadenza.
Assessment tools
Level of sedation
Level of sedation was assessed both with the Ramsay score and with BIS monitor-
ing. The Ramsay score consists of 6 sedation levels, ranging from 1 (agitated and 
restless) to 6 (no response to stimulus)24. This score is easy to use also in pallia-
tive care25, and has been validated for intensive care and surgical patients26, 27. 
BIS monitoring measures the level of sedation based on a 4-points EEG. Level of 
sedation is expressed as the bispectral index, which is a dimensionless parameter 
ranging from 0 (flat line EEG) to 100 (fully awake). We used the BIS Vista monitor 
(Covidien, Mansfield, U.K.) with the commercially available adult BIS quarto-
sensor placed on the patient’s forehead. During a BIS registration a single BIS 
value was saved every minute. In this study, the minimum duration of a single 
registration was 30 minutes.
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Pain
Pain was assessed in one of two ways, based on the patient’s capacity to com-
municate. Communicative patients self-reported a Numeric Rating Scale (NRS) 
score for pain, from 0 (no pain) to 10 (worst possible pain). A NRS pain score of 
4 or higher is considered to reflect moderate to severe pain28. The NRS is con-
sidered a valid tool to assess cancer pain intensity29, 30. For non-communicative 
patients, nurses applied the NRS to provide a proxy-score and in addition applied 
the Rotterdam Elderly Pain Observations Scale (REPOS)31. The REPOS is recom-
mended in Dutch national palliative guidelines for specific non-communicative 
patient groups4. The REPOS consists of 10 behaviours, which the observer scores 
as either present or absent after having observed the patient for two minutes31. 
Thus, the score range is 0-10; a score of 3 of higher is indicative for pain.
Delirium
The Delirium Observation Screening (DOS) scale consists of 13 verbal and non-
verbal behaviours which are scored for their presence three times a day, resulting 
in a total score ranging from 0 to 39. This total score is divided by 3 and a result-
ing mean of 3 or higher for those three observations over 24 hours is indicative 
for delirium. The DOS scale has been validated for use in patients with a high risk 
for delirium32. 
Comfort
The degree of comfort was measured with an NRS-comfort score from 0 (no 
comfort at all) to 10 (optimal comfort)33. Communicative patients self-reported 
the NRS-comfort score, and for non-communicative patients nurses assigned a 
score based on the following reasoning: ‘what total comfort score would you give 
for the patient’s present situation, imagining a score of 10 as the most comfort-
able situation the patient can be in?’34. An NRS-comfort score of 5 or less was 
defined as reflecting insufficient comfort.
Procedures
The above-mentioned scales for pain, delirium and comfort were applied daily by 
the responsible nurse or the first author (AM). In patients receiving sedatives, 
level of sedation was assessed with the Ramsay score at least once a day and if 
possible more often during BIS monitoring.
In newly included patients, BIS monitoring was first tested, if possible during 
a regular sleep without the need for a sedative. This test measurement was 
started just before the patient went to sleep, either during the day or at night, 
and stopped after the patient woke up. It served to familiarize the patient and 
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family with the procedure and to identify potential problems. Next, more reg-
istrations were made, provided that the patient’s condition permitted this, and 
especially when sedative drugs were administered, including a single dose. If 
the test measurement proved valid, the data obtained were also included in the 
analysis. BIS monitoring was applied for research purposes only, and medical 
treatment was not based on BIS values. The monitor was not covered and values 
were visible to caregivers and relatives.
Next to validity, feasibility and clinical utility of BIS monitoring were consid-
ered. Feasibility was defined on the basis of aspects such as ease of use, the need 
and time for training of caregivers, and the acceptability for patients and their 
family 35. Clinical utility was defined on the basis of aspects such as the relation of 
the BIS values with norm values for sedation and the fact whether BIS monitoring 
adds information to the already available measurement tools for symptoms 35.
Medication
A record was kept of all drugs administered, and notably the consumption of mor-
phine, midazolam and haloperidol was analysed. Drugs were prescribed accord-
ing to the Dutch national palliative guidelines 4. In our practice, for continuous 
palliative sedation midazolam is usually given in subcutaneous boluses 6 times a 
day via a subcutaneous-access device (insulfon™) and titrated individually to a 
level of sedation in which the patient is sufficiently asleep (detailed in appendix 
1).  ‘A single midazolam dose’ was defined as one administration not preceded, 
within 4 hours, by another dose.
We assumed that the BIS might be influenced by a subcutaneous bolus 
morphine or midazolam over a period of 4 hours after administering and for 
haloperidol a period of 24 hours was set. These timeframes were chosen based 
on the dosage frequency of 6 times daily for morphine and midazolam or once 
daily for haloperidol4.
Other variables
Demographic characteristics (age, gender, diagnoses, and duration of admission), 
the primary diagnosis and the number of comorbidities were extracted from the 
electronic medical records. The primary diagnosis refers to the WHO’s Interna-
tional Classification of Diseases (ICD-10 classification) coding for the patient’s 
terminal illness. Reasons for exclusion and refusal were recorded.
statistics
Two aspects of validity were considered, namely concurrent validity and sensitiv-
ity to change. For the concurrent validity, Spearman’s rank correlation coefficient 
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was calculated between BIS values and Ramsay scores and between mean BIS 
values and dichotomized pain, comfort and delirium scores. For validity of the 
BIS values, the correlation coefficient should exceed 0.30 36. At the times when a 
Ramsay score, pain (REPOS) or comfort (NRS-comfort) score was/were assigned, 
mean BIS values during 10 minutes (5 minutes before and 5 minutes after the 
assessment) were calculated and included in this analysis. Since delirium was 
scored with the DOS over a period of 24 hours, mean BIS values within the same 
24 hours were used to correlate BIS with the DOS. Dichotomization was based 
on the cut-off values for the respective measurement scales, as described above.
For the sensitivity to change analysis, paired mean BIS values before and 
after a single midazolam dose were selected. Mean BIS-before values were cal-
culated based on the 30 minutes before a midazolam administration. Midazolam 
administered via the subcutaneous route reaches a maximum plasma level at 
20 to 30 minutes after administration37, 38. To account for this maximal effect of 
midazolam, a mean BIS-after value was calculated over a 30-minute period, i.e. 
from 30 to 60 minutes after administration. The Wilcoxon signed-rank test was 
applied to compare BIS-before and BIS-after values of single midazolam doses.
A linear mixed model was used to evaluate both the effect of medication 
(midazolam, morphine and haloperidol) and the time till death on BIS values. 
The dependent variable in this model was the longitudinal BIS values, and the 
independent variables were midazolam use during the last 4 hours (yes/no), 
morphine use during the last 4 hours (yes/no), haloperidol use during the last 
24 hours (yes/no), and natural cubic splines of the time till death. This cubic 
spline function was required to model the complex nonlinear effects of time till 
death on BIS values. A B-spline basis matrix was used to parameterize the spline 
variables. The number of knots in the spline function was selected using the 
Bayesian information criterion, based on which 4 knots and thus 5 spline vari-
ables were included for the effect of time till death. A random intercept and an 
ARMA(1,1) error covariance matrix were used to account for the within-subject 
correlations. Only BIS registrations of the last week (7 days) before death were 
selected for this analysis. Mean values per 60 minutes for BIS values and the 
medication variables were calculated to reduce the strength of the within-subject 
correlations, to ensure that modelling these within-subject correlations would 
not lead to an overly complicated model. For this linear mixed model, only data 
of patients for whom the exact time of medication administration was recorded 
could be analysed.
Differences in background characteristics between included patients and 
refusals were checked with the Pearson’s chi-square test, Mann-Witney test and 
Fisher’s exact test as appropriate. A two-sided p-value <0.05 was considered 
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statistically significant. The statistical software programs IBM SPSS Statistics 21 
and R (version 3.1.2)39 with the packages nlme and splines were used to analyse 
the data.
rEsuLts
Participants 
During the study period a total of 516 patients were assessed for eligibility. One 
hundred sixty-five (32%) patients were informed of the study, of whom 65 (39%) 
gave consent. Figure 1 shows the flow chart of patient inclusion. Four (7%) 
patients and/or family withdrew from the study after initially giving consent; in 



 
 
 
 
 
 
 
 



 
 


 
 


Figure 1. Flow chart patients
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3 (5%) patients a BIS registration was not performed because of a very quick 
deterioration; and thus 58 patients were included in the final analysis. Their 
median age was 75 years (IQR 63 to 82), 55% were female, and the median 
duration of admission was 36 days (IQR 17 to 54). Advanced malignancy, mainly 
of respiratory and digestive organs, was the main reason for admission (97% of 
patients). None of the background characteristics considered differed significantly 
between participants and refusals (n=67). Table 1 provides the characteristics of 
the included patients (N=58).
Thirty-three participants (57%) were continuously sedated during admission. 
Their median daily midazolam dose during sedation days was 30 mg (IQR 15 to 
70).
Feasibility
In total 167 BIS registrations (in 58 patients) were made, 18 (11%) of which 
were excluded from analysis because of poor quality or too short duration (<30 
minutes). Too short duration was mostly the result of the patient removing the 
sensor in a confused state of mind.
Table 1. Characteristics of included patients
Characteristic N =58
Gender in N (%)
Male : female 26 (45) : 32 (55) 
Age in years; Median (IQR) 75 (63 to 82)
Duration of admission in days; Median (IQR) 36 (17 to 54)
Primary diagnosis in N (%)
Neoplasms 56 (97) 
Respiratory and intra-thoracic organs 17 (30) 
Digestive organs 15 (27) 
Lymphoid and hematopoietic tissue 5 (9) 
Female genital organs 4 (7) 
Urinary tract 4 (7) 
Ill-defined, secondary and unspecified sites 4 (7) 
Male genital organs 3 (5) 
Eye, brain and other parts of central nervous system 3 (5) 
Other 1 (2) 
Disease of nervous system 1 (Parkinson’s disease) 
Disease of circulatory system 1 (Heart failure) 
Co-morbidities
Median (IQR) number of diagnoses 2 (1 to 3) 
IQR, interquartile range
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Nurses needed no more than approximately 10 minutes’ instruction to ensure 
an adequate BIS registration, since the use of the monitor and the application of 
BIS sensor on the patient’s forehead were fairly easy.
BIS monitoring was acceptable to patients and their relatives. Participants felt 
they were carefully looked after, even if they would become unable to communi-
cate symptoms. Relatives felt supported by the measurement. Even the medical 
appearance of the sensor on the patients’ forehead did not bother relatives. 
Patients and their relatives explicitly told us that they were very thankful for 
participation in this study.
validity 
For the analyses, 149 BIS registrations of 58 individual patients were used, with 
a median of 2 (IQR 1 to 3) BIS registrations per patient and a median duration 
of 520 minutes (IQR 249 to 844 minutes) per registration. Thirty-one patients 
(53%) were studied till death.
For 26 patients Ramsay scores were available during a BIS registration, with 
a median of 4 (IQR 2 to 7) Ramsay scores per patient.  The Spearman’s rank 
correlation coefficient between BIS and Ramsay scores was 0.47, which indicates 
a moderate correlation. Figure 2 shows a boxplot relating BIS values and Ramsay 
scores. Notably, BIS values varied from below 30 to above 90, even when the 
Ramsay score indicated that the patient did not respond to a stimulus. 
Median (IQR) BIS values during symptom assessments (pain, comfort and/
or delirium) and the accompanying Spearman’s rank correlations coefficients 
are given in Table 2. Spearman’s rho varied from 0.03 for delirium to 0.30 for 
comfort, which indicates weak correlations.
Regarding sensitivity to change, figure 3 shows a boxplot of 42 paired mean 
BIS values before and after the administration of a single dose of midazolam 
during 34 registrations of 24 patients. The median BIS-before value of 76 (IQR 65 
to 82) was reduced to a median BIS-after value of 60 (IQR 54 to 76). This change 
was statistically significant (p<0.001).
The exact times of medication administration were recorded for 40 patients, 
and in 33 of those BIS registrations had been made in their last week before 
death. Data of these 33 patients were included in the linear mixed model analy-
sis. Figure 4 shows a plot of the predicted BIS values, with the 95% confidence 
interval, in the last week before death, for patients who had not received mor-
phine, midazolam or haloperidol. On the last day before death, a steep decline 
in BIS values is seen, with a remarkable spike just before death. In this model, 
midazolam treatment resulted on average in a statistically significant reduction of 
the BIS values of -4.5 (95% CI -7.0 to -2.0, p<0.001). Morphine and haloperidol 
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had no statistically signifi cant effect, p=0.85 and 0.35 respectively; with an aver-
age reduction of BIS values of -0.8 (95% CI -6.1 to 4.4) for morphine and -2.5 
(95% CI -7.8 tot 2.7) for haloperidol. In addition, patients who received either 
midazolam, morphine or haloperidol would have had a similar pattern of predicted 
BIS values in their last days as displayed in fi gure 4, with the only difference a 
reduction of 0.8 to 4.5 in BIS values depending on the medication administered.
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Figure 2. Boxplot for BIS values at different levels of Ramsay scores
This fi gure shows median and 25th and 75th percentiles [box top and bottom] and 5th and 95th 
percentiles [whiskers]
Table 2. BIS values during symptom assessments
symptoms assessment Number of assessments 
(number of patients)
bis value
Median (IQR)
spearman’s rho
Pain
Yes (NRS score 4 to 10)
No (NRS score 0 to 3)
10 (8)
124 (22)
68 (59 to 76)
58 (48 to 75)
0.11
Comfort
Yes (NRS score 6 to 10)
No (NRs score 0 to 5)
115 (21)
23 (11)
54 (46 to 69)
66 (60 to 80)
0.30
Delirium
Yes (DOSscore >3/24hrs)
No (DOSscore <3/24hrs)
12 (9)
37 (27)
71 (62 to 75)
71 (65 to 79)
0.03
NRS, Numeric Rating Scale; DOS, Delirium Observation Screening; IQR, interquartile range
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Figure 3. Boxplot for BIS values before and after a single administration of midazolam 
(42 doses)
This fi gure shows median and 25th and 75th percentiles [box top and bottom] and 5th and 95th 
percentiles [whiskers]. The change in BIS value before and after was statistically signifi cant 
(p<0.001)
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Figure 4. Plot of predicted BIS values, including the 95% confi dence interval, in last 
week before death, for patients who have not received morphine, midazolam or halo-
peridol
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DisCussiOn
This study considered the concurrent validity, sensitivity to change and feasibility 
of BIS monitoring in end-of-life patients. We found only a moderate correlation 
between BIS and Ramsay scores (concurrent validity) due to varying BIS levels 
(between 30 and 90) in patients with a Ramsay score indicating deep sleep, as 
was reported for midazolam sedation in intensive care and surgical patients40-42. 
This suggests that BIS might be of added value in these cases as suggested by 
another recent paper as well43. Next, BIS values were significantly lower after 
midazolam treatment but the difference was too small to be clinically relevant. 
We found some anecdotal arguments that BIS monitoring may be of relevance 
for family and nurses, like found in other studies on BIS monitoring in palliative 
patients22, 23. 
Another aspect of concurrent validity we studied was the correlation of BIS 
and pain scores, which was weak. Another variable measured during BIS moni-
toring - electromyography of the forehead (EMG) - may be of value for pain as-
sessment44. Future research may incorporate EMG as an additional and probably 
relevant parameter for both sedation and pain assessment.
Regarding the clinical utility, norm BIS values for adequate anaesthesia range 
from 40 to 6045. However, norm values for continuous palliative sedation with 
midazolam are not available and cannot be established on the basis of our data. 
Moreover, in our population only 50% of patients reached BIS values below 60 
after a single midazolam dose. Since norm values are lacking and BIS values for 
comfortable and adequately sedated patients are variable (illustrated in 2 cases 
in appendix 2), further research is needed to use BIS values for individual drug 
titration of palliative sedation. In addition, palliative patients differ in several 
aspects from other patients groups (e.g. intensive care patients) for which seda-
tive monitoring by BIS is used; differences in administered sedatives drugs and 
their route of administration41, 46, disease status and/or emotional burden for 
patient and family, and possible changes in brain processes during end-of-life 
could affect BIS values.
Worth mentioning is the remarkable peak in BIS values in more than half of the 
registrations just before death, which is also reflected in the predicted effect curve 
for time till death in the linear mixed model (figure 4 and appendix figure 2). This 
typical phenomenon was also seen in a case series of intensive care patients47 
and in the other two previous studies on BIS monitoring in dying patients22, 23. 
Chawla and co-workers47 propose several explanations for this phenomenon: 1. 
External artefacts causing unreliable BIS values, 2. Muscular activity interfering 
with BIS values and 3. Cerebral ischemia resulting in a loss of electrical potential 
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and a cascade of electrical activity. In addition, this peak effect and other fluctua-
tions were found to be comforting for families in those studies, like in our study.
Some limitations of this study have to be addressed. The main limitation of 
this study is the use of non-validated scales for terminally ill patients. Validated 
scales were not available at the time of the data collection for the current study. A 
non-validated sedation scale (not otherwise named), which resembles the Ram-
say scale, is described in the Dutch guideline for palliative sedation48. Therefore, 
the use of the Ramsay score for our study was, at that time, an obvious choice. In 
addition, validated pain and delirium scales were lacking for terminally ill patients 
at the time we prepared for this study and in later years, publications became 
available7, 16, 49. Regarding the delirium score, DOS, we found its use in pallia-
tive patients sometimes inappropriate, since some items could not be scored in 
unresponsive patients, like Detroyer et al published recently50. The accuracy of 
observational scales in palliative patients may be questioned for another reason, 
since the ability to react with facial expressions or body movements may be 
diminished in the end-of-life stage. With monitoring palliative sedation we aim 
for a comfortable patient with a relaxed posture and a calm facial expression, but 
what if unresponsiveness is not equal to unawareness17? We consider the Ramsay 
scale as a measure to distinguish between unresponsiveness and responsiveness, 
and that BIS might be of valuable in the unresponsive patient but future studies 
should use the more recently validated instruments for sedation, delirium and 
pain. Another limitation is that pain and comfort were assessed only once daily. 
In conclusion, based on our results we were not able to support the state-
ment that BIS would differentiate between the various levels of sedation during 
midazolam treatment. Further research is needed to consider BIS as a tool for 
monitoring the level of sedation in palliative patients in daily practice.
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APPEnDix
Dosing regimen of midazolam for continuous palliative sedation
Based on the Dutch national palliative guidelines4, continuous palliative sedation 
is started with a loading dose of midazolam 10 mg subcutaneously, followed by 
subcutaneous bolus injections of 5 mg midazolam six times daily. In case of insuf-
ficient effect, an additional bolus dose of 5 mg midazolam may be administered 
after 2 hours and after minimal 4 hours the midazolam maintenance therapy 
may be increased with 50% (to 7.5 mg) subcutaneously six times daily. A subcu-
taneous pump for continuous administration of midazolam was used when high 
dosages (a volume of at least 3 millilitres per time) were needed.
two illustrative cases 
Appendix Figure 1 illustrates BIS graphs over a 24-hour period of two patients 
who needed very large doses of midazolam that day (260 to 295mg/day). For 
both patients a subcutaneous pump had to be started, since bolus injections were 
no longer appropriate due to large volumes of the injection fluid (over 3ml per 
bolus) needed. These two registrations show different patterns toward a comfort-
able and asleep status; one with a somewhat abrupt decline in BIS values at the 
time a subcutaneous midazolam pump is started (graph A) and the other with 
great variability in BIS values even during continuous midazolam administra-
tion (graph B). In both registrations the influence of the muscle activity of the 
forehead (EMG) can be seen; BIS values increase and decrease synchronous with 
EMG. Later, both registrations became more stable, with BIS values between 30 
and 50 till death 2 to 3 days later (Appendix Figure 2, A and B correspond to 
the same patients as in Appendix Figure 1). Notably, both registrations show an 
abrupt decline in BIS values with a remarkable peak shortly before death. In all 
registrations till death we found decreasing BIS values during the last hours or 
minutes of life; this could be either a slow decrease or an abrupt steep decline. 
This peak in values was seen in 17 (55%) of the 31 registrations till death.
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Appendix Figure 2. Two BIS registrations of the last 12 hours till death
BIS, bispectral index; EMG, electromyography
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AbstrACt
background: In end-of-life care, symptoms of discomfort are mainly managed 
by drug therapy, the guidelines for which are mainly based on expert opinions. 
A few papers have inventoried drug prescriptions in palliative care settings, but 
none has reported the frequency of use in combination with doses and route of 
administration.
Objective: To describe doses and routes of administration of the most frequently 
used drugs at admission and at day of death.
setting: Palliative care centre in the Netherlands. 
Method: In this retrospective cohort study, prescription data of deceased pa-
tients were extracted from the electronic medical records.
Main outcome measure: Doses, frequency and route of administration of pre-
scribed drugs.
results: All regular medication prescriptions of 208 patients, 89% of whom 
had advanced cancer, were reviewed. The three most prescribed drugs were 
morphine, midazolam and haloperidol, to 21%, 11% and 23% of patients at 
admission, respectively. At the day of death these percentages had increased 
to 87%, 58% and 50%, respectively. Doses of these three drugs at the day of 
death were statistically significantly higher than at admission. The oral route of 
administration was used in 89% of patients at admission versus subcutaneous in 
94% at the day of death.
Conclusions: Nearing the end of life, patients in this palliative care centre re-
ceive discomfort-relieving drugs mainly via the subcutaneous route. However, 
most of these drugs are unlicensed and guidelines are based on low level of 
evidence. Thus, there is every reason for more clinical research on drug use in 
palliative care.
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intrODuCtiOn
In 2011 approximately 136,000 persons died in the Netherlands, almost one third 
of them from the consequences of cancer1. A systematic review on symptom 
prevalence in patients with incurable cancer found that the most reported symp-
toms were: fatigue (88%), appetite loss (56%), pain (45%), dyspnoea (39%), 
drowsiness (38%), dry mouth (34%), constipation (29%), confusion (24%), 
nausea (17%), and insomnia (14%)2.
The goal of palliative care is symptom control by a combination of non-
pharmacological measures and drugs. Palliative experts have reached consensus 
on the essential drugs to treat specific symptoms. These have been compiled in 
two different but largely overlapping lists: one published by the International 
Association for Hospice and Palliative Care (IAHPC)3 and one based on a survey 
of Australian palliative care physicians4. Regrettably, both lack recommendations 
on optimal dose or route of administration. 
Existing recommendations5, 6 on dose and route of administration are mainly 
based on level 3 and 4 evidence from case studies or from expert panels. Level 
1 evidence from a systematic review or randomized controlled trials is available 
only for NSAIDs administered to relieve nociceptive pain7 and morphine to al-
leviate dyspnoea8. Level 3 evidence is available for the treatment of cancer pain 
with oral morphine9. Haloperidol treatment of a delirium in hospitalised patients 
is based on level 2 evidence from well designed, non-randomized trials10. Recent 
updates of systematic reviews for morphine and haloperidol found no new signifi-
cant information11, 12.
The choice of drug and dose tailored to the individual patient is thus hardly 
supported by evidence from prospective clinical trials. Likewise, there is little evi-
dence for the optimal route of administration, although the subcutaneous route 
is often preferred in palliative care. Dose adjustment may be needed because 
liver and kidney function undergo changes at the end of life13, 14. It follows that a 
number of drugs used in palliative care are unlicensed or off-label15, 16.
Only a few studies in palliative care units17-19 and services for mainly outpatient 
groups20-23 have described medication use in palliative care. To our knowledge, 
there are no published studies describing the most used drugs with their doses 
and administration routes, on admission and at the day of death in a large group 
of patients receiving palliative care.
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AiM Of tHE stuDy
The aim of this study was to evaluate what drugs were administered, and at what 
dose and route of administration, from admission to day of death in patients 
admitted to a single palliative care centre.
EtHiCAL APPrOvAL
Ethical approval from a review board was not required, since this is a descriptive 
retrospective study. For retrospective analysis of patient files ethical approval is 
waived according to Dutch law. All patient data were handled and processed in 
accordance with the recommendations of Good Clinical Practice.
MEtHODs
Design and setting
This retrospective cohort study was performed in Laurens Cadenza in Rotterdam, 
the Netherlands. This is the largest palliative care centre in the Netherlands, with 
20 beds for terminal care and symptom management; from 200 to 250 patients 
are admitted annually. A multidisciplinary team of health care professionals is 
available 24 hours per day.
Measurements and technical information
Age, gender, primary diagnosis, comorbidities, and duration of admission were 
extracted from the electronic medical records. The primary diagnosis was as-
signed according to the WHO’s International Classification of Diseases (ICD-10 
classification) coding for the patient’s terminal illness. 
Medication data of all deceased patients in 2010 were extracted: name, dose, 
frequency, and route of administration, and dates of start and discontinuation of 
the prescription. Only the regular prescriptions for maintenance therapy were 
included, because the electronic prescription system does not detail how much 
as needed medication was given. 
Drugs were prescribed according to the symptom-specific Dutch national pal-
liative guidelines 5. The presence of symptoms was daily checked by the nurses 
and reported to the physicians, but validated assessment instruments were not 
standard of care.
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Two top-10s of individual drugs prescribed were constructed: One covering the 
day of admission (Ta), the other the day of death (Td). 
Medication was categorized by the anatomical therapeutic chemical (ATC) 
classification system 24. The ATC system groups the drugs into 5 different levels 
according to the organ or system on which they act and according to their chemi-
cal, pharmacological and therapeutic properties. For this study we used the main 
therapeutic-group level. Furthermore, the WHO classification of analgesic drugs 
was applied: non-opioids, NSAIDs and opioids.
Morphine and haloperidol doses per 24 hours were calculated taking into ac-
count route of administration. Oral bioavailability of morphine and haloperidol is 
30% and 50%, respectively, versus almost 100% after subcutaneous, intravenous 
and intramuscular administration. Equivalent subcutaneous doses of oral drugs 
were calculated by dividing oral morphine doses by 3 and oral haloperidol doses 
by 25, 25, 26. An oral morphine dose of less than 300 mg/24hours is considered a 
low-to-moderate dose27-29. Consequently, a daily subcutaneous morphine dose of 
less than 100 mg/24hours was considered a low-to-moderate dose. 
Fentanyl is mainly given via transdermal patches, which are replaced every 
2-3 days. The daily dose was calculated as the dose of the prescribed patch 
divided by the number of days the patch was in place. Midazolam for continuous 
palliative sedation was administered either by subcutaneous boluses six times 
every 24 hours or by constant subcutaneous infusion. Insomnia was mainly 
treated by a single subcutaneous bolus of midazolam or by intermittent boluses.
statistics
Data were analysed using descriptive statistics. Data are presented as mean 
(standard deviation; SD) in case of normally distributed variables and as median 
(interquartile range = IQR or minimum-maximum range = range) in case of non-
normally distributed variables. IBM SPSS Statistics 20 was used for data analysis. 
McNemar test served to detect differences in numbers of patients receiving 
the 3 most frequently used drugs both at Ta and Td. We limited ourselves to these 
3 drugs to prevent repeated testing with too small samples. Differences in the 
daily doses of these drugs for patients receiving these both at Ta and Td were 
evaluated with the Wilcoxon signed rank test. A p-value of < 0.05 (two-sided) 
was deemed statistically significant.
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Participants
In the study year 2010, 234 patients had been admitted. Ten had been dis-
charged in the course of 2010 and 16 were still alive at 1st January 2011. All other 
208 patients died in the palliative care centre and were included for analysis. 
Their median age was 76 years (IQR 63 to 83 years), 50.5% were female, and 
the median duration of admission was 11 days (IQR 5 to 29 days). Advanced 
malignancy, mainly of the digestive or respiratory organs, was the main reason 
for admission (88.9% of patients). A median of two comorbidities (IQR 1 to 4) 
had been documented. Patient characteristics are given in Table 1.
Prescriptions
Drug prescriptions had not been issued for two patients; one died quickly after 
admission and stayed for a few hours only, all medications for the other patient 
had already been discontinued shortly before admission. A total of 4890 prescrip-
tions for 206 patients has been extracted, of which 3032 were regular prescrip-
Table 1. Background characteristics of the included patients
Characteristics N=208
Gender, in number (%) 
Male / female 103 (49.5) / 105 (50.5) 
Age, in years; Median (IQR) 76 (63 to 83)
Duration of admission, in days; Median (IQR) 11 (5 to 29)
Primary diagnosis, in number (%)
Neoplasm 185 (88.9) 
Digestive organs 50 (27.0) 
Respiratory and intra-thoracic organs 47 (25.4) 
Breast 13 (7.0) 
Urinary tract 12 (6.5) 
Unspecified or unknown sites 12 (6.5) 
Lymphoid, hematopoietic and related tissue 10 (5.4) 
Eye, brain and other parts of central nervous system 9 (4.9) 
Male genital organs 8 (4.3) 
Other 24 (13.0) 
Disease of circulatory system 11 (5.3) 
Other 12 (5.8) 
Co-morbid conditions, in number; Median (IQR) 2 (1 to 4)
IQR, interquartile range
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tions (62.0%) for 203 patients. Regular prescriptions were issued for 194/198 
(98.0%) patients at Ta and for 202/206 (98.0%) patients at Td. 
The median number of drugs per patient at Ta was six (IQR 3 to 8) and this 
number had decreased to four (IQR 3 to 5) at Td.
Top-10 individual regular drugs
The top-10 individual drugs prescribed at Ta and Td are given in Table 2. Figure 1 
shows percentages of patients with a prescription of these top-10 drugs at Ta and 
Td. Morphine, midazolam, haloperidol, butyl scopolamine and fentanyl were pre-
scribed more frequently at Td than at Ta. Numbers of patients with a prescription 
of morphine, midazolam or haloperidol increased statistically significantly from Ta 
to Td (all p-values <0.001). This increase was most notable during the last week 
before Td as shown in Figure 2. Prescriptions of lactoluse-senna mix, rabeprazole, 
acetaminophen, metoclopramide, temazepam, dexamethasone, macrogol/salts 
and metoprolol had been discontinued before Td.
Morphine, midazolam and haloperidol were often prescribed concomitantly 
(Table 3). Thirty-one per cent of the patients received all three at Td, but 11% 
had neither a prescription of morphine, midazolam nor haloperidol at Td.
Table 2. Top-10 individual regular drugs (in bold) at the day of admission (Ta) and the 
day of death (Td); given in descending order for the day of death
individual drug
Top 10
Ta (N=194) Td (N=202)
N (%)
Dose/24hours
Median (IQR)
N (%)
Dose/24hours
Median (IQR)
Morphine* 41 (21.1) 30 (17.5 to 60) mg 175 (86.6) 60 (30 to 65) mg
Midazolam 22 (11.3) 10 (5 to 10) mg 118 (58.4) 60 (20 to 90) mg
Haloperidol* 45 (23.2) 2 (range 0.25 to 4) mg 101 (50.0) 2 (range 0.5 to 5) mg
Butyl scopolamine 4 (2.1) 80 mg 68 (33.7) 80 (range 40 to 80) mg
Fentanyl 29 (14.9) 16.7 (8.3 to 25) mcg/hr 61 (30.2) 16.7 (8.3 to 25) mcg/hr
Lactulose-senna mix 65 (33.5) 15 (range 10  to 60) ml 30 (14.9) 15 (range 7.5 to 60) ml
Rabeprazole 99 (51.0) 20 (range 10 to 80) mg 21 (10.4) 20 (range 20 to 40) mg
Acetaminophen 65 (33.5) 4000 (range 1000 to 4000) 
mg
20 (9.9) 4000 (range 3000 to 
4000) mg
Metoclopramide 24 (12.4) 40 (30 to 40) mg 16 (7.9) 40 (30 to 40) mg
Temazepam 31 (16.0) 10 (10 to 20) mg 13 (6.4) 10 (10 to 20) mg
Dexamethasone 34 (17.5) 8 (4 to 12) mg 9 (4.5) 8 (5.5 to 16) mg
Macrogol/salts 28 (14.4) 1 (1 to 2) sachets 7 (3.5) 1 (1 to 2) sachets
Metoprolol 30 (15.5) 50 (50 to 100) mg 4 (2.0) 50 (31.25 to 87.5) mg
Ta, day of admission; Td, day of death; IQR, interquartile range
*The route of administration is taken into account; the subcutaneous dose equivalent is given
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Figure 1. Differences in top-10 individual drugs at admission (dark grey bars) and at 
day of death (white bars); shown in descending order for the day of death
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Figure 2. Prescriptions of top-3 drugs; morphine (diamond), midazolam (square) and/
or haloperidol (triangle), at several time points during admission
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Top-10 regular drug classes
Top-10s of ATC drug classes prescribed at Ta and Td are given in supplemen-
tary Table S1. Three classes were prescribed more frequently at Td than at Ta: 
analgesics, psycholeptics and drugs for functional gastrointestinal disorders. 
While the top-10 at Ta included beta blocking agents, psycho-analeptics and 
anti-thrombotic agents, those drug classes were not included in the top-10 at Td. 
(Table S1, see supplement). Percentages of patients with a prescription of the 
top-10 drug classes at Ta and Td are shown in supplementary Figure S1.
Numbers of patients with analgesics classifi ed by the different grouping sys-
tems are given in supplementary Table S2. The two most frequently prescribed 
opioids, i.e. morphine and fentanyl, are included in the top-10 of individual drugs 
in Table 2. The frequencies of combinations of prescriptions of non-opioids, 
NSAIDs and opioids are given in supplementary Table S3.
Drug doses
The median daily doses for each individual drug prescribed at Ta and Td are 
displayed in Table 2. The median daily doses of the top-3 drugs at Td were: 
morphine 60 mg, midazolam 60 mg, and haloperidol 2 mg. Patients receiving 
these drugs both at Ta end Td were prescribed statistically signifi cantly higher 
doses at Td than at Ta (morphine (n=40) p<0.001, midazolam (n=18) p=0.003 
and haloperidol (n=37) p=0.028).
At Td, 83% of the patients receiving morphine had a low-to-moderate subcu-
taneous equivalent morphine dose of less than 100mg/24hours.
routes of administration
The three most common routes of administration were: oral (solid and liquids), 
subcutaneous, and transdermal. Percentages of patients with prescriptions of 
Table 3. Combination of prescription for top-3 drugs; morphine, midazolam and halo-
peridol (N=202)
Single or combination of regular prescriptions at day of death N (%)
Morphine, midazolam and haloperidol 63 (31.2)
Morphine and midazolam 46 (22.8)
Morphine 36 (17.8)
Morphine and haloperidol 30 (14.9)
No morphine, midazolam or haloperidol 22 (10.9)
Midazolam and haloperidol 6 (3.0)
Midazolam 3 (1.5)
Haloperidol 2 (1.0)
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solid oral drugs declined from 89.2% (n=173) at Ta to 21.3% (n=43) at Td. 
Use of the subcutaneous route increased from Ta (47.9%; n=93) to Td (93.6%; 
n=189). Prescriptions of a transdermal drug almost doubled from Ta to Td, from 
16.0% (n=31) to 31.7% (n=64) of patients (Table 4).
Morphine, midazolam and haloperidol were almost exclusively given via the 
subcutaneous route. At Ta morphine was given subcutaneously to 95.1% (39/41) 
of the patients, midazolam to 90.0% (20/22) and haloperidol to 66.7% (30/45). 
At Td these percentages had even increased to 98.9% (173/175), 100% (118) 
and 99% (100/101) respectively.
DisCussiOn
This study found that morphine, midazolam and haloperidol were the most 
frequently prescribed drugs at the day of death for patients in the largest pal-
liative care centre in the Netherlands. Doses of these drugs were statistically 
significantly higher than those at the day of admission. Upon admission almost 
90% of patients received oral medication but over the admission period a shift 
Table 4. Prescriptions via the various routes of administration at the day of admission 
(Ta) and the day of death (Td); given in descending order for the day of death
routes of 
administration
Ta (N=194) Td (N=202)
N (%)
Number of 
drugs per 
patient
(median; IQR)
N (%)
Number of 
drugs per 
patient
(median; IQR)
Subcutaneous 93 (47.9) 1 (1 to 2) 189 (93.6) 3 (2 to 3)
Transdermal 31 (16.0) 1 64 (31.7) 1
Oral, liquid 115 (59.3) 1 47 (23.3) 1
Oral, solid 173 (89.2) 4 (3 to 6) 43 (21.3) 3 (2 to 5)
Intramuscular 5 (2.6) 28 (13.9)
Cutaneous* 15 (7.7) 16 (7.9)
Inhalation 29 (14.9) 12 (5.9)
Rectal 20 (10.3) 11 (5.4)
Intravenous 4 (2.1) 3 (1.5)
Ocular 4 (2.1) 2 (1.0)
Intravesical - 2 (1.0)
Intrathecal - 1 (0.5)
Nasal 1 (0.5) 1 (0.5)
Ta, day of admission; Td, day of death; IQR, interquartile range
*The cutaneous route is used for local skin treatment
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occurred to the effect that at the day of death more than 90% of patients received 
subcutaneous medication. 
Other studies, too, found that morphine, midazolam and haloperidol were the 
most prescribed drugs in the palliative setting30-33. These drugs are given to 
relieve symptoms such as pain, restlessness and agitation, which are frequently 
seen in advanced cancer2. Nauck and co-workers17 in a similar study found that 
26% of patients received morphine at admission (versus 21% in the present 
study), but corresponding figures at the end of treatment were 42% versus 87%. 
The latter difference is probably explained by the fact that Nauck and co-workers 
also included patients who were discharged from the centre, whereas we solely 
considered patients who died in the palliative centre. Nevertheless, other stud-
ies reported opioid use in 82% to 97%28, 30, 32, and morphine use in 66% to 
93%27, 28, 30, 32 of patients at the end of life, which percentages correspond well 
with our results. 
We found that midazolam was prescribed for 58% of patients at the day of 
death, while in other studies this was the case for 23% of patients in the last 48 
hours of life30 or 82% of patients in their last week31. An explanation for this wide 
range could be the studied time frame. Midazolam is often stopped in the last 
days before death, to avoid that patients become comatose. On the other hand, 
midazolam may be started for palliative sedation, notably in the last 24 hours 
before death.
Many more patients in the present study were prescribed haloperidol than in 
the study by Nauck et al17; at admission 23% versus 3%, respectively, and at end 
of treatment 50% versus 13%, respectively. Our higher figures may be explained 
by the difference in the studied patient population; we only included patients 
who died in the palliative centre. Other studies, however, found percentages (21-
43%) comparable to the present study30-33. Haloperidol is the drug of first choice 
to treat delirium. In other studies, delirium was suspected in approximately 50% 
of cancer patients admitted to a palliative care centre and in up to almost 90% 
of all cancer patients in the last day or hours before death34, 35. We suspect, 
however, that haloperidol is also prescribed in agitated or restless patients who 
have not been clearly diagnosed with a delirium. Therefore, assessing delirium 
with a validated scale, such as the Confusion Assessment Method, should become 
standard of care36, 37.
In the present study the median number of drugs decreased from 6 to 4 
as death approached, probably because in our centre oral drugs are stopped 
when a patient enters a recognizable dying phase38. Other studies, however, have 
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reported increasing numbers of drugs towards death20, 22, 23, possibly to control a 
new or advancing symptom.
The doses of the top-10 drugs compared well to the titration schemes given in 
the national symptom specific guidelines5. Eighty-three percent of patients in the 
present study received a subcutaneous morphine dose of less than 100 mg/24hrs 
at the day of death, which is considered a low-to-moderate dose27-29. In two other 
studies more than 90% of the patients received low-to-moderate morphine doses 
either upon admission27 or in the last 24 hours before death28.
The median subcutaneous midazolam dose (60 mg/24hrs) at the day of death 
in the present study fits within the range found in other studies; mean midazolam 
doses of 26 to 70 mg/24hrs during the last days of life30, 31, 39. Moreover, these 
doses (IQR 30-65mg/24hrs, in present study) are recommended in the Dutch 
national guideline for palliative sedation5. However, midazolam dose titration 
should be guided by regular assessment of level of sedation. 
The median haloperidol dose was 2 mg/day, both at admission and the day of 
death. Other studies found median haloperidol doses of 2.5 to 3.8 mg/day during 
the last days of life30, 32. The Dutch national guideline for delirium treatment, 
however, recommends a maximum parenteral maintenance dose of 10 mg/day5. 
In practice the recommended starting dose of 0.5 to 2 mg/day seems sufficient to 
treat delirium in most patients. Moreover, in elderly patients a low starting dose 
is recommended to prevent neurological and cardiovascular effects25.
Over the admission period a shift occurred from the oral route to mainly the 
subcutaneous route, in line with recommendations from both guidelines5, 6 and 
the Liverpool Care Pathway for the dying38. The subcutaneous route is preferred 
in palliative care because most patients are unable to take oral medication at 
the end of life and the intravenous route is often complicated by infection or 
discomfort. Absorption via the subcutaneous route may be suboptimal, however, 
especially in cachectic cancer patients with very little or no subcutaneous fat. 
Although the subcutaneous route is preferred in palliative care, this route has 
not been fully studied. In addition, midazolam and haloperidol are unlicensed 
or off-label in this patient group15, 16, 40, 41. Regarding opioids, only small and 
mostly non-randomized controlled clinical trials have compared the subcutaneous 
route with another route of administration12, 42. In those studies similar feasibility, 
efficacy and opioid doses were found for the subcutaneous route and the intra-
venous route. Moreover, in some studies the subcutaneous route was preferred 
because of lower complication risks. Only small and outdated prospective stud-
ies are available for midazolam, which all found subcutaneous administration 
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of midazolam to be feasible and effective39, 43, 44. Regarding haloperidol, only 
retrospective descriptive studies or overview articles are available, even without 
addressing the administration route45-48. In conclusion, strict monitoring of the 
efficacy of subcutaneous morphine, midazolam and haloperidol is essential and 
more pharmacokinetic and pharmacodynamics studies are needed.
strengths and limitations
A strength of the present study is that actually administered regular medication 
in the palliative care setting was evaluated at two significant time points, detail-
ing drug doses and routes of administration. In addition, electronically recorded 
prescriptions were available, preventing the errors of written medication orders 
when extracting data.
Several limitations should be addressed however. First, this was a single-centre 
study of which the results cannot be extrapolated to other palliative care settings 
or other countries as prescription practices may differ. Second, as needed pre-
scriptions were excluded from analysis, since our electronic prescription system 
did not detail how much as needed medication was actually given. In our centre, 
‘as needed’ prescriptions mainly serve to increase the already prescribed doses 
of the medications, for example when worsening of symptoms is expected. When 
a patient is given the ‘as needed’ medication on a regular basis, the maintenance 
prescription dose is adapted accordingly.  Unfortunately, also indications for drugs 
could not be analysed, since this information was not electronically recorded. In 
future research, both the as needed medication and the indications should be 
included, so as to provide a complete overview of administered symptom-specific 
drugs. Lastly, outcomes of validated assessment instruments for pain, sedation 
and delirium were not available. In future research these assessments should be 
included to add information on the efficacy of drugs.
From the above it follows that pharmacotherapy in palliative care offers room for 
improvement. Therefore, we would recommend to strictly monitor the efficacy 
of the subcutaneously administered drugs with the use of validated pain, seda-
tion and delirium assessment instruments. This will help recognize worsening of 
symptoms and enable to taper treatment to a patient’s needs.
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Supplement Table S1. Top-10 ATC drugs classes (in bold) at admission (Ta) and the 
day of death (Td); given in descending order for the day of death
Drug classes
Top 10
Ta (N=194) Td (N=202)
N (%) N (%)
Analgesics 110 (56.7) 191 (94.6)
Psycholeptics 103 (53.1) 161 (79.7)
Drugs for functional gastrointestinal 
disorders 36 (18.6) 84 (41.6)
Laxatives 100 (51.5) 37 (18.3)
Drugs for acid related disorders 118 (60.8) 28 (13.9)
Corticosteroids for systemic use 55 (28.4) 16 (7.9)
Anti-epileptics 31 (16.0) 14 (6.9)
Dermatological preparations 12 (6.2) 13 (6.4)
Drugs for obstructive airway disease 29 (14.9) 12 (5.9)
Diuretics 28 (14.4) 12 (5.9)
Beta blocking agents 40 (20.6) 8 (4.0)
Psycho-analeptics 31 (16.0) 8 (4.0)
Antithrombotic agents 52 (26.8) 5 (2.5)
Supplement Table S2. Analgesics at admission (Ta; N=194) and at the day of death 
(Td; N=202); given in descending order for the individual drugs per drug class at the 
day of death
AtC 
therapeutic 
subgroup
WHO 
groups
ta td individual 
drugs
ta td
N (%) N (%) N (%) N (%)
Analgesics
Opioids 82 (42.3) 187 (92.6)
Morphine 41 (21.1) 175 (86.6)
Fentanyl 29 (14.9) 61 (30.2) 
Oxycodone 16 (8.2) 4 (2.0)
Hydromorphone 1 (0.5) 2 (1.0)
Tramadol 5 (2.6) 1 (0.5)
Non-opioids 66 (34.0) 20 (9.9) Acetaminophen+codeine
65 (33.5)
1 (0.5)
20 (9.9)
-
Anti-
inflammatory 
and anti-
rheumatic 
drugs
NSAIDs 19 (9.8) 5 (2.5)
Diclofenac 11 (5.7) 3 (1.5)
Ibuprofen or 
naproxen
4 (2.1) 2 (1.0)
Celecoxib or 
etoricoxib
4 (2.1) -
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Supplement Table S3. Combinations of analgesics according to the WHO grouping 
at admission (Ta) and the day of death (Td); given in descending order for the day of 
death
Single or combination of regular 
analgesics
Ta (N=194) Td (N=202)
N (%) N (%)
Single opioid 36 (18.6) 119 (58.9)
Combination of opioids 3 (1.5) 49 (24.3)
Non-opioid and opioid(s) 33 (17.0) 15 (7.4)
Single non-opioid 24 (12.4) 3 (1.5)
NSAID and opioid(s) 5 (2.6) 3 (1.5)
Non-opioid, NSAID and opioid(s) 5 (2.6) 1 (0.5)
Non-opioid and NSAID 4 (2.1) 1 (0.5)
Single NSAID 5 (2.6) -
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Drugs for functional gastrointestinal disorders
Laxatives
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Drugs for obstructive airway disease
Diuretics
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Psycho-analeptics
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Supplement Figure S1. Differences in top-10 ATC drugs classes at admission (dark 
grey bars) and at the day of death (white bars); shown in descending order for the 
day of death
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AbstrACt
background: Pathophysiological changes at the end of life may affect phar-
macokinetics of drugs. However, caregivers typically do not extensively monitor 
patients’ laboratory parameters at the end of life.
Objective: To describe laboratory parameters of hospice patients in the week 
before death. 
Methods: A cohort study on available laboratory results in the week before 
death, including clinical chemistry and haematology tests.
Setting/Subjects: Patients in a palliative care centre.
results: Laboratory data of 125 patients were included, assessed at a median of 
3 days before death. Eighty percent of patients had anaemia and almost all had 
hypoalbuminemia (97%). Elevated levels of gamma-glutamyltransferase were 
found in 75%, of alkaline phosphatase in 60%, of aspartate aminotransferase in 
60% and of calcium in 68%. Alanine aminotransferase, bilirubin, sodium and po-
tassium were abnormal in from 8.8% to 36.0% of patients. A previous unknown 
poor kidney function was found in 60% of patients. Thirteen patients (22%) 
with a regular morphine prescription and one patient treated with an NSAID had 
severe kidney failure. 
Conclusions: Abnormal laboratory results were expected due to the pathophysi-
ological changes that occur during the last phase of life. Remarkably, however, 
electrolytes (sodium and potassium) were balanced even shortly before death. 
eGFR, reflecting the kidney function, seems the most clinically relevant labora-
tory parameter, since it may guide drug choice and dosing.
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bACkGrOunD
In Europe most patients (>90%) who are cared for in a hospice suffer from an 
advanced malignancy1. In contrast, the proportion of cancer patients is notably 
smaller (40%) in hospices in the United States2. These patients often show a 
gradual decline in physical health and functional status, like in chronic illness3, 4. 
This, combined with a lower oral intake may result in weight loss and cachexia, 
liver impairment and kidney failure5, 6, eventually leading to end-stage organ 
failure, affecting the heart, kidneys, lung and gastro-intestinal tract7, 8. The most 
marked deterioration is clinically seen in the last few days. Several aspects of 
pharmacokinetics, including the absorption, distribution, metabolism and elimi-
nation of drugs, may then change as well (table 1). As these pharmacokinetic 
changes have hardly been systematically described in palliative patients7, 9, 10, 
they are extrapolated from other patient populations, such as cancer patients11, 12, 
elderly patients13-19 and intensive care patients20-23. 
The pharmacokinetic changes can result in a prolonged drug effect and ac-
cumulation of drugs. To prevent side effects it may be necessary to reduce the 
doses of sedatives and analgesics, which are often prescribed at the end of life24, 
or to choose another drug. The latter is recommended by European Association 
of Palliatieve Care (EAPC)25 and the Dutch palliative pain guideline26 for the use 
of opioids in palliative patients with renal failure; both recommend prescribing 
another opioid, such as fentanyl, buprenorphine or hydromorphone, instead of 
Table 1. Potential pharmacokinetic changes at the end of life
Pharmacokinetic 
parameter
Pathophysiological change or 
relevant disease state
Effect
Absorption Malignancy of digestive organs
Intestinal complications (vomiting or 
ileus)
Subcutaneous route of administration
Diminished absorption of drugs
Distribution Change in body composition
Lowered serum albumin (both due to 
cachexia in advanced malignancies or 
chronic disease state)
Lowered volume of distribution 
of lipophilic drugs
Greater portion unbound drug 
in serum
Metabolism Hepatic disease (primary malignancy or 
secondary disease, like metastasis)
Reduced hepatic function 
Increase in half-life of drugs 
metabolized by the liver
Increased risk for drug-drug 
interactions
Elimination Kidney disease (primary or secondary 
disease)
Decrease of GFR
Increase in half-life of renally 
eliminated drugs
GFR, glomerular filtration rate 
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morphine in patients with renal failure. The latter guideline proposes to adjust 
drug doses in the case of liver of kidney failure26 to avoid a negative impact on 
the quality of dying. 
Only a few studies describe actual laboratory results during the last month27, 28 
or last week29-31 of life. However, the primary aim of these studies was not to 
describe laboratory results in relation to pharmacokinetics, and in most cases 
only few parameters were assessed, such as sodium, potassium and albumin. 
Therefore we aimed to describe the results of a more complete panel of labo-
ratory results of hospice patients in the week before death. Furthermore, we 
evaluated the relevance of the laboratory parameters for the pharmacokinetics of 
drugs often used in patients at the end of life. As pronounced pathophysiological 
changes occur prior to death, we hypothesised, that laboratory results of patients 
shortly before death may be quite abnormal with consequences for the choice of 
drugs and the dosing of sedatives and analgesics.
MEtHODs
Design and setting
This observational cohort study was performed in Laurens Cadenza in Rotterdam, 
the Netherlands. This is the largest palliative care centre in the Netherlands, with 
20 beds for end-of-life care and symptom management; 200 to 250 patients are 
admitted annually. A multidisciplinary team of health care professionals, includ-
ing specialised nurses and elderly care physicians specialised in palliative care, is 
available 24 hours per day. Dutch palliative guidelines form the core for clinical 
practice, including the abstinence, in principle, of artificial fluids or nutrition in 
the last few days of life26.
Data collection
All available laboratory results, including clinical chemistry and haematology 
tests, from April 2009 till September 2013, were extracted from the electronic 
medical records. Subsequently, only the last results of patients in their last week 
before death were selected. All patients died in the palliative care centre. There 
is no policy for routine testing at admission or during the admission. In practice, 
laboratory testing, including clinical chemistry and haematology tests, is often 
done in the first one or two weeks after admission and as follow-up testing if 
needed. In a number of patients (48/125, 38.4%) laboratory tests were requested 
in the context of a drug study, and in the other patients laboratory testing was 
done at the physician’s discretion and for clinical purposes only. Common indica-
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tions for laboratory testing were monitoring a patient’s health status, guiding 
medication use, finding causes of symptoms or guiding symptom management, 
such as weighing the need for a blood transfusion in the case of severe anaemia.
Laboratory parameters
The following serum parameters were available for the majority of patients in 
their final week: haemoglobin (Hb), alanine aminotransferase (ALAT), aspartate 
aminotransferase (ASAT), gamma-glutamyltransferase (gGT), alkaline phospha-
tase (ALP), total bilirubin (Bili), albumin, sodium (Na), potassium (K), calcium 
(Ca) and creatinine (from which the glomerular filtration rate was calculated). 
The reference values of the hospital laboratory are given in Table 2. 
Table 2. Laboratory results of palliative patients in the final week before death 
(N=125), including the corresponding laboratory reference values
Parameter n
Laboratory result
Median; IQR
Abnormal results Laboratory reference 
valuesN (%)
male female low high male female
Hb
in mmol/l
(in g/dl)
86
6.3; 5.3 to 
7.5
(10.1; 8.5 to 
12.1)
6.4; 4.8 to 7.6
(10.3; 7.7 to 
12.2)
69 
(80.2) -
8.5 to 11.0
(13.7 to 
17.7)
7.5 to 10.0
(12.1 to 
16.1)
ALAt
in U/l 106 18; 10 to 34 18; 8 to 47 -
27 
(25.4) 0 to 41 0  to 31
AsAt
in U/l 104 39; 23 to 83 36; 28 to 65 -
62 
(59.6) 0 to 37 0 to 31
gGt
in U/l 108 61; 44 to 145 95; 45 to 343 -
81 
(75.0) 0 to 50 0 to 35
ALP
in U/l 108 139; 89 to 301 -
65 
(60.2) 0 to 120
bili
in umol/l
(in mg/dl)
100 11; 7 to 20(0.6; 0.4 to 1.2) -
27 
(27.0)
0 to 17
(0 to 1.0)
Albumin
in g/l 115 23; 20 to 27
112 
(97.4) - 35 to 50
na
in mmol/l 114 137; 133 to 140
41 
(36.0) 10 (8.8) 135 to 145
k
in mmol/l 113 4.2; 3.7 to 4.7
13 
(11.5)
18 
(15.9) 3.5 to 5.0
Cacorr
in mmol/l
(in mg/dl)
94 2.76; 2.63 to 2.95(11.0; 10.5 to 11.8) -
64 
(68.1)
2.20 to 2.65
(8.8 to 10.6)
eGfr 115 63; 33 to 94 Displayed in table 4
For Hb, Bili, and Ca also, the values in US units are given between parentheses.
ALAT, alanine aminotransferase; ALP, alkaline phosphatase; ASAT, aspartate aminotransferase; 
Bili, total bilirubin; Ca, calcium; Cacorr, calcium level corrected for albumin level; eGFR, estimated 
glomerular filtration rate; gGT, gamma-glutamyl transferase; Hb, haemoglobin; IQR, interquartile 
range; K, potassium; Na, sodium
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The calcium levels were corrected for albumin levels according to the following 
equation: Ca+0.025(40-albumin)32. The corrected calcium levels are presented 
(Cacorr).
The glomerular filtration rate (eGFR) was estimated using the Modification of 
Diet in Renal Disease (MDRD) formula33. This MDRD formula includes four vari-
ables: serum creatinine, age, ethnicity and gender and is accurate for estimating 
eGFR across a wide range of subgroups for eGFR <60ml/min/1.72m2. An eGFR of 
less than 30ml/min is considered to reflect a poor kidney function.
Other variables
Age, gender, diagnoses, and duration of admission were extracted from the elec-
tronic medical records; the primary diagnoses and the number of comorbidities 
were evaluated. The primary diagnoses refer to the WHO’s International Classifi-
cation of Diseases (ICD-10 classification) coding for the patient’s terminal illness. 
For each patient pre-existing liver diseases, (including primary or secondary liver 
malignancies, cirrhosis and hepatitis) and pre-existing kidney diseases (including 
primary or secondary kidney malignancies) were recorded. 
The prescriptions of regular medication were extracted from the pharmacy 
database, including drug name, dose, frequency, route of administration, and 
dates of start and discontinuation of the prescription. Drugs were prescribed 
according to the symptom-specific Dutch national palliative guidelines26. For this 
study data of morphine (administered orally or subcutaneously) and non-steroidal 
anti-inflammatory drugs (NSAIDs, administered orally or rectally) were analysed.
Daily morphine doses were calculated taking into account the route of ad-
ministration, so a subcutaneous equivalent was used for analysis26, 34. A daily 
subcutaneous morphine dose of less than 100 mg/24hours was considered a 
low-to-moderate dose35-37.
statistical analysis
Data were analysed using descriptive statistics. Data are presented as mean 
(standard deviation; SD) in case of normally distributed variables and as median 
(interquartile range = IQR or minimum-maximum range = range) in case of 
non-normally distributed variables. Data analyses were performed using IBM 
SPSS Statistics 20 (IBM Corp., Armonk, NY). A p-value of < 0.05 (two-sided) was 
deemed statistically significant.
Ethics
Given the retrospective nature of the study ethical approval was waived according 
to Dutch law. All patient data were handled and processed in accordance with the 
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recommendations of Good Clinical Practice. For patients participating in a drug 
study (48/125) permission from the Medical Ethics Review Board of the Erasmus 
University Medical Centre was granted and written informed consent had been 
obtained from them for study purposes, including laboratory testing.
rEsuLts
Participants
Laboratory results from in total 285 patients were available over the given time 
period. Final week results were available of 125 patients, of which the last (or 
only) ones had been assessed at a median of three days (IQR 1 to 4) before 
death. These 125 patients’ median age was 75 years (IQR 64 to 81 years), 52% 
were female, and the median length of stay was 13 days (IQR 7 to 34 days). 
An advanced malignancy, mainly of the respiratory or digestive organs, was the 
reason for admission in 116 patients (93.6%). A pre-existing liver disease was 
recorded in 38 patients (30.4%), and a pre-existing kidney disease in 18 patients 
(14.4%). See further Table 3.
Laboratory results
In 80.2% of 86 patients the Hb levels were below the reference values. Median Hb 
levels were 6.3mmol/l (10.1g/dl) for men and 6.4mmol/l (10.3g/dl) for women. 
Albumin levels were markedly below the reference values in 97.4% of 115 pa-
tients, with a median level of 23g/l (IQR 20 to 27). The median levels of several 
liver enzymes were too high for a major proportion of patients: gGT in 75.0% of 
108 patients, ALP in 60.2% of 108 patients and ASAT in 59.6% of 104 patients. 
The median Cacorr levels were above the normal range for 68.1% of 94 patients. 
ALAT, Bili, Na and K were abnormal in smaller proportions (8.8% to 36.0%) of 
patients. The median eGFR was 63 mL/min (IQR 33 to 94). See further table 2.
In 25/115 patients (21.7%) the eGFR was <30ml/min, indicating a poor kid-
ney function. Only 10 of the patients (40.0%) were known with a pre-existing 
kidney disease (table 4). In 12 of the patients (48.0%) an eGFR <30ml/min was 
accompanied with an increased Cacorr (>2.65mmol/l).
Levels of the liver enzymes (table 5) were within the normal range in fewer 
patients with a documented pre-existing liver disease (10.5 to 47.4% of 38 
patients) than in patients without that disease (26.4 to 71.3% in 87 patients). 
Moreover, the median levels of ASAT, ALP and gGT were distinctly higher in the 
patients with a pre-existing liver disease.
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Table 3. Patient characteristics
Characteristics N=125
Gender in %
Male / female 48 / 52 
Age in years; Median (IQR) 75 (64 to 81)
Duration of admission in days; Median (IQR) 13 (7 to 34)
Assessment days before death; Median (IQR) 3 (1 to 4)
Primary diagnosis in N (%)
Neoplasms 117 (93.6) 
Respiratory and intra-thoracic organs 32 (27.4) 
Digestive organs 29 (24.8) 
Lymphoid, hematopoietic and related tissue 13 (11.1) 
Breast 9 (7.7) 
Female genital organs 7 (6.0) 
Male genital organs 6 (5.1) 
Urinary tract 5 (4.3) 
Eye, brain and other parts of central nervous  system 4 (3.4) 
Ill –defined, secondary and unspecified sites 4 (3.4) 
Other 8 (6.8) 
Disease of circulatory system 4 (3.2) 
Disease of digestive system 2 (1.6) 
Other 2 (1.6) 
Pre-existing liver disease in N (%)
Yes 38 (30.4) 
Secondary malignancy in liver 33 (86.8) 
Primary malignancy in liver 3 (7.9) 
Other 2 (5.3) 
No or not documented clearly 87 (69.6) 
Pre-existing kidney disease in N (%)
Yes 18 (14.4) 
Not otherwise specified 8 (44.5) 
Primary malignancy in kidney 4 (22.2) 
Secondary malignancy in kidney 2 (11.1) 
Drug induced kidney disease 2 (11.1) 
Other 2 (11.1) 
No or not documented clearly 107 (85.6) 
Co-morbidities
Median (IQR) number of diagnoses 3 (1 to 4) 
IQR, interquartile range
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Prescriptions of nsAiDs and morphine
Medication data during the last week of life in combination with an eGFR value 
were available for 102/125 patients (81.6%); for 22/25 (88.0%) patients with a 
poor kidney function and for 80/90 (88.9%) with an eGFR >30ml/min. 
Table 4. Renal function in patients with and without a pre-existing kidney disease 
eGfr categories
in ml/min/1.73m2
total 
N=125
Pre-existing 
kidney disease
 N=18
no known
pre-existing 
kidney disease 
N=107 
Number (%) of 
patients
Number (%) of 
patients
Number (%) of 
patients
0-14
(kidney failure)
6 (4.8) 3 (16.7) 3 (2.8)
15-29
(severe kidney disease)
19 (15.2) 7 (38.9) 12 (11.2)
30-59
(moderate kidney disease)
31 (24.8) 6 (33.3) 25 (23.4)
60-89
(mild kidney disease)
27 (21.6) 1 (5.6) 26 (24.3)
>90
(very mild or no kidney 
disease)
32 (25.6) 1 (5.6) 31 (29.0)
eGFR was not assessed in 
the final week
10 (8.0) -- 10 (9.3)
eGFR, estimated glomerular filtration rate
Table 5. Results of liver test for patients with and without pre-existing liver disease
Liver 
tests
total 
N=125 
Pre-existing liver disease 
N=38
no known pre-existing liver 
disease
N=87
Number (%) of 
patients within 
normal range
Number (%) of 
patients within 
normal range
Laboratory 
result
Median (IQR)
Number (%) of 
patients within 
normal range
Laboratory 
result
Median (IQR)
Bili 73/100 (73.0) 18 (47.4) 14 (7 to 53) 55 (63.2) 10 (7 to 15)
ALAT 79/106 (74.5) 17 (44.7) 34 (17 to 79) 62 (71.3) 14 (9 to 27)
ASAT 42/106 (39.6) 6 (15.8) 85 (36 to 273) 36 (41.4) 34 (23 to 45)
ALP 43/108 (39.8) 6 (15.8) 312 (158 to 
766)
37 (42.5) 117 (81 to 153)
gGT 27/108 (25.0) 4 (10.5) 315 (95 to 897) 23 (26.4) 56 (32 to 103)
ALAT, alanine aminotransferase; ALP, alkaline phosphatase; ASAT, aspartate aminotransferase; Bili, 
total bilirubin; gGT, gamma-glutamyl transferase; IQR, interquartile range
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Twelve patients were on regular treatment with oral or rectal NSAIDs in the 
last week of life. One of six of these patients whose kidney function was checked 
in the last week had severe renal failure (eGFR 20ml/min). 
Morphine was prescribed on a regular basis via the oral or subcutaneous route 
for 94/102 patients (92.2%). Kidney function was checked in 60 of them (63.8%) 
and in 13 of those (21.7%) had severe renal failure: median eGFR of 21ml/min 
(range 5 to 28). A low to moderate subcutaneous equivalent morphine dose 
(<100mg/day) was administered to 12/13 patients (92.3%) with poor kidney 
function versus 39/47 (83.0%) patients with an eGFR >30ml/min. The median 
morphine daily dose in patients with severe kidney failure was 30mg (IQR 15 to 
60) and not different from the 30mg (IQR 15 to 75) morphine dose in patients 
with eGFR >30ml/min.
DisCussiOn
This study found that most patients had anaemia (80%) or hypoalbuminemia 
(97%) in their last week of life and that many (60 to 75%) had elevated levels 
of gamma-glutamyltransferase (gGT), alkaline phosphatase (ALP), aspartate 
aminotransferase (ASAT) or corrected calcium (Cacorr) levels. Notably, levels of 
alanine aminotransferase (ALAT), bilirubin, sodium and potassium were within 
the normal range for most patients (abnormal in 8.8% to 36.0%). In 60% of 
patients whose kidney function proved to be poor (eGFR <30ml/min) this was 
not documented in the medical history. Some patients with severe kidney failure 
were on treatment with a NSAID and morphine (1 and 13 patients respectively), 
which is not recommended in palliative treatment guidelines25, 26. 
Both lowered albumin and haemoglobin levels are related to chronic disease 
and are therefore not surprising in this population of mainly oncology patients. 
Severe anaemia (Hb < 5.0mmol/l, 8.0g/dl)38 was found in 20% of patients. The 
prevalence of anaemia in the present study (80%) is comparable to that in other 
studies in palliative care patients (72% to 82%)27, 28, 39. Differences in case mix or 
patient population and in timing of laboratory testing (table 6) will influence the 
prevalence of anaemia. To illustrate this, one study excluded the very ill patients 
and found anaemia in 77% of men and 68% of women39. 
The prevalence of hypoalbuminemia (albumin <35g/l) differs between studies. 
In the present study almost all patients had hypoalbuminemia (97%) compared 
to only two thirds in the referred studies27, 28. This discrepancy might be explained 
by a difference in the median time till death (table 6); 3 days in the present study 
versus about 1 month in the other studies27, 28. Moreover, hypoalbuminemia is 
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expected in end-of-life patients since these patients often suffer from oedema, 
ascites, carcinomatous pleural effusion and are in a cachectic state28. Some stud-
ies suggest that albumin level may help predict the time till death in oncology 
or palliative patients; the lower the level, the nearer to death40-42. However, this 
prognostic value of albumin levels was not confirmed in all studies; especially in 
studies testing multiple factors different outcomes are described43-45. 
Albumin is an important protein for the transport of various drugs in 
plasma46, 47. Therefore, hypoalbuminemia may lead to a significant decrease of 
protein binding capacity of drugs and an increase in the unbound drug fraction, 
which could strengthen the pharmacological effect. The extent of this phenom-
enon is debated; the theory and clinical relevance may be contradictory. Benet 
and co-workers concluded that, clinically, for changes in plasma protein binding 
adjustment of a drug dose is not necessary, except for drugs with a high extrac-
tion ratio and a narrow therapeutic index that are given parenterally48. Midazolam 
and haloperidol are often prescribed in palliative care24 and both are listed in the 
referred paper as drugs in which protein binding may influence clinical drug expo-
sure48. However, the actual consequences for in clinical practice remain unknown.
The abnormal liver enzyme test results in the present study do not all tally 
with those in previous studies27. Laboratory tests of liver enzymes are notori-
ously bad indicators for liver function. Unfortunately, the levels of liver enzymes, 
even if severely elevated, do not predict a change in hepatic function, including 
drug metabolism49, 50. Moreover, liver enzymes may be elevated for other reasons 
than liver disease only, such as polypharmacy, alcohol consumption, metastatic 
disease or other organ diseases51. Bilirubin levels may reflect bile duct related 
problems (obstruction), while metabolic liver capacity is normal.
Hypercalcemia was found in 68% of patients in the present study versus 7% 
in another study27. This discrepancy might be explained by the median time till 
death (table 6), i.e. 3 days versus 26.5 days. In 48.0% of patients hypercalcemia 
was accompanied with kidney failure, possibly due to severe dehydration.
The median eGFR in our study population was 63ml/min. Seeing that the 
median age of this population was 75 years, this value reflects the physiological 
changes in renal function associated with advanced age52. Severe kidney failure, 
however, was found in 19% of patients. Kidney function impairment may be the 
result of a variety of underlying causes in cancer patients, including dehydration 
and extra-renal obstruction11. While an altered kidney function may be caused by 
drug treatment, poor renal function in its turn can have pharmacological conse-
quences. This is illustrated by the finding of higher metabolite concentrations in 
patients with a worse kidney function7, 53. Those patients with kidney failure might 
be at risk for opioid-induced side effects, since metabolites will accumulate. In 
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our study most patients with poor kidney function were on treatment with a 
low-to-moderate morphine daily dose (92%), perhaps because the accumulation 
had resulted in stronger effects, and the dose needed to be reduced.
Remarkably, most of our patients had normal levels of sodium and potassium. 
This is also described in other studies during the last month27 and the last week of 
life29-31, indicating that these electrolytes even shortly before death are balanced.
To the best of our knowledge, this is the first overview of laboratory results 
in the week before death in hospice patients. We were also able to include data 
on actual morphine and NSAID use. An additional strength of our study is that 
we related the laboratory results to probable pharmacokinetic effects. Generally, 
in such a vulnerable patient population, the possibly negative impact of blood 
taking should be weighed against the benefits of the laboratory results. However, 
even in end-of-life patients, laboratory testing may be used to monitor or guide 
pharmacological treatment, to assess the need for additional treatment like blood 
transfusion or to explain symptoms like fatigue, confusion or vomiting. This is 
illustrated by one study in a palliative care unit, which concluded that 96% of 
the cases of laboratory testing were clinically relevant to confirm or exclude a 
diagnosis and that 30% resulted in a change of drug therapy54. 
Several limitations of this study have to be addressed however. This was a 
single-centre study in patients with mainly oncologic disease, so that findings 
should be extrapolated with caution. Furthermore, clinical details on diagnoses, 
mainly liver and kidney disease, could be incomplete. In a palliative care set-
ting the observation of impaired kidney function will not lead to an exhaustive 
diagnostic work-up to identify the cause. This might have consequences for the 
classification of patients having a pre-existing kidney or liver disease. In addition, 
the exact severity of the kidney or liver disease was not detailed and all diseases 
states were therefore grouped together. Unfortunately, symptoms had not been 
routinely recorded with validated objective scoring instruments. And then, not 
for all included patients medication data were available. It would be of added 
value to relate laboratory results to validated symptom scores and administered 
medication in future research, since this may give additional insights into the 
clinical relevance of the abnormal laboratory results.
COnCLusiOn
In conclusion, although clinically relevant abnormal values were found for several 
laboratory parameters, five out of eleven parameters studied were within the 
normal range for most of patient in their last week of life. Anaemia and hypo-
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albuminemia were not unexpected, due to the physiological changes that occur 
during the last phase of life. Remarkably, electrolytes were balanced even shortly 
before death. The most clinically relevant laboratory parameter seems to be 
eGFR, reflecting the kidney function, as for some drugs (including morphine and 
NSAIDs) adverse effects may negatively impact on quality of life and knowledge 
of eGFR may assist in deciding on drugs and their dosing.
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AbstrACt
Background and objective: Morphine dosing can be challenging in terminally 
ill adult patients due to the heterogeneous nature of the population and the 
difficulty of accurately assessing pain during sedation. To determine the phar-
macokinetics of morphine (M), morphine-3-glucuronide (M3G) and morphine-6-
glucuoride (M6G) in this population, and to find clinically relevant parameters for 
dose individualisation we performed a population pharmacokinetic analysis.
Methods: Blood samples were randomly collected from 47 terminally ill patients 
in both the pre-terminal and terminal phase. Non-linear mixed-effects modelling 
(NONMEM) was used to develop a population pharmacokinetic model and perform 
covariate analysis.
results: The data were accurately described by a two-compartment model for 
morphine with two one-compartment models for both its metabolites. Typical 
morphine clearance (Cl) was 48L/h and fell exponentially by more than 10L/h in 
the last week before death. Decreased albumin levels and a decreased estimated 
glomerular filtration rate (eGFR) resulted in lower metabolite clearance. Between-
subject variability in CL was 52% (morphine), 75% (M3G) and 79% (M6G) and 
changed to 53, 29 and 34%, respectively, after inclusion of the covariates.
Conclusion: Our results show that morphine clearance decreased up to time 
of death, falling by more than 10l/h (26%) in the last week before death, and 
that M3G and M6G accumulated due to decreased renal function. Further studies 
are warranted to determine whether dose adjustment of morphine is required in 
terminally ill patients.
PK of morphine in terminally ill adults 113
intrODuCtiOn
Morphine is widely used to treat pain and dyspnoea in terminally ill patients1. 
A recent study showed that at the time of death, 87% of the patients in pal-
liative care were treated with morphine2. Morphine is metabolised mainly into 
morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G). M6G is phar-
macologically active and contributes to the analgesic effect3-5. M3G does not have 
any analgesic properties yet it has been suggested that it may be responsible 
for the side effects of morphine6, 7. As the morphine dose is determined clinically 
according to the patients’ need, accurate pain assessment is crucial. However, in 
terminally ill patients this can be difficult as pain assessment can be complicated 
by delirium or palliative sedation8-11. Another difficulty with morphine dosing in 
this population is that its pharmacokinetics are likely to be highly variable. To 
date, no studies have been conducted on the pharmacokinetics of morphine in 
this specific population, although variability between patients is to be expected 
due to the heterogeneous nature of this population, e.g. differences in age, di-
agnosis and comorbidities. This variability is further increased by changes within 
patients over time, which can be caused by the physiological changes that occur 
as death approaches, such as cachexia and a decrease in renal function12-15.
Together with the difficulty of assessing pain in these patients, this significant 
interpatient and intrapatient variability indicates the need for a dosing algorithm. 
The first step in developing an individualised dosing regimen is to gain more 
insight in the pharmacokinetics in this specific patient population. There have 
been very few studies performed in hospice patients and to our knowledge no 
population pharmacokinetics of morphine have been performed in terminally 
ill patients. To determine the pharmacokinetics in this population and to find 
clinically relevant parameters for individualised dosing, we therefore performed 
a population pharmacokinetic analysis of morphine, M3G and M6G in terminally 
ill patients.
MAtEriALs AnD MEtHODs
study design
This prospective observational study in terminally ill patients was approved by the 
Medical Ethics Committee of the Erasmus University Medical Centre, Rotterdam, 
the local directors’ board of the Laurens organisation agreed to the practicability 
and this study was performed in accordance with the principles of the Declaration 
of Helsinki and its later amendments. The study was conducted in the palliative 
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Figure 1. Dose and concentration data of a representative patient over time. This 
individual had a decrease in renal function with a drop in eGFR form 41.1 to 16.3 at 
T=283h.
A: Daily doses of subcutaneous morphine over time until the time of death B: Morphine concen-
trations over time. Post-hoc predictions (solid line) and measured morphine concentrations (open 
circles) C: Metabolite concentrations over time. Post-hoc predictions of M3G (solid line) and M6G 
(dashed line), as well as measured M3G (triangles) and M6G (crosses) concentrations. eGFR, esti-
mated glomerular filtration rate; M3G, morphine-3-glucuronide; M6G, morphine-6-glucuronide
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care centre, Laurens Cadenza, Rotterdam, the Netherlands, over a 2-year period. 
Patients were included in the study upon admittance to the palliative care centre 
and were followed until the time of death. Inclusion criteria were terminal illness, 
prognosis survival of more than 2 days and less than 3 months, administration of 
morphine and patients had given informed consent.
Morphine was administered for pain and dyspnoea and was administered 
according to national palliative guidelines, daily doses ranging from 15mg to 
540mg16, 17. Figure 1 A shows a representative patient receiving increasing daily 
morphine doses over time. Morphine was administered orally as controlled re-
lease tablets or immediate-release liquid, or administered subcutaneous as bolus 
injection or infusion. The exact times of administration were recorded in the pa-
tient record. Any concomitant use of codeine was also registered in the patient’s 
record. Demographic characteristics (age, sex, weight, race, primary diagnosis, 
and time of death) were extracted from the electronic medical records. Primary 
diagnosis of the patient’s terminal illness was classified using the International 
Statistical Classification of Diseases and Related Health Problems–10th Revision 
(ICD-10).
Blood samples were collected randomly at various time points in both the pre-
terminal and terminal phases. The terminal phase was defined as the last hours 
to days before death in which a patient becomes bedbound, semi-comatose, is 
not able to take more than sips of fluid and is no longer able to take oral medica-
tion18. After collecting blood via either venipuncture or indwelling venous catheter 
samples were centrifuged, after which the plasma was collected and stored at 
-80°C until analysis. Blood sampling was preferably performed in combination 
with sampling for clinical chemistry (standard of care) for which serum levels 
of albumin, creatinine, urea, bilirubin, gamma-glytamyl transpeptidase (GGT), 
alkaline phosphatase (ALP), alanine transaminase (ALT), aspartate transaminase 
(AST), and C-reactive protein (CRP) were determined. With regard to these 
clinical chemical values, blood was collected in heparin tubes, centrifuged and 
analysed by the clinical chemistry laboratory as standard care for these patients.
Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) 
analysis
Morphine, M3G and M6G were analysed in the plasma samples using Liquid 
Chromatography-Tandem Mass Spectrometry (LC-MS/MS) with electrospray 
ionization in the positive ionization mode on a Shimadzu LC-30 (Nishinokyo-
Kuwabaracho, Japan) system coupled to a ABSciex (Framingham, MA, USA) 5500 
Qtrap MS. To 10µl of patients’ plasma, 75µl acetonitril/methanol 84:16 (v/v%) 
containing the internal standards morphine-d3, M3G-d3 and M6G-d3 was added 
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to precipitate proteins. Samples were vortexed, stored at -20°C for 30 minutes 
to optimise protein precipitation, vortexed again and centrifuged. A total of 3 µl 
was injected into a Thermo Scientific Hypersil Gold HILIC (50 x 2.1mm, 1.9µm) 
column. A stepwise chromatographic gradient was applied using 1% ammonium 
formate / 2% formic acid in water as mobile phase A and acetonitrile as mobile 
phase B. The flow rate was 0.6ml/min and the column was kept at 40°C. Using 
multiple reaction monitoring (MRM), morphine, M3G and M6G were measured as 
[M+H]+ using the mass transitions 286.1/165.1, 462.2/286.2 and 462.2/286.2, 
respectively. Retention times for morphine, M3G and M6G were 0.44, 2.77 and 
2.58 respectively. For the internal standards morphine-d3, M3G-d3 and M6G-d3 
were used with the same retention times and mass transitions of 289.1/165.1, 
465.2/289.2 and 465.2/289.2, respectively.
The method was validated over a range of 2 – 500µg/L for all compounds 
with six calibration curves each containing seven concentrations. The accuracies 
ranged from 93.5% to 105.5%. Intraday and interday precision were calculated 
with six replicates of four concentrations (2, 6, 60 and 500µg/L) for all com-
pounds and resulted in intraday and interday precisions below 9.6% and 12.9%, 
respectively. Three quality controls (low level 2µg/L, medium level 60 µg/L and 
high level 500µg/L) were validated and used for this method.
Population Pharmacokinetic modelling
Pharmacokinetic analysis was conducted by non-linear mixed-effects modelling 
using NONMEM® version 7.2 (ICON Development Solutions, Ellicott City, MD, 
USA) and PsN® version 3.7.6.
Base model development
The data were log-transformed and concentrations of M3G and M6G were ad-
justed to their morphine equivalents using the molecular weight. Bioavailability 
of subcutaneous morphine was assumed to be 100%19, 20. One- two- and three-
compartment models were tested for morphine and its metabolites using the 
first-order conditional estimation method with interaction (FOCE+I) and the 
ADVAN5 subroutine. First, a structural model for morphine was developed. These 
parameters were then fixed to test the different structural models for M3G and 
M6G. In the final model all parameters were estimated, with the exception of the 
transformation ratios for M3G and M6G. Since there was no information on the 
mass balance, the fractions of morphine transformed into metabolites and frac-
tions excreted could not be determined independently. These ratios were there-
fore set to previously described values, i.e. 0.55 for M3G and 0.10 for M6G21-23.
PK of morphine in terminally ill adults 117
Between-subject variability (BSV) was assessed on each parameter using an 
exponential and additive model, and residual variability was incorporated as an 
additive error on the log scale. Model selection was based on minimum objective 
function values (OFVs), parameter precision, error estimates, shrinkage values 
and visual inspection of the goodness-of-fi t plots.
Covariate model development
Demographic and disease characteristics including age, sex, race, primary 
diagnosis, renal function (estimated glomerular fi ltration rate (eGFR), plasma 
creatinine, and plasma urea), hepatic function (plasma levels of bilirubin, GGT, 
ALP, ALT, and AST), CRP, albumin, and the concomitant use of codeine, were 
evaluated as potential model covariates. Time to death (TTD) was also evaluated 
as a covariate. This parameter cannot be used as a covariate parameter for a 
priori prediction of individual pharmacokinetic changes but it may give insight in 
quantitative changes at the end of life that are not predicted by standard blood 
chemistry tests. As heart and respiratory rates are not measured in a palliative 
care centre, standard disease severity scoring systems used in internal medicine 
(e.g. the simple clinical score or rapid emergency medicine score) cannot be used 
in this situation. The relationship between covariates and individual estimates 
was fi rst investigated graphically and was further tested in a univariate analysis. 
Covariates that signifi cantly improved the model, (p ≤ 0.05) were added to the 
full model. A backward elimination process was then performed with statistical 
signifi cance indicated by p ≤ 0.001.
Continuous covariates were normalised to the population median values and 
incorporated as power model functions (Eq. 1). Categorical covariates were 
transformed to binary covariates and incorporated as shown in Eq. 2.
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With θi being the individual model-predicted pharmacokinetic parameter (e.g. 
clearance) for an individual with covariate value covi, θpop being the population 
estimate for that par meter, covm representing the median covariate valu  and 
θcov representing the covariate effect. In the equation for categorical covariates, 
covi is either 1 or 0.
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To evaluate the time to death (TTD) as a covariate, time-dependency of the 
parameters was modelled as a fi rst-order process given to following equation 
(Eq. 3).
representing the median covariate value and θcov the covariate effect. In the equation for 
categorical covariates covi is either 1 or 0. 
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In which θΔ is the change in parameter value from its initial value and θrate is a 
fi rst-order rate constant determining the rate with which the parameter v lue 
cha ges over time.
Model evaluation
A bootstrap with 500 runs was performed on the fi nal model to evaluate the valid-
ity of the parameter estimates and their corresponding 95% confi dence intervals 
(CIs). Due to the study design, i.e. sparse sampling, different dosing regimens 
and both oral and subcutaneous administrations, a visual predictive check could 
not be performed to evaluate the model. We therefore evaluated the predictive 
pe formance of the fi nal mod l using a normalised p ediction distr bution er-
rors (NPDE) analysis. NPDE is a simulation-based diagnostics which can be used 
to evaluate models developed on datasets with variable dosing regimens. The 
analytical value of this method has been previously described by Comets et al24.
rEsuL
A total of 47 terminally ill patients were included in the study. Their median age 
was 71 years (range 43 – 93), 55.3% were female and the median duration of 
admittance (from moment of admittance until time of death) was 33 days (range 
7 – 457). Almost all patients (95.7%) had advanced malignancy as primary di-
agnosis. Patient characteristics are given in Table 1. From these patients, a total 
of 152 blood samples were collected and analysed for morphine, M3G and M6G 
concentrations. Figures 1B and 1C show the concentrations of morphine, M3G 
and M6G over time for a representative patient. As shown in these graphs, the 
morphine concentration increases as the dose increases, and near the end of life 
M3G and M6G concentrations increase signifi cantly. Circa 12% of the plasma con-
centrations were below the quantifi cation limit (BLQ), largely due to two patients 
who had had blood samples taken more than 10 days after the last morphine 
dose. BLQ data were therefore discarded using the M1 method discussed before 
by Ahn et al25.
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Table 1. Patient characteristics
Characteristics n = 47
Age, years (median, range) 71 (43 - 93)
Male, n (%) 21 (44.7)
Female, n (%) 26 (55.3)
Ethnic origin, n (%)
Caucasian 45 (95.7)
Afro-Caribbean 2 (4.3)
Primary diagnosis, n (%)
Neoplasm 45 (95.7)
Disease of the circulatory system 1 (2.1)
Disease of the respiratory system 1 (2.1)
Blood chemistry, serum levels at admission (median, range)
Albumin, g/l 26 (14-39)
Urea, mmol/l 7.2 (1.5-43.4)
Bilirubin, umol/l 8 (3-256)
Gamma-glytamyl transpeptidase, U/l 64 (7-3859)
Alkaline phosphatase, U/l 112 (20-2117)
Alanine transaminase, U/l 12 (7-406)
Aspartate transaminase, U/l 32 (14-255)
C-reactive protein, U/l 67 (1-188)
Creatinine, umol/l 72 (22-229)
eGFR by standard MDRDa, ml/min/1.73 m2 96 (27-239)
eGFR by original MDRDb, ml/min/1.73 m2 83 (22-202)
Patients using codeinec, n (%) 2 (4.2)
Duration of stay, days (median, range) 33 (7 - 457)
Blood samples collected, n (median, range) 2 (1 – 10) 
eGFR, estimated glomerular fi ltration rate; MDRD, Modifi cation of Diet in Renal Disease
a The abbreviated MDRD equation consists of four variables (age, sex, race and serum creatinine) 
as shown in Eq. 4
b The original MDRD formula consist of six variables (age, sex, race, serum creatinine, serum albu-
min and serum urea) as shown in Eq. 5
c During any moment while receiving morphine treatment
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structural model
The data were best described by a two-compartment model for morphine and 
two one-compartment models for both its glucuronidated metabolites (Figure 2). 
Since limited data was available in the absorption phase, the absorption constants 
(Ka) could not be estimated, and were therefore fixed to known literature values 
(10 h-1 for subcutaneous injection, 6 h-1 for immediate-release liquid and 0.8 h-1 
for controlled release tablets)26, 27. The population mean estimates for volume 
of distribution were, 185 L (relative standard error [RSE] 28%) for the central 
morphine compartment (V1); 243 L (RSE 33%) for the peripheral morphine 
compartment (V2); 7.65 L (RSE 33%) for the M3G compartment; and 7.1L (RSE 
30%) for the M6G compartment. The population mean estimates for clearance 
were 37.2L/h (RSE 9%) for morphine; 1.48L/h (RSE 8%) for M3G and 1.87L/h 
(RSE 8%) for M6G. An overview of all parameter estimates is given in Table 2.
Including BSV on morphine clearance and bioavailability (F) of oral morphine 
both significantly improved the model fit with a change in OFV (ΔOFV) of -43.3 
and -7.05 respectively. The correlation between BSV of M3G and M6G clearance 
was high and fixed to unity. A similar approach was used for BSV on the volumes 
Figure 2. Schematic representation of the two-compartment model for morphine and 
its two main metabolites.
F, bioavailability of oral morphine; V1, central compartment for morphine; V2, peripheral compart-
ment for morphine; Q, intercompartmental clearance of morphine; Clt, total morphine clearance, 
Fm1, fraction of morphine clearance responsible for M3G formation; Fm2, fraction of morphine 
clearance responsible for M6G formation; Clr, remaining morphine clearance (Clt*1-(Fm1+Fm2)); 
ClM3G, clearance of M3G; ClM6G, clearance of M6G, M3G, morphine-3-glucuronide; M6G, morphine-6-
glucuronide
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Table 2. Parameter estimates of the base model, final model and bootstrap analysis
Parameter structural model 
final 
model
rsE 
%
shrinkage 
%
Bootstrap of the final model
Estimate 95% CI 
(lower)
95% CI 
(upper)
OFV -323.7 -351.6
Morphine
F 0.28 0.30 13.6 - 0.31 0.18 0.53
Cl (L/h) 37.2 47.5 11 - 49.9 39.1 75.6
V1 (L) 185 190 28 - 190 116 369
Q (L/h) 75 76.1 35.7 - 65.1 9.95 146
V2 (L) 246 243 19 - 248 121 377
M3G
Fm1 0.55a 0.55 a N/A - 0.55 a 0.55 a 0.55 a
Cl (L/h) 1.48 1.44 4.8 - 1.44 1.30 1.59
V1 (L) 7.65 8.02 33.2 - 7.75 3.62 14.9
M6G
Fm2 0.1 a 0.1 a N/A - 0.1 a 0.1 a 0.1 a
Cl (L/h) 1.87 1.78 6.8 - 1.79 1.56 2.05
V1 (L) 7.1 8.24 30.7 - 7.97 3.77 14.0
Covariate effect on M3G and M6G clearance
eGFRb 0.83 0.673 16.8 - 0.67 0.50 1.03
Albumin - 1.1 23.3 - 1.06 0.332 1.56
Covariate effect on M3G and M6G clearance
TTDc (Δ), days - 17.6 24.7 - 19.2 9.48 46.6
TTDc (rate), days - 0.13 32 - 0.12 0.05 0.31
Between subject variability (%)
F 48.2 37.8 38.3 9.5 38.7 1.7 58.0 
morphine Cl 54.0 53.4 30.1 13.3 50.0 31.7 71.8 
M3G Cl 39.7 29.3 29.2 5.5 29.3 20.4 41.7 
M6G Cl 43.5 34.3 29.2 5.5 34.1 23.8 48.4 
M3G V1 135.5 151.7 31.4 6.1 147.9 80.3 203.1 
M6G V1 130.4 143.0 31.4 6.1 141.5 76.8 194.4 
Residual variability
Morphine 0.448 0.432 10.4 10 0.425 0.335 0.510
M3G 0.250 0.246 9.3 10 0.239 0.194 0.282
M6G 0.261 0.265 6.6 10 0.254 0.218 0.294
RSE, relative standard error; CI, confidence interval; OFV, objective function value; F, bioavail-
ability; Cl, clearance; V1, central compartment; Q, intercompartmental clearance; V2, peripheral 
compartment; M3G, morphine-3-glucuronide; Fm1, fraction of morphine clearance responsible for 
M3G formation; M6G, morphine-6-glucuronide; Fm2, fraction of morphine clearance responsible for 
M6G formation; eGFR, estimated glomerular filtration rate; TTD, time to death; MDRD, Modification 
of Diet in Renal Disease; GFR, glomerular filtration rate
a Transformation ratios for M3G and M6G were fixed to known literature values
b GFR was estimated using the standard four-variable MDRD equation
c TTD was incorporated as a first order process, with TTDΔ (overall change in clearance) as the 
change in parameter value from its initial value and TTDrate (change in clearance per day as de-
scribed by the first order process) as the first order rate constant
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of distribution of the M3G and M6G. Adding BSV on metabolite clearance and 
metabolite volume signifi cantly improved the model fi t with a change in objective 
function of 157.0 and 41.1, respectively. In all cases, an exponential model for 
BSV proved superior to an additive model.
Since M3G and M6G are renally cleared, and because there were patients who 
developed renal failure over time, a measure for renal failure was added to the 
structural model. This was done by evaluating the covariate effect of creatinine 
levels, urea levels, and eGFR on metabolite clearance. Glomerular fi ltration rate 
was estimated using the generally excepted four-variable, Modifi cation of Diet 
in Renal Disease (MDRD) equation consisting of age, sex, ethnicity, and serum 
creatinine levels (Eq. 4)28. Estimated GFR gave the best results (ΔOFV -75.97 
vs -73.58 for creatinine levels and -66.77 for urea levels) and was therefore 
included in the structural model.
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Covariate analyse 
The structural model including eGFR on metabolite clearance was used as a reference for the 
covariate analysis. The univariate analysis resulted in a further eight significant covariates. Three 
of which were correlated with morphine clearance (i.e. time to death, bilirubin, and urea). Two 
were correlated with metabolite clearance (i.e. albumin and CRP). There were also two significant 
covariates correlated with the volume of distribution of the metabolites (i.e. creatinine and urea) 
and one was correlated with bioavailability (i.e. race). The results of the univariate analysis, in 
terms of decrease in OFV and covariate effect are shown in table 3. After the backwards elimination 
with P<0.001 only albumin levels on metabolite clearance and time to death on morphine 
clearance remained in the final model. 
Because the final model had both eGFR and albumin levels as covariates on metabolite 
clearance, we also tested if these two covariates could be replaced by the eGFR estimated using 
the original 6-variable MDRD formula (Eq. 5)28. This formula calculates GFR using not only gender, 
weight, race and creatinine levels but also takes into account albumin and urea levels. This more 
elaborate version of the MDRD equation did however not improve the model fit (OFV -342.9 versus 
-351.6 for the standard 4-variable MDRD equation). Estimated GFR and serum albumin together 
decreased the unexplained variability on M3G and M6G clearance from 75.4% and 79.1% to 29.3% 
and 34.3%. They hereby explain 61.1% of the BSV in M3G clearance and 56.6% of the BSV on 
M6G clearance. The covariate time to death did not decrease the unexplained variability on 
morphine clearance; however it did decrease the RSE on the volumes of both metabolites (from 
65.7% to 33.2% for M3G and from 63.8% to 30.7% for M6G).  
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variate analyse
 structural model including eGFR n metabolite clearance was used as a refer-
ence for the covariate analysis. The univariate analysis resulted in a further eight 
signifi cant covariates, three of which were correlated with morphine clearance 
(i.e. TTD, bilirubin, and urea), two were correlated with metabolite clearance 
(i.e. albumin and CRP), two were correlated with the volume of distribution of the 
metabolites (i.e. creatinine and urea), and one was correlated with bioavailability 
(i.e. race). The results of the univariate an lysis, in t rms of decrease in OFV and 
ovariate effect, are shown in Table 3. After backwards elimination of p<0.001, 
only albumin levels on metabolite clearance and TTD on morphine clearance 
remained in the fi nal model.
Because the fi nal model had both eGFR and albumin levels as covariates on 
metabolite clearance, we also tested if these two covariates could be replaced by 
the eGFR estimated using the original six-variable MDRD for ula (Eq. 5)28. This 
formula calc lates GFR using not only sex, weight, race and creatinine levels but 
lso takes into account albumin and urea levels. However, this more elaborate 
version of the MDRD equation did not improve the model fi t (OFV -342.9 versus 
-351.6 for the standard four-variable MDRD equation). Together, estimated GFR 
and serum albumin decreased the unexplained variability on M3G and M6G clear-
ance from 75.4% and 79.1% to 29.3% and 34.3%, respectively. They hereby 
explain 61.1% of the BSV in M3G clearance and 56.6% of the BSV on M6G clear-
ance. The covariate TTD did not decrease the unexplained variability on morphine 
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clearance; however, it did decrease the RSE on the volumes of both metabolites 
(from 65.7% to 33.2% for M3G, and from 63.8% to 30.7% for M6G).
 
   
Simulations 
Based on the final model the M3G clearance is reduced with about 30% (from 1.6L/h to 1.1L/h) 
when eGFR decreases form 90 to 50ml/min and albumin concentrations remain stable at 25g/L. A 
further reduction of eGFR to 30ml/min decreases M3G clearance to a value of 0.8L/h (Figure 5). 
The effect of a reduction of eGFR on metabolite clearance is shown in figure 1C where the 
concentrations of M3G and M6G increase in the last few hours. This individual had indeed a 
decrease in renal function with a drop of eGFR from 41.4 to 16.3 at T=283 hours. The final model 
also implies that with a stable eGFR of 78ml/min a decrease in albumin from 35g/l to 25g/l 
produces a 31% decrease of M3G clearance (from 2.1L/h to 1.4L/h) (Figure 6). Respective changes 
in M6G clearance are shown in Figures 5 and 6 as well and are similar to changes in M3G 
clearances. 
 (5)
simulations
Based on the fi nal model, the M3G clearance is reduced by approximately 30% 
(from 1.6L/h to 1.1L/h), while eGFR decreases form 90 to 50ml/min and albumin 
concentrations remain stable at 25g/L. A further reduction of eGFR to 30ml/min 
decreases M3G clearance to a value of 0.8L/h (Figure 3). The effect of a reduction 
Table 3. Covariate effects in univariate analysis compared with the structural model
Covariate ΔOFV Covariate effect included after 
backward elimination
Structural model -
Covariates on bioavailability
Afro-Caribbean Racea 6.36 0.52 No
Covariates on morphine Cl
Time to Death 9.65 20.2 and 0.11b Yes
Plasma Urea 7.04 -0.28 No
eGFRc 4.38 0.18 No
Plasma Bilirubin 4.06 -0.16 No
Covariates on metabolite Cl
CRP 16.4 -0.21 No
Plasma albumin 15.4 1.10 Yes
Plasma GGT 6.10 -0.11 No
Covariates on metabolite Vd
eGFRc 9.42 0.33 No
Plasma creatinine 8.16 -0.40 No
Time to death 7.92 -14.7 and 0.08b No
Plasma urea 6.65 -0.26 No
OFV, objective function value; CL, clearance; eGFR, estimated glomerular fi ltration rate; CRP, C-
reactive protein; GGT, gamma-glutamyl transpeptidase; Vd, volume of distribution; TTD, time to 
death; GFR, glomerular fi ltration rate; MDRD, Modifi cation of Diet in Renal Disease
a Compared with subjects of Caucasian race
b 21.6 is the value for TTDΔ (overall change in clearance) and 0.10 is TTDrate (change in clearance 
per day as described by the fi rst order process)
c GFR was estimated using the abbreviated MDRD equation
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of eGFR on metabolite clearance is shown in Figure 1C, where the concentrations 
of M3G and M6G increase in the last few hours. Indeed, this individual had a 
decrease in renal function, with a drop of eGFR from 41.4 to 16.3 at T=283 hours. 
The final model also implies that with a stable eGFR of 78ml/min, a decrease in 
albumin from 35g/l to 25g/l produces a 31% decrease of M3G clearance (from 
2.1L/h to 1.4L/h) (Figure 4). Respective changes in M6G clearance are also shown 
in Figures 3 and 4, and are similar to changes in M3G clearances.
Based on the covariate model, morphine clearance will decrease with 13%, 
from 46.4L/h 3 weeks before death to 40.6L/h 1 week before death. In the 
final week before death, morphine clearance would decrease by another 26% to 
29.9L/h on the day of death. As a result, the area under the curve of morphine 
will be significantly increased in the final days of life, as can be seen in the 
simulations of morphine concentrations in Figure 5.
Evaluation of the final model
Goodness-of-fit plots of the final model showed the population predictions and 
individual predictions were evenly distributed around the line of unity. The con-
ditional weighted residuals (CWRES) were normally distributed and did not show 
any correlation with the population predictions (Figure 6).
A bootstrap analysis was performed to obtain 95% CIs for all parameters. 
Results of the bootstrap are shown in Table 2. Evaluation of the predictive perfor-
mance by NPDE analysis showed accurate predictive ability, with distribution of 
the NPDEs not significantly deviating from a normal distribution (global adjusted 
  
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



 
 
 
 






 



Figure 5. Simulated plasma profiles of morphine in the case of 50mg six times daily 
subcutaneous bolus infusion, 2 weeks (dotted line), 1 week (dashed line) and 1 day 
(solid line) before death
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Figure 6. Goodness of fit plots of the final model
The top two panels show the PRED and IPRED concentrations versus the DV for morphine (open 
circles), M3G (open triangles), and M6G (crosses), with the solid line displaying the line of unity. 
The bottom two panels show the correlation of CWRES with the PRED concentrations , including the 
trend line and the distribution of the CWRES with the PRED concentrations, including the trend line 
and the distribution of the CWRES in grey bars and dashed line.
PRED, population predicted; IPRED, individual prediction; DV, observed concentrations; CWRES, 
conditional weighted residuals; M3G, morphine-3-glucuronide; M6G, morphine-6-glucuronide
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p value, morphine 0.84, M3G 0.19, and M6G 0.09), and the majority of the 
NPDEs lay between the values -2 and 2 (Figure 7).
DisCussiOn
This is the first population pharmacokinetic study of morphine in end-of-life 
patients, performed in a nonacademic palliative care setting. We even included 
data of patients shortly before death, and were able to accurately describe the 
pharmacokinetics of morphine, M3G and M6G with a two-compartment model 
for morphine and with two one-compartment models for both its metabolites. As 
we followed patients until the time of death, we were able to show a decrease 
in morphine clearance as patients are nearer to time of death. We also showed 
that eGFR, together with albumin levels, were the best predictors for metabolite 
clearance, explaining approximately 60% of the unexplained variability between 
patients.
To the best of our knowledge, there have not been any population pharma-
cokinetic studies on morphine, M3G, and M6G in terminally ill patients. In the 
1980’s, Säwe et al. demonstrated that the bioavailability of oral morphine in 
cancer patients ranged between 15 and 64%29, which is comparable with our 
results in which we found a variability on morphine bioavailability of 38%, with 
individual values for morphine bioavailability of between 16 and 52%. Because 
the bioavailability of morphine is dependent on first-pass metabolism, this vari-
ability is probably due to changes in liver blood flow as morphine has a high 
extraction ratio and glucuronidation is well-preserved, even in the case of sever 
liver disease30-32.
In this same study, Säwe and co-workers found a morphine clearance ranging 
from 0.3 to 0.97L/h/kg, which would mean 21-67L/h for a 70kg individual. The 
latter compares favourably with our finding of 47.5L/h. Two other population 
pharmacokinetic studies on data from cancer patients and one study in intensive 
care patients reported similar values for morphine clearance of 63.8L/h and 
35L/h respectively27, 33, 34. Interestingly, in studies of neurosurgical patients and 
healthy volunteers, higher clearances have been reported (110L/h and 75.3L/h 
respectively)21, 23. This indicates that morphine clearance is reduced in critically 
ill patients23.
In the referred study in healthy volunteers, Lötsch et al. showed a delay 
between the rise of morphine concentrations and the formation of M6G; this 
delay was modelled using a transit compartment23. In our study, the addition of 
transit compartments did not improve the fit of the metabolite concentration to 
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the population model due to the sampling frequency in our study being too low in 
comparison with the reported transit time of 17 minutes for M6G26.
In the previous studies in neurosurgical and cancer patients, a larger clear-
ance for M3G and M6G was found than in our study (M3G clearance 2.67L/h in 
neurosurgical patients and 3.36L/h in cancer patients; M6G clearance 2.52L/h 
in neurosurgical patients and 3.36L/h in cancer patients)21, 27, 34. A possible ex-
planation is that the patients in our study were closer to the time of death and 
had therefore had reduced renal clearance. Similarly, in the study of Ahlers and 
colleagues it was demonstrated that M3G clearance was significantly reduced in 
intensive care patients compared to healthy individuals due to decreased creati-
nine clearance33.
Our results show large interpatient variability, especially in the volume of 
distribution of M3G and M6G, with values of 152% and 143%, respectively. A pre-
vious study in neurosurgical patients showed much less interpatient variability, 
which could be explained by this population being less heterogenic, and also that 
this study only included nine patients21. The high BSV in our study was mainly 
due to two patients with very high estimated volumes of distribution for M3G and 
M6G. A possible explanation for the large interpatient variability observed in our 
study might be a change in body weight, which we could not test as a covariate. 
Particularly during the last phases of life, patients can have decreased lean body 
weight or may have oedema, which could influence the volume of distribution of 
the metabolites35.
The covariate analysis resulted in three significant covariates, with the first 
being time to death. Morphine clearance decreased exponentially as time to death 
decreased, falling by more than 10L/h (26%) in the last week before death. As 
none of the other covariates tested gave a similar significant effect on morphine 
clearance, this might association may be caused by a combination of factors. It 
may be the result of a physiological change (e.g. a decrease in hepatic blood flow) 
that is not detected with standard blood chemistry tests. This observed decrease 
in clearance implicates that morphine dose may have to be decreased according to 
life expectancy. Life expectancy is difficult to predict, as is, for instance, shown by 
the range of admittance in this study being significantly longer than the 3 months 
stated as an admittance criterion for the hospice. However, the terminal phase 
(where a patient will die within hours or days) is usually well-recognised based 
on several clinical signs (i.e. the patient becoming bedbound, semi-comatose, 
and that oral medication and fluid intake is no longer possible)18, 36. In this case, 
a clinical protocol, specific for the terminal phase, is started and specific domains 
will be registered in the patient record as standard of care37. Therefore, it might 
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be possible to re-evaluate the morphine dose when this phase is started as our 
model showed the biggest decrease in morphine clearance in the last week of life.
The two other covariates, eGFR and plasma albumin levels, were correlated 
with M3G and M6G clearance. The fact that eGFR is correlated with M3G and 
M6G clearance was expected as both metabolites are eliminated through the 
kidneys. Previous studies have indeed shown that M3G and M6G can accumulate 
in patients with impaired renal function38, 39.
The effect of albumin on metabolite clearance has not been shown previously 
in other studies. As M3G and M6G are not highly bound to plasma albumin, it 
is unlikely that this effect will be due to changes in unbound fractions of the 
metabolites. A possible explanation for this effect of albumin may lie in the fact 
that some terminally ill patients will become cachectic, which also leads to hy-
poalbuminemia14. The MDRD equation is not appropriate for calculating GFR in 
cachectic patients due to severe muscle loss and thereby overestimation of GFR 
based on creatinine levels. Therefore, low albumin levels may be an indicator for 
patients in which GFR is overestimated. Another explanation why the combina-
tion of albumin and eGFR are a better predictor than eGFR alone may be that 
albumin can be an indication that a patient is closer to the time of death. Several 
studies have shown that low albumin levels can predict prognosis in palliative 
cancer patients40-42. If a patient is closer to the time of death, eGFR might be 
significantly decreased (for instance due to dehydration). As the MDRD formula 
also overestimates GFR when GFR is very low, in this case the addition of albumin 
levels in the model might partly compensate for this overestimation. Combining 
both eGFR and albumin levels will therefore result in better prediction of M3G and 
M6G clearance.
The main limitation of our study is the fact that we lacked data to evaluate 
associations between weight and the pharmacokinetic parameters. As mentioned 
above, this might affect the estimates of volume of distribution, and there is 
also a possible correlation with metabolite clearance since, as described before, 
renal function can be overestimated in patients with low body weight. Precise 
monitoring of weight is not common practice in palliative care because it does 
not contribute to the treatment and because patients might find it difficult to be 
confronted with their weight loss. However, as weight is possibly an important 
covariate, we recommend that it is monitored in future pharmacokinetic studies 
in terminally ill patients.
Another possible limitation of the study is that the absorption constant of all 
three dosing forms were fixed to known literature values. This was necessary as 
there were insufficient data points in the first 30 minutes after a dose administra-
tion due to the sparse sampling design. This could have biased the estimation of 
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volume of distribution for the central compartment as absorption rate and volume 
of distribution both affect the initial concentration. In the terminally ill population, 
patients receive morphine for extended periods of time; therefore, clearance (and 
BSV on clearance) instead of volume of distribution is the predominant parameter 
effecting total morphine exposure.
In addition, it was not possible to determine the transformation ratios of M3G 
and M6G. These ratios were set to previously described values, i.e. 0.55 for M3G 
and 0.10 for M6G21-23. This could have biased the results for the parameters of 
metabolite clearance and volume of distribution as these are both proportional 
to the transformation ratio (Cl/F and Vd/F). However, we consider the values 
of 0.55 and 0.10 to be valid as the liver’s capacity for glucuronidation of drugs 
is reasonably stable, even in critically ill patients and in patients with mild to 
moderate cirrhosis30, 31, 33. The fact that there is between subject variability on 
morphine bioavailability (which is a result of first-pass metabolism) is most likely 
to be caused by a variation in liver blood flow instead of metabolic capacity as 
morphine is drug with a high extraction ratio32. In this case, the clearance of 
morphine will differ; however, the formation ratios should remain unchanged. 
Furthermore, setting the transformation ratios to 0.55 and 0.10 resulted in com-
parable estimates for clearance and volume of distribution for both metabolites 
(Table 2). This seems to be appropriate as both metabolites have an almost iden-
tical molecular structure and are therefore expected to have similar molecular 
properties. To establish whether the transformation ratios are not altered in these 
patients, information about the mass balance is required. This can be obtained by 
measuring the fractions of morphine, M3G, and M6G in urine samples.
In conclusion, our study again confirms that a reduction in eGFR resulted in a 
decreased clearance of M3G and M6G, which can have clinical consequences as 
M6G is a metabolite with analgesic activity, while M3G has been suggested to 
contribute to side effects. As a result, the morphine dose may be reduced in 
patients with renal failure, or analgesic therapy may be switched to an opioid 
with less or no active metabolites (e.g. oxycodone or fentanyl). We also found 
that eGFR combined with albumin levels was a better predictor for M3G and M6G 
clearance than eGFR alone. Therefore, dose adjustments should also take into ac-
count albumin levels besides eGFR. In addition, a positive correlation was found 
between time to death and morphine clearance. This important insight into the 
pharmacokinetics of morphine in terminally ill patients is a first step in develop-
ing an individualised dosing regimen for terminally ill patients. It suggests that 
morphine doses might be adjusted to a patient’s creatinine and albumin levels 
and life expectancy. However, accurate prediction of the time of death can be 
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difficult and the need for morphine does not solely depend on pharmacokinetics. 
Therefore, further studies on the pharmacodynamics in this patient population 
are needed before any firm conclusions can be drawn on dose adjustments.
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ADDEnDuM
study design and setting
This prospective observational study in terminally ill patients was conducted dur-
ing two years in the palliative care centre, Laurens Cadenza, in Rotterdam, the 
Netherlands. This is the largest palliative care centre in the Netherlands, with 
20 beds for end-of-life care and symptom management; 200 to 250 patients are 
admitted annually. A multidisciplinary team of health care professionals, includ-
ing specialised nurses and elderly care physicians specialised in palliative care, 
is available 24 hours per day. In addition, many volunteers perform supporting 
tasks.
Participants
Patients were included in the study upon admittance to the palliative care centre 
and were followed until the time of death. Inclusion criteria were terminal illness, 
prognosis survival of more than 2 days and less than 3 months, administration of 
morphine and given informed consent. Patients admitted during the study period 
were asked to participate in this study, except those with a prognosis of survival 
of less than 2 days, those who could not consent themselves and those who 
were admitted temporally. The researcher (A.M.) informed the patients about 
this study after asking the responsible physicians and/or nurses for eligibility and 
appropriate timing. If possible, the patient was informed in the presence of a 
relative. They were given at least 24 hours to consider their decision before writ-
ten permission was given. During participation and especially during the dying 
phase the patient and/or the family were asked renewed consent for participating 
in this study.
During the study period a total of 399 patients were assessed for eligibility. One 
hundred thirty-six (34%) patients were informed of the study, of whom 68 (50%) 
gave consent. Additional figure 1 shows the flow chart of patient inclusion. Of 16 
(24%) patients no morphine sample was available, either morphine was not ad-
ministered or no blood sample was taken after morphine administration; 3 (4%) 
patients and/or family withdrew from the study after initially giving consent; in 2 
(3%) patients no blood sample was taken because of a very quick deterioration; 
and thus 47 patients were included in the final analysis of morphine’s pharma-
cokinetics.
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Assessed for eligibility (n=399) 
 
) Excluded (n=263) 
 At admission in very poor condition (n=148) 
 Not able to consent due to cognitive impairment (n=41) 
 Goal of admission was short term care (n=14) 
 Physician advised not to introduce the research (n=13) 
 Extensive admission (n=6) 
 Patient underwent therapy in hospital (n=4) 
 Other reasons (n=37) 
Informed (n=136) 
Refused (n=39) 
 Patient declined to participate (n=33) 
 Family declined to participate (n=6) 
Died before consent was given (n=19) 
Excluded by researcher and physician (n=10) 
Excluded from analysis (n=21) 
 No morphine sample (n=16) 
 Withdrawn (n=3) 
 Quick deterioration (n=2) 
Analysed (n=47) 
 
Consented (n=68) 
 
Additional Figure 1. Flow chart patients
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The overall aim of this thesis was two-fold: 1. to evaluate the validity of assess-
ment tools for pain and depth of sedation for unresponsive end-of-life patients; 
2. to gain more knowledge on several aspects of pharmacotherapy in palliative 
care. This chapter first summarizes the main findings of the studies presented 
in this thesis in relation to the research questions. Several of these findings 
are interpreted in more detail and related to the available literature. Then, the 
strengths and limitation of the studies are discussed and implications for clinical 
practise as well as directives for future research are given.
MAin finDinGs 
1. Is the Rotterdam Elderly Pain Observation Scale (REPOS) a reliable and valid 
tool for pain assessment in non-communicative or unresponsive end-of-life pa-
tients?
The REPOS showed adequate internal consistency, sufficient concurrent valid-
ity and was sensitive to change after a pain-reducing intervention. We concluded 
that the REPOS a reliable and valid tool for pain assessment in non-communicative 
or unresponsive end-of-life patients, even in their last days of life. 
2. Is Bispectral Index (BIS) monitoring a feasible and valid tool for assessing the 
depth of sedation in terminally ill patients?
For the assessment of the depth of palliative sedation the BIS monitor (an 
electrophysiological device) seems feasible and some anecdotal arguments were 
found that BIS monitoring may be of relevance for family and nurses. However, 
we were not able to support the statement that BIS would differentiate between 
the various levels of sedation during midazolam treatment. Further research is 
needed to consider BIS as a tool for monitoring the level of palliative sedation in 
daily practice.
3. What drugs are administered, and at what dose and route of administration, 
from admission to day of death in patients admitted to a palliative care centre?
Morphine, midazolam and haloperidol were the most frequently prescribed 
drugs at the day of death. Doses of these drugs on the day of death were statisti-
cally significantly higher than those at the day of admission, with clinical rel-
evance for morphine and midazolam. Median doses compared well to the titration 
schemes described in the national symptom-specific guidelines. Upon admission 
almost 90% of patients received oral medication but over the admission period 
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a shift occurred to the effect that at the day of death more than 90% of patients 
received subcutaneous medication. 
4. Are laboratory parameters of patients at the end of life disturbed such that 
it may have consequences to the pharmacokinetics of drugs often used in those 
patients?
Abnormal laboratory results were expected to be found due to the physi-
ological changes that occur during the last phase of life. Remarkably, levels of 
aspartate aminotransferase, alanine aminotransferase, bilirubin, sodium and 
potassium were within the normal range for most patients. Both the very high 
prevalence of hypoalbuminemia and the disturbed kidney function might have 
implications for the pharmacokinetics of drugs often used in end-of-life care.
5. What are the pharmacokinetics of morphine and its two major metabolites in 
terminally ill patients and what are the clinically relevant parameters for individu-
alized dosing based on a population PK model approach?
The data were best described by a two-compartment model for morphine and 
two one-compartment models for both its glucuronidated metabolites (M3G and 
M6G). We found that the nearer to the time of death, the more morphine clear-
ance decreases and that kidney function together with albumin levels are related 
to metabolite clearance. These findings suggest that morphine doses should be 
adjusted to a patient’s kidney function and albumin levels and life expectancy.
intErPrEtAtiOn Of tHE finDinGs
Assessment of pain and depth of sedation
Numerous pain assessment tools have been developed to recognize pain and pre-
vent under- or overtreatment for several patients groups unable to self-report, 
including very young children, patients with intellectual disabilities and elderly 
with and without cognitive impairment1-3. However, to the best of our knowledge, 
only one validated observational tool for end-of-life patients is available, the 
Multidimensional Objective Pain Assessment Tool (MOPAT)4. This tool has a major 
disadvantage in that it includes blood pressure and heart rate measurements, 
which seem not sensitive for pain alone and not routinely assessed in end-of-life 
care5-8 or stopped just before the end of life9. In contrast, the REPOS is based on 
pain-indicative behaviours only, including facial expression, body movements and 
vocalisation. In table 1 the items of the REPOS and MOPAT are displayed.
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The REPOS showed promising psychometric properties in nursing home resi-
dents10. We found that it is also valid to assess pain in palliative patients, even 
in their last days of life. It also meets the criteria of the European Association for 
Palliative Care (EAPC)11; being easy to use, valid, sensitive to treatment effect, 
validation studies performed in palliative care and multilingualism. Already before 
the validation in the palliative setting, the use of the REPOS was recommended in 
Dutch national palliative guidelines12 and in a report on quality indicators in pal-
liative care, published by the Netherlands Institute for Health Services Research 
in 201013. 
In two small previous studies, BIS monitoring in palliative care was found to be 
acceptable for patients, family and professional caregivers14, 15. Although we also 
found BIS monitoring feasible in the palliative care setting, its validity may be 
insufficient and further research is needed.
The BIS monitor was initially developed to evaluate the effects of anaesthet-
ics16; later also its ability to prevent awareness and overdosing was studied17, 18. 
Clear differences between anaesthesia and palliative sedation may contribute to 
the wide range of BIS values we found in palliative patients; the patient popula-
tion (surgery versus end-of-life patients), the administered medication (inhala-
Table 1. An overview of items scored in two different observational pain tools: REPOS 
and MOPAT
Pain-indicative 
items rEPOs MOPAt
Behavioural items
Tense face Tense muscles 
Eyes (almost) squeezed
Frowning/Grimacing Raising upper lip
Grimace
Frightened/fearful look
Moving body parts
Restless
Panicky, panics attack
Moaning/groaning
Patient soundsSounds of restlessness/verbal 
expressions
Physiological items
Blood pressure
Heart rate
Breath holding/faltering respiration Respirations
Diaphoresis (sweating)
All REPOS items are scored for presence of absence. MOPAT behavioural items are scored on a 
4-points scale (none/normal, mild, moderate, severe) and MOPAT physiological items are scored 
based on change (usual/no change, change form usual)
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tion or intravenous anaesthetics versus subcutaneous sedatives) and primary 
aim of sedation (being unaware of surgery versus dying while being sedated). 
Moreover, the BIS monitor processes frontal EEG, which may not adequately 
represent an overall effect of sedative drugs, since it only reflects the degree of 
EEG suppression.
In our study on BIS monitoring, most patients were deeply sedated. The 
physicians frequently targeted at a status of deep sedation, ensuring that refrac-
tory symptoms are relieved. In practices, however, different approaches were 
seen: either start with mild sedation and deepen when necessary or initial deep 
sedation19. Those different approaches are related to the presenting symptoms, 
the wishes of the patient and relatives and the physicians’ perceptions on com-
munication, possible awakening or the dying process. For that matter, the Dutch 
national guideline for palliative sedation12 states that sedation should be applied 
proportionally, but lacks recommendations on how to systematically guide or 
monitor this in practice. 
The professional caregivers and even family of patients were very interested 
in the BIS registrations. The nurses hoped the BIS monitor would be an appropri-
ate tool to assess the depth of sedation because at times they found it difficult 
to achieve adequate palliative sedation. Such impact of research on professional 
caregivers was also mentioned previously20. 
Against our expectations, relatives did not seem to mind placement of the BIS 
sensor on the patient’s forehead. Some patients and their relatives even told us 
that they were thankful for participation in this study (See case description 1). 
Such positive reactions to palliative research are also described in literature21-25 
and might be a stimulus for researchers to study this vulnerable population.
Case description 1. Thanks for using the BIS monitor for my 
mother, it helped me to say goodbye
I spoke with a woman whose mother had died the night before. Her 
mother participated in our study on BIS monitoring. I thanked the 
daughter for the participation, and she responded as follows:
‘Thank YOU for this research, since it helped me a lot!
Last night my mother was not comfortable. She was restless and not 
well asleep with her sedative medication. Also she was in pain. The 
BIS monitor showed high values and the line was spiky. Also, the 
values representing her muscle activity of the forehead (EMG) were 
high. She was frowning. After my mother was given extra medica-
tion, she became calmer and could relax a bit and fall asleep. Then, I 
saw on the BIS monitor that the EMG values went lower and also the 
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values for level of sleep were lower and more equal; about 45. Then 
I also went to sleep, because I was sure my mother was comfortable 
and well asleep.
Later that night I was woken by the nurse who cared for my mother. 
It seemed that my mother was ‘taking the last track before death’. 
More and more she was sliding towards a deeper state. The BIS mon-
itor also showed this, de values decreased to about 5. At that time, 
I started talking and singing to her and the BIS values increased to 
about 12. This meant a lot to me; I felt like she heard me. I even got 
a reaction of her! 
At long last, my mother passed away peacefully. I and the nurse 
were there with her. When the nurse said, your mother has died, I 
found a confirmation on the BIS monitor; the values were 0.
Your research really helped me during this last phase. My mother, 
literally and figuratively, was sliding deeper and deeper.’
Pharmacotherapy in palliative care
We found that 94% of patients received subcutaneous medication at the day 
of death. Although the subcutaneous route is recommended in palliative guide-
lines9, 12, 26 and considered as the preferred route of choice for patients unable to 
take oral medications27, this route has not been studied in great detail. 
The most often prescribed subcutaneous drugs at the end of life, morphine, 
midazolam and haloperidol, are used off-label. Still, small prospective or retro-
spective trials  found subcutaneous administration of morphine28, 29 and midazol-
am30-32 feasible and effective. For haloperidol the optimal route of administration 
was not qualified33-36. Therefore strict monitoring of the efficacy of the off-label 
drugs with validated assessment tools is highly recommended. Furthermore, in 
future, pharmacokinetic based dosing needs to be an essential role in drug dosing 
in this vulnerable group of patients to prevent over and/or under dosing.
One important aspect of the subcutaneous route is the absorption of drugs. 
This might be suboptimal in end-of-life patients, who are often in a cachectic 
status or in contrast may have extensive oedema37. Furthermore, it is unknown 
which anatomical site is most optimal38, 39 or what mode of subcutaneous adminis-
tration is better; intermittent bolus injections40, 41 versus continuous infusion42, 43. 
Therefore the subcutaneous route deserves to be further studied.
Theoretically seen, we expected to find abnormal laboratory results during the last 
week of life in view of the disease status of most patient, advanced malignancy 
in combination with a decreased nutritional intake. In practise, an overview of 
150 CHAPTER 7
laboratory results near death was lacking and only was described in the light of 
dehydration44-46. Although the timing of analysis differed in our two studies on 
this topic, in both, remarkably, we found most median laboratory results within 
the normal range values.
Some laboratory results are of greater relevance for pharmacotherapy in 
end-of-life care. A lowered albumin level is seen in the majority of end-of-life 
patients and showed to be an important determinant, together with kidney func-
tion, for the clearance of morphine metabolites. The lower the albumin level 
and the kidney function, the more the clearance of morphine metabolites will 
decrease. Theoretically, hypoalbuminemia may also have consequences for the 
pharmacokinetics of midazolam and haloperidol47, in that lower doses of these 
drugs can be prescribed at the end of life. Furthermore, kidney function can help 
predict the clearance of morphine and its metabolites and consequently may 
guide morphine dosing. In a further study we will develop a dosing algorithm for 
morphine by pharmacokinetic and pharmacodynamic (PK-PD) modelling. Also the 
PK-PD of midazolam and haloperidol are being studied.
We were able to accurately describe the pharmacokinetics of morphine and its 
two major metabolites in end-of-life patients. This is, to our best knowledge, the 
first PK model of morphine in this patient population. Therefore, this model is a 
very important step towards an evidence based and tailor-made dosing regimen 
of morphine for these patients.
strEnGtHs AnD LiMitAtiOns
The data in this thesis is unique and adds importantly to existing literature, since 
all data was collected in a hospice setting and is representative for patients whose 
death is near. Much of the palliative literature either does not clearly define the 
patient group48, 49, or excludes the very ill patients50. In contrast, we succeeded 
to include the very ill patients: REPOS observations done at a median of 3 days 
before death were presented; the laboratory results all concerned the last week 
before death. Such data near the very end of life was not published before, to the 
best of our knowledge.
In addition, our series of palliative studies is the first of its kind; the first study 
describing medication use on the day of admission and the day of death, includ-
ing the dose and route of administration; the first study that gives an overview 
of laboratory results in the final week before death and the first pharmacokinetic 
study of morphine in end-of-life patients. 
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Another strength lies in the relatively large samples sizes. First, our BIS study 
included 58 patients versus only 1 to 12 patients in previous studies14, 15. Next, 
we studied the pharmacokinetics of morphine in 47 palliative patients until death. 
Previous studies on the pharmacokinetics of subcutaneous morphine concerned 8 
or 10 patients with cancer pain51, 52 and 22 elderly patients53.
Several limitations have to be addressed, too. All our studies were performed in 
one hospice. Clinical practice in other palliative care settings and other countries 
may differ.
Because of the overall lack of validated assessment tools in palliative care4, 54 at 
the time we started our studies, we used assessment tools validated only in other 
patient populations. The Ramsay score for depth of sedation has been validated 
in adult intensive care and surgical patients55, 56 and has been found easy to use 
in palliative care57. However, it contains only one item scored from 0 ‘no response 
to test stimulus’ to 6 ’agitated’. One could question if this information is useful 
in the clinical setting, since the aim for end-of-life patients is overall comfort, 
including a relaxed posture, a calm facial expression and without being fidgety or 
restless. In our opinion the Ramsay score represents the level of consciousness, 
which may be helpful to evaluate the course of palliative sedation, but it might 
not be quite suited to evaluate the efficacy of the sedation.
The Delirium Observation Screening (DOS) scale has been validated for use 
in elderly patients with a high risk for delirium58. However, we found its use 
in palliative patients sometimes inappropriate, since some items could not be 
scored in unresponsive patients. Other delirium assessment tools could perhaps 
be recommended59, 60, such as the Confusion Assessment Methods (CAM)61. This 
scale includes the criteria for the psychiatric diagnosis of delirium based on the 
Diagnostic and Statistical Manual of Mental Disorders (DSM), including the acute 
onset and the fluctuating course of a delirium, which are lacking in the DOS score. 
In addition, the used assessment tools were not standard of care and were 
initially implemented for research purposes only in the non-academic hospice 
setting. The nurses were sceptic about the extra workload and pointed at the 
risk of ‘invasion’ to the patients’ and families’ privacy. Therefore assessments 
were made only once a day; more frequent assessments were preferred, for both 
clinical practice and study purposes.
Lastly, the expected inclusion rates were too optimistic. For both the BIS study 
and the pharmacokinetics study we had to prolong the planned inclusion period 
because many more patients than foreseen were in a very poor condition upon 
admission and expected to die within 2 days, which was an exclusion criterion. No 
more than 11% (58/516) of admitted patients were included in the BIS study and 
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17% (68/399) in total for the pharmacokinetics studies (morphine, midazolam 
and haloperidol). Markedly, these figures seem representative for other clinical 
studies in palliative care, which succeeded to include 8% to 21% of screened 
patients62-64. Yet some other studies even failed to recruit a sufficient number of 
patients and had to discontinue their efforts65-67.
iMPLiCAtiOns fOr CLiniCAL PrACtiCE 
We have demonstrated that the REPOS can be considered a valid tool for the as-
sessment of pain in non-communicative end-of-life patients. We think that after a 
brief training course every professional palliative caregiver will be able to use. A 
REPOS instruction sheet, an educational CD-ROM (in a Dutch and English version) 
and a website68 are available to guide training and implementation. In the brief 
training course, correct interpretation of the items is explained and observations 
in practice together with an already trained professional are recommended.
However, pain assessment can only have clinical implications when the scores 
are documented in the patients’ medical record, when assessed pain is treated 
effectively and when re-assessments after a change in treatment are performed. 
In other words: when a treatment decision-tree is available and used. However, 
in practice it appears that pain assessments and notes regarding pain medication 
are inadequately recorded69-71, pain treatment is frequently not sufficient72-74 and 
professional caregivers may tend to forego reassessment73, 75, 76. To overcome 
these barriers, various interventions are described75-79, such as education, ap-
pointing nurse ‘champions’ and the implementation of pain protocols. These in-
terventions may result in a better compliance to pain assessment and treatment 
algorithms75, 76, 80 and may also be applicable for symptoms other than pain, such 
as delirium.
Assessing pain in non-communicative palliative patients can be difficult even 
when a validated tool such as the REPOS is used. Pain assessment tools will not 
only identify pain, but also other forms of distress81-83, since there are no signs 
or behaviours exclusively for pain. This is also reflected in our REPOS study by 
the high number (23/107, 21%) of false-positive scores (REPOS score indicative 
for pain whereas the accompanying NRS score was low). Other assessment tools, 
such as a delirium scale or a combination of assessments, might help to recognize 
which form of distress—pain, delirium, fear or anger —is predominant84, 85 (See 
case description 2).  In addition, the experiences of relatives are more and more 
a topic of interest in palliative research86, 87. In family-centred care, relatives can 
be given an active role, including pain assessment and pain management.
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Case description 2. Distress; distinguishing between pain or else?
A woman in a study was given palliative sedation but the family pres-
ent had the impression that she was not comfortable. She moved her 
hands from time to time and the family was afraid she was in pain 
or suffered from confusion. The responsible nurse also observed the 
movements and asked me to have a look also, because she thought 
the patient was comfortable enough. To me the movements mim-
icked rolling a cigarette and taking puffs of a cigarette. I knew this 
patient had been an intense smoker. I did a REPOS observation dur-
ing washing. The score was not indicative for pain. The DOS score 
was not adequately representative, since the patient was sedated. I 
told the family about the pain score and gave them my explanation 
for her movements, namely her former smoking habits. This fully 
satisfied the family. Pain observations were repeated at least once a 
day, to confirm that pain was not present. However, no medication 
was added to treat confusion.
Since we were now not able to recommend BIS monitoring as standard daily 
practice, further research is needed before it can be considered as the right 
device to monitor palliative sedation. Other electrophysiological devices88, 89 may 
also be inappropriate to use in end-of-life patients. Then, the only method to as-
sess the efficacy of palliative sedation would be an observational sedation scale. 
Most observational sedation scales (e.g. Ramsay score) have not been validated, 
however, for palliative care facilities54, 90, 91. Since the start of our study in 2008, 
the validity of only a few scales are limitary studied in palliative care, including 
the Richmond Agitation-Sedation Scale (RASS)91, 92 and the Consciousness Scale 
for palliative care (CSPC)93. Moreover, there is no consensus on the preferred 
scale and on whether symptom control or sedation depth should be assessed 
used54, 90. Furthermore, distress behaviour may be subdued in the end-of-life 
stage and patients could therefore mistakenly be considered to be comfortable 
upon behavioural assessment only90, 94. Probably, a combination of validated 
symptom and sedation measures, together with the subjective assessment of 
experienced professional caregivers, will be the best strategy to monitor pallia-
tive sedation.
At the end of life, the most clinically relevant laboratory parameter seems to be 
kidney function, for a few reasons. First, poor kidney function has implications 
for drug choice and dosing (of renally cleared drugs), as shown in the morphine 
pharmacokinetics study. Second, we also found that poor kidney function was not 
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documented in up to 60% of cases. Several explanations may serve to explain 
this: the patient was actively dying and evaluation of kidney function was not 
seen as relevant anymore; kidney function could have declined rapidly as death 
approached; or the medical history might be incomplete. Still, kidney function 
is an important parameter as for some drugs (including morphine and NSAIDs) 
adverse effects may negatively impact the quality of dying and interfere with 
humane aspects. Therefore, both the European Association of Palliative Care 
(EAPC)28 and the Dutch palliative pain guideline12 for the use of opioids in pallia-
tive patients with kidney failure recommend prescribing another opioid, such as 
fentanyl, buprenorphine or hydromorphone, instead of morphine.
Based on our pharmacokinetics study, clinicians should be careful in escalating 
morphine doses in the last days of life. One paper proposed that for patients 
with a steady state concentration on regular oral opioids, only intermittent use 
of opioids may be sufficient in the last days before death95. Assuming that the 
medication is not cleared due to liver and kidney failure and excretion is delayed, 
the intermittent use suffices to maintain the effects of the prior steady state 
concentrations as drug half-life is significantly increased. Indeed, we showed 
that during the last week of life the clearance of morphine and its metabolites 
decreased most intensely. 
In addition, this decreased clearance of morphine may result in accumulation 
and consequently in prolonged effects, including both the analgesic effect and 
adverse effects.  Not only morphine itself is responsible for those effects, also 
the metabolites of morphine are of clinical importance; morphine-6-glucuoride 
(M6G) has analgesic activity96-98, while morphine-3-glucuronide (M3G) has been 
suggested to contribute to side-effects, such as hyperalgesia, allodynia, myoc-
lonus and the development of tolerance99, 100. In future, we hope that based on 
the pharmacokinetics of morphine, doses can be adjusted more rapidly and ad-
equately after the initiation or during therapy. For instance, the interval between 
start of morphine administration and adequate symptom relief may be shortened 
by a higher starting dose; an impairment of renal function should result in a 
reduction of the administered dose or a switch to another opioid with less or no 
active metabolites (fentanyl).
However, more research is needed on the extent to which the morphine dose 
should be adapted to prevent accumulation or prolonged effects. In anticipation 
to the results of future studies, in practice is would be hard to convince clini-
cians to lower a morphine dose as the patients’ death approaches. Perhaps a 
change of attitude towards more interest in non-pharmacological interventions 
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such as complementary and alternative medicines, including massage and music 
therapy101-104, would be helpful therein.
DirECtivEs fOr futurE rEsEArCH
Since many practices in palliative care are based on experiences and consensus 
only50, 105, 106, there is much room for further research. Below, some suggestions 
arising from the studies presented in this thesis. 
- Validation of the REPOS in other languages, including English, is preferred. 
Now only the Dutch version of the REPOS has proven its validity in nursing 
home residents and end-of-life patients. 
- Validation of assessment tools to monitor palliative sedation, including depth 
of sedation measures and tools for symptoms other than pain; such as a 
delirium scale like the Confusion Assessment Methods (CAM)61, and a se-
dation scale like the Richmond Agitation-Sedation Scale (RASS)91, 92 or the 
Consciousness scale for palliative care (CSPC)93.
- Studies on the pharmacokinetics of subcutaneous administered drugs, includ-
ing midazolam and haloperidol. Nowadays, subcutaneous drugs are often 
prescribed off-label and might have relevant individual variations, which are 
so far unknown.
- More detailed studies on subcutaneous administered drugs to determine the 
optimal anatomical site of administration and the most effective mode of 
administration, either intermittent bolus injections or continuous infusion.
- Studies on the pharmacodynamics of palliative drugs, including morphine, 
midazolam and haloperidol, to gain more knowledge on also the clinical ef-
fects of drugs.
- Pharmacogenetics is an emerging topic of interest also in palliative care107-111 
and also recommended to be incorporated in future research. Especially in 
cases of whom earlier in life abnormal responses were observed or very high 
doses were needed. 
- Gaining more knowledge about the factors that may influence the complexity 
of palliative sedation and to define a risk profile. Sedation of palliative patients 
can be cumbersome; most striking is when a patient suddenly awakes after a 
period of effective palliative sedation. Also a ‘long track’ of titrating medica-
tion till an adequate level of sedation is found, is an undesirable situation. The 
reactions of surrounding persons can be different in such situations (See case 
descriptions 3 and 4). So far it is still unclear for which patients sedation will 
be difficult and consequently for whom an adapted starting dosing or another 
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choice of drugs is needed. Although some factors are suggested for this risk 
profile, such as a younger age, being underweight, having experienced a de-
lirium previously, comorbidity and concomitant drug use12, 112, 113, these have 
not been prospectively studied.
Case descriptions 3 and 4. Awake during palliative sedation; both-
ersome or relieved?
A 46-year-old female with a carcinoma of the rectum and multiple 
metastases in lungs and liver
Since the day of admission, her abdominal girth increased and she 
was progressively tired. She still wanted to do many things, which 
she could not accomplish. She experienced more and more bad days 
and became puffier. She was saying goodbye to many people around 
her.
One day she was very restless and tense and was afraid she would 
choke. She said: ‘This is enough, I cannot handle this any longer and 
I want to sleep.’ The clinician agreed and started palliative seda-
tion. After a few hours she woke up and was moaning. Extra seda-
tive medication was given, but after two hours she woke up again 
and could answer some questions. She did not have pain and had no 
shortness of breath. Again, extra medications were administered and 
a clinician was consulted and increased the dose of the sedative drug. 
The family present found it hard to see her awake again. She had 
been promised that she would go to sleep and never wake up. This 
had happened, nevertheless. 
Before the following doses of sedative medication were scheduled, 
she woke up and was panicky. Extra sedative medication was ad-
ministered and the dose was increased, but she was still restless. 
Other medication was added, but after one and a half hours she was 
still restless and more medication was administered. Finally, with 
three types of sedative medication and medication to treat pain and 
confusion, she was deeply asleep. She died calmly a few hours later, 
without family and only a nurse being present.
A 72-year-old female with a carcinoma of the rectum and multiple 
metastases in lungs, liver and abdomen
Since the day of admission she was confused from time to time and 
felt her own deterioration. The clinician assured her that she could 
ask for sedative medication to sleep during day or night. In the first 
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week she used this medication one evening and slept well for a few 
hours. In the following two weeks she asked again for the sedative 
medication.
She became progressively tired, had more pain and became less able 
and willing to communicate. After being cared for in the morning, 
she fell asleep. One day she woke up after a few hours and was not 
comfortable. A clinician was consulted and palliative sedation was 
started, in accordance with the wish of herself and her family. First 
she seemed adequately sedated, but after a few hours she woke up 
suddenly while her son was sitting next to her. At that moment she 
had pain and was restless. Extra sedative medication was adminis-
tered and she fell asleep again. Her children were very sad and hoped 
that she would not suffer much longer. In the evening, she calmly 
died in the presence of her children.
The next day I spoke to her children and they were actually glad 
and relieved that their mother had been awake during sedation. 
They thought that she had received too much medication, was fully 
drugged and had deteriorated as a result of all those drugs. They now 
were more confident that the medication had been precisely titrated 
to her as an individual.
The ethics of research in palliative patients are addressed in many pa-
pers50, 105, 114-119; from the one extreme that research in these patients should 
not be conducted115 to the other that this research is absolutely necessary to 
provide the best palliative care possible105, 116. In addition, numerous strategies 
are suggested to encounter the challenges of research in palliative care, both 
methodological and ethically20, 25, 62-64, 67, 105, 120-126. The following list is a selec-
tion of strategies that were crucial to our studies in these vulnerable end-of-life 
patients and may be essential for future palliative research as well. 
- Having a full-time researcher on the floor for the inclusion process and the 
retention of patients into the study, to ensure an independent decision of the 
patient, without interference of the doctor-patient relationship62, 64, 105.
- The researcher has to be sensitive for the context of palliative care, e.g. 
sensing the right time to contact patients and relatives25, 121 and setting the 
right tone is essential for commitment to the study25, 122. 
- The informed consent process has to be adapted to the type of study and 
the setting. We therefore recommend seeking renewed consent should be 
standard in ongoing research. Such an evaluation of the patients’ willingness 
to participate enhances the patients’ autonomy123 and opens the conversation 
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towards the potential burden of study participation. Next, seeking advanced 
consent from autonomous patients could help anticipate the problem that 
at a later stage they might be unable to give consent67. Lastly, we obtained 
consent from both the patients and a relative. In this way the relative served 
as a witness and could give renewed consent at the time the patient would be 
unable to do so, because the relative knew the patient’s reasons for participa-
tion. 
- The researcher has to be aware that patients may want to tell their life stories. 
Patients will often appreciate the opportunity to express and share their ex-
periences of care with the researcher21, 122, 123. Time is needed for this aspect, 
before information, consent and adequate participation to the study can be 
accomplished.
- Intensive collaboration between the researcher and the professional team of 
caregivers is encouraged20, 119, 122-124. On the one hand this stimulates com-
mitment of the caregivers’ team, and on the other hand the researcher is 
informed about the actual status of patients, including physical or relevant 
psychosocial and spiritual aspects. This may also overcome the phenomenon 
of gatekeeping25, 62, 105, 122, 123, 125, by which is understood the tendency of 
professional caregivers to overprotect the patients, thereby passing the op-
portunity for the patient to make an informed consent on participation (See 
case descriptions 5 and 6).
- Since end-of-life patients are often extremely tired and have to save their 
valuable time for important moments, the burden of data collection should be 
minimized. This can be done by incorporating several sub-studies in the main 
study64. Also, integrating validated symptoms scores into the daily clinical 
routine can help prevent overburdening.
Case descriptions 5 and 6. Gate keeping: opening or closing the 
gate
At the day of admission the responsible clinician told the patient of 
ongoing research. Sometimes I was present at this first conversation, 
or I met the patient within 2 days. The way in which the research 
was introduced could influence the potential participation; either the 
patient was encouraged to listen to my information about the ongoing 
study or was indirectly pushed towards refusal. The following quotes 
illustrate two different styles:
1. ‘This hospice is actively involved in scientific studies; our research-
er will visit you soon to give more information about the ongoing 
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studies’; a neutral way of presenting research that opens the gate for 
the researcher.
2. ‘An ongoing study will be introduced to you by a young doctor, but 
you may decline to participate since studies will always have impact 
on you’; a somewhat negative implication that may close the gate for 
the researcher.
COnCLusiOns
Although palliative research is challenging, this thesis proves that is doable. The 
following conclusions were reached. 
- The REPOS is a promising pain assessment tool for end-of-life patients who 
cannot longer communicate verbally. 
- BIS monitoring is feasible in a hospice setting and we found some anecdotal 
arguments that BIS monitoring may be of relevance for family and nurses. 
However, the wide range of BIS values in deeply sedated and comfortable 
patients seems to hamper its use in daily clinical practice now.
- The subcutaneous route is the general route for drug administration in pal-
liative patients. Most drugs are prescribed off-label and without detailed 
knowledge about for instance the absorption rate via this route. 
- Assessment of the kidney function should have a role at the end of life, 
because kidney function can have implications for the pharmacokinetics of 
drugs and may guide drug choice and their dosing, as illustrated by morphine 
pharmacokinetics.
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In 2013 approximately 141,000 persons died in the Netherlands, almost one 
third of whom from the consequences of cancer, mainly localized in the digestive 
or respiratory organs. The most reported symptoms in patients with incurable 
cancer are: fatigue (88%), appetite loss (56%), pain (45%), dyspnoea (39%), 
drowsiness (38%), dry mouth (34%), constipation (29%), confusion (24%), 
nausea (17%), and insomnia (14%). The main goal of palliative care is to relieve 
and control these symptoms by a combination of non-pharmacological measures 
and a variety of drugs, such as analgesics and sedatives. This regimen may 
fail to provide adequate symptom relief, however. Then, continuous palliative 
sedation may be an option of last resort in the last days of life, as proposed by 
the Royal Dutch Medical Association (KNMG) in a national Guideline Palliative 
Sedation (2009).
Patients’ self-report of pain or discomfort-symptoms is considered the ‘gold 
standard’. However, terminally ill patients may not be able to do this due to 
various reasons, such as advanced illness state, cognitive failure or effects of 
multiple drugs such as sedatives often seen prior to death. Most observational 
scales for pain assessment have not been validated for the use in palliative care 
facilities. 
Evaluation of the adequacy of sedation is equally important, but so far there is 
no general consensus on how the effect of palliative sedation should be assessed. 
In addition, there is a lack of validated methods to monitor palliative sedation.
The choice and dose of drugs for symptom relief should be preferably tailored 
to the individual patient, but evidence from prospective clinical trials is lacking. 
Likewise, there is little evidence for the optimal route of administration, although 
the subcutaneous route is often preferred in palliative care, according to the 
Dutch palliative guidelines (2010). Remarkably, to our knowledge, there are even 
no published studies describing the most prescribed drugs in palliative patients, 
let alone their doses and routes of administration.
Moreover, drug dose adjustment may be needed as death approaches due 
to changes in liver and kidney function, among other things, but this has not 
been studied in detail. Evidence from prospective studies on the pharmacological 
effects of often used palliative drugs is lacking. 
The work presented in this thesis was performed in Regional Palliative Care Cen-
tre, Laurens Cadenza, in Rotterdam, the Netherlands. This is the largest ‘hospice’ 
in the Netherlands, with 20 beds for end-of-life care and symptom management.
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vALiDAtiOn Of rEPOs fOr PAin AssEssMEnt
In chapter 2 we present a validation study for pain assessment in non-communi-
cative or unresponsive end-of-life patients. The Rotterdam Elderly Pain Observa-
tion Scale (REPOS) was applied which tool that was originally developed and 
validated to assess pain in nursing home residents.
For this study we analysed 183 REPOS observations in 100 palliative patients. 
The observations were done at a median of 3 days (IQR 1 to 13) before death. 
Adequate internal consistency of the REPOS was shown with a Cronbach’s alpha 
coefficient of 0.73. For concurrent validity a high Pearson product moment cor-
relation coefficient was found; ranging from 0.64 to 0.80 between REPOS and 
numeric rating scale (NRS) scores. In addition, the REPOS was found sensitive to 
change for a pain-reducing intervention; REPOS scores declined with a median of 
2 points (IQR 1 to 4) after a pain-reducing intervention (p<0.001). We concluded 
that the REPOS has promising psychometric properties to use for palliative pa-
tients, even in their last days of life.
vALiDAtiOn Of bis MOnitOr fOr tHE AssEssMEnt Of tHE 
DEPtH Of sEDAtiOn
In chapter 3 we present a validation study for assessing the depth of sedation with 
an electrophysiological measuring device, the Bispectral Index (BIS) monitor, in 
unconscious end-of-life patients. Previous studies described that BIS monitoring 
was acceptable for patients, family and care-givers. We wanted to determine, 
whether BIS monitoring is feasible and also valid for use in a hospice setting.
For this study we analysed 149 BIS registrations in 58 palliative patients. BIS 
monitoring was acceptable to patients, relatives and medical staff. BIS values 
were moderately correlated with a validated observation score for sedation, the 
Ramsay scores (r=0.46), but BIS values were highly variable for deeply sedated 
patients. BIS was sensitive to change for the administration of the sedative drug 
midazolam; BIS values changed significantly before and after a midazolam dose 
(p<0.001). In addition, midazolam treatment resulted on average in a statisti-
cally significant reduction of the BIS values (-4.5, 95% CI -7.0 to -2.0). However, 
this reduction was not clinically relevant. Based on these findings we concluded 
that although BIS monitoring is feasible in the palliative care setting, its validity 
seems insufficient, mainly on the grounds of the wide range of BIS values in 
deeply sedated and comfortable patients. Therefore we were not able to support 
the statement that BIS would differentiate between the various levels of sedation 
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during midazolam treatment. Further research is needed to consider BIS as a tool 
for monitoring the level of sedation in palliative patients in daily practice.
MOst OftEn ADMinistErED PALLiAtivE DruGs
In chapter 4 we present a study describing doses and routes of administration of 
the most frequently used drugs at admission and at the day of death in patients 
admitted to a palliative care centre. For this study regular medication prescrip-
tions of 208 patients were reviewed. The median length of stay of those patients 
in the palliative care centre was 11 days (IQR 5–29 days). Morphine, midazolam 
and haloperidol were the three most prescribed drugs at the day of death (87, 
58 and 50% of patients, respectively). Doses of these drugs at the day of death 
were statistically significantly higher (p<0.001, p=0.003 and p=0.028, respec-
tively) than those at the day of admission and compared well to the titration 
schemes described in the national symptom specific guidelines. The oral route 
of administration was used in almost 90% of patients at admission, but over the 
admission period a shift occurred to the subcutaneous route, so that at the day 
of death more than 90% of patients received subcutaneous medication. This shift 
in route of administration is in line with recommendations from both the national 
palliative guidelines and the Liverpool Care Pathway for the dying. 
Most of these drugs are unlicensed for this specific application, optimal doses 
are unknown, and guidelines are based on low level of evidence. We would 
recommend to strictly monitor the efficacy of the subcutaneously administered 
drugs with the use of validated pain, sedation and delirium assessment instru-
ments.  In addition, prospective clinical trials are needed to formulate evidence 
base guidelines that can guide the choice and dose of drugs. Thus, there is every 
reason for more clinical research on drug use in palliative care.
LAbOrAtOry PArAMEtErs At tHE EnD Of LifE
In chapter 5 we present a study describing laboratory parameters of hospice pa-
tients in the week before death. Laboratory data of 125 patients, at a median of 
3 days before death were analysed. Abnormal laboratory results were expected 
to be found due to the physiological changes that occur during the last phase of 
life. Eighty percent of patients had anaemia and almost all had hypoalbuminemia 
(97%). Elevated levels of gamma-glutamyltransferase were found in 75%, of al-
kaline phosphatase in 60%, of aspartate aminotransferase in 60% and of calcium 
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in 68%. Alanine aminotransferase, bilirubin, sodium and potassium were abnormal 
in from 8.8% to 36.0% of patients. Although, the median estimated glomerular 
filtration rate (eGFR), as a parameter of renal function, had a normal value for this 
population (63ml/min, IQR 33 to 94), a previous unknown poor kidney function 
was found in 60% of patients. Thirteen patients (22%) with a regular morphine 
prescription and one patients treated with an NSAID had severe kidney failure. 
Both the very high prevalence of hypoalbuminemia and possible disturbed labora-
tory liver and kidney tests might have implications for the pharmacokinetics of 
drugs often used in end-of-life patients. eGFR seems the most clinically relevant 
laboratory parameter, since it may guide drug choice and dosing.
tHE PHArMACOkinEtiCs Of MOrPHinE
In chapter 6 we present a population pharmacokinetic analysis characterizing 
the pharmacokinetics of morphine and its two major metabolites (morphine-3-
glucuronide and morphine-6-glucuoride) in terminally ill patients. Clinically rel-
evant parameters for individualized dosing were also determined. For this study 
152 blood samples of 47 palliative patients were analysed for the concentrations 
of morphine and its major metabolites.  The data were best described by a two-
compartment model for morphine and two one-compartment models for both its 
glucuronidated metabolites. The time till death and the renal function (based on 
the eGFR) combined with albumin levels were identified as relevant covariates; as 
patients are nearer to time of death the morphine clearance decreases and eGFR 
together with albumin levels were the best predictors for metabolite clearance, 
explaining approximately 60% of the unexplained variability between patients. 
These findings suggest that morphine doses should be adjusted to a patient’s 
creatinine and albumin levels and life expectancy. However, more research is 
needed on the pharmacodynamics of morphine in this population before a dose 
algorithm can be implemented in daily clinical practice.
intErPrEtAtiOn Of tHE finDinGs
In chapter 7 the findings from the studies reported in this thesis are interpreted 
and discussed with a view on future directives. Among others, studies regarding the 
pharmacokinetics, pharmacodynamics and pharmacogenetic of palliative drugs, in-
cluding morphine, midazolam and haloperidol are recommended. Also, some crucial 
strategies are listed to encounter the challenges of research in palliative care.
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In 2013 overleden in Nederland ongeveer 141.000 personen. Van hen overleed 
bijna een derde aan de gevolgen van kanker, voornamelijk van het maag- en 
darmkanaal en de luchtwegen, waaronder de longen. Patiënten met ongeneeslijke 
kanker hebben het meeste last van: moeheid (88%), weinig eetlust (56%), pijn 
(45%), benauwdheid (39%), slaperigheid (38%), droge mond (34%), obstipatie 
(29%), verwardheid (24%), misselijkheid (17%), en slapeloosheid (14%). Het 
belangrijkste doel van palliatieve zorg is om deze symptomen te verlichten door 
een combinatie van niet-farmacologische interventies en geneesmiddelen zoals 
pijnstillers en rustgevende middelen. Mocht dit niet toereikend zijn, dan kan 
continue palliatieve sedatie een redmiddel zijn in de laatste dagen van het leven, 
zoals is voorgesteld door de KNMG in een nationale Richtlijn Palliatieve Sedatie 
(2009).
De zelfrapportage van een patiënt over pijn of symptomen van niet-welbevin-
den wordt gezien als de ‘gouden standaard’. Maar terminaal zieke patiënten zijn, 
om diverse redenen, niet altijd meer in staat zelf te rapporteren. In plaats van 
zelfrapportage kan observatie door anderen worden gebruikt, maar de meeste 
instrumenten daarvoor zijn niet gevalideerd voor het gebruik in de palliatieve 
zorg. 
Tot nu toe bestaat er geen algemene overeenstemming over hoe het effect 
van palliatieve sedatie het beste gemeten kan worden, en ontbreken gevalideerde 
methoden voor dit doel.
De keuze en dosering van geneesmiddelen zou bij voorkeur moeten worden 
afgestemd op de individuele patiënt. Maar er is zeer weinig bewijs vanuit pros-
pectieve klinische studies daarvoor. Eveneens is er weinig bewijs over de optimale 
wijze van toediening van geneesmiddelen. Toch heeft in de palliatieve zorg de 
subcutane route vaak de voorkeur zoals ook is aangegeven in de Nederlandse 
Palliatieve Richtlijnen, te vinden op pallialine.nl (2010). 
De dosering van geneesmiddelen moet wellicht worden aangepast als de dood 
dichterbij komt, omdat onder andere de lever- en nierfunctie zullen veranderen, 
maar daar is nog weinig over bekend.
De onderzoeken die in dit proefschrift worden beschreven, hebben plaatsgevon-
den in Laurens Cadenza, een regionaal palliatief centrum in Rotterdam. Dit is het 
grootste hospice van Nederland, met 20 bedden voor palliatieve en terminale 
zorg.
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vALiDAtiE vAn DE rEPOs OM PiJn tE MEtEn
In hoofdstuk 2 wordt een validatiestudie gepresenteerd van de Rotterdam Elderly 
Pain Observation Scale (REPOS) bij terminale patiënten die niet goed kunnen 
communiceren of reageren. De REPOS is een schaal die eigenlijk is ontwikkeld en 
gevalideerd om pijn te meten bij verpleeghuisbewoners.
Voor deze studie werden 183 REPOS-observaties van 100 palliatieve patiënten 
geanalyseerd. De observaties werden uitgevoerd gemiddeld 3 dagen (mediaan; 
IQR 1 tot 13) voor het overlijden . Uit de Cronbach’s alfa coëfficiënt van 0,73 
bleek een voldoende interne consistentie van de REPOS. Voor de concurrent 
validiteit werd een hoge Pearson product moment correlatie coëfficiënt gevon-
den; variërend van 0,64 tot 0,80 tussen de REPOS en de Numeric Rating Scale 
(NRS) scores. Bovendien bleek de REPOS gevoelig voor de verandering na een 
pijnverlichtende interventie; de score was gemiddeld 2 punten (mediaan; IQR 1 
tot 4) lager na een dergelijke interventie (p <0,001). Concluderend, de psycho-
metrische eigenschappen van de REPOS zijn veelbelovend voor het gebruik bij 
palliatieve patiënten in de laatste dagen van hun leven.
vALiDAtiE vAn DE bis-MOnitOr OM DE DiEPtE vAn sEDAtiE 
tE MEtEn
In hoofdstuk 3 wordt een validatiestudie gepresenteerd van de Bispectral Index 
(BIS) monitor bij patiënten met een verminderd bewustzijn aan het einde van hun 
leven. De BIS-monitor meet de diepte van de sedatie met een elektrofysiologisch 
apparaat, We wilden graag weten of het gebruik van de BIS monitor toepasbaar 
en valide zou zijn in de setting van een hospice en of dit acceptabel zou zijn voor 
alle betrokkenen.
Voor deze studie hebben we 149 BIS-registraties van 58 palliatieve patiënten 
geanalyseerd. Het gebruik van de BIS-monitor bleek acceptabel voor zowel de 
patiënten als hun naasten en de medische staf. De BIS-waarden correleerden 
redelijk met een gevalideerde observatiescore voor sedatie, de Ramsay score 
(r=0,46), maar waren zeer variabel bij diep gesedeerde patiënten. De BIS bleek 
gevoelig voor een verandering na het toedienen van het slaapmiddel midazolam. 
Dit bleek uit een statistisch significante verlaging van de BIS waarden (-4,5; 95% 
CI -7,0 tot -2,0). Toch was deze verlaging niet klinisch relevant. Ook vanwege 
de grote variatie in BIS-waarden bij diep gesedeerde patiënten kunnen we het 
gebruik van de BIS-monitor om de diepte van sedatie te meten niet aanbevelen 
in de dagelijks klinische praktijk van een hospice.
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DE MEEst GEbruiktE GEnEEsMiDDELEn in DE PALLiAtiEvE 
zOrG
In hoofdstuk 4 wordt een studie gepresenteerd naar de dosering en wijze van 
toediening van de meest gebruikte geneesmiddelen in een hospice. Voor deze 
studie werden de reguliere (vaste) voorschriften van geneesmiddelen van 208 
patiënten nagegaan op de dag van opname én de dag van overlijden. De mediane 
opnameduur van deze patiënten was 11 dagen (IQR 5 tot 29). Morfine, midazolam 
en haloperidol waren de drie meest voorgeschreven geneesmiddelen op de dag 
van overlijden (87, 58 en 50% van de patienten, respectievelijk). De dosering 
van de geneesmiddelen was op de dag van overlijden statistisch significant hoger 
dan op de dag van opname. Deze doseringen komen overeen met de titratie-
schema’s in de nationale richtlijnen daarvoor. Op de dag van opname kreeg bijna 
90% van de patiënten de geneesmiddelen via de mond (oraal) toegediend, maar 
gedurende de opname vond een verschuiving plaats maar de subcutane route 
(via het onderhuidse vet), die op de dag van overlijden bij meer dan 90% van 
de patiënten werd gebruikt. Dit is in overeenstemming met de aanbevelingen uit 
zowel de Nationale Palliatieve Richtlijnen (pallialine.nl) als het Zorgpad voor de 
Stervensfase.
De meeste van deze geneesmiddelen zijn echter niet gelicenseerd voor 
subcutane toediening, de optimale dosering is onbekend en de richtlijnen zijn 
gebaseerd op bewijs van laag niveau. We raden aan hun effectiviteit te beoorde-
len met gevalideerde meetinstrumenten voor pijn, sedatie en delirium. Ook zijn 
prospectieve klinische studies nodig om evidence-based richtlijnen op te stellen 
voor de keuze en dosering van geneesmiddelen.
LAbOrAtOriuMuitsLAGEn AAn HEt EinDE vAn HEt LEvEn
In hoofdstuk 5 wordt een studie gepresenteerd naar de laboratoriumuitslagen 
van 125 patiënten gedurende de laatste week voor het overlijden (mediaan 
3 dagen voor het overlijden). Wij verwachtten abnormale uitslagen te vinden 
omdat er fysiologische veranderingen plaatsvinden gedurende de laatste fase 
van het leven. Tachtig procent van de patiënten bleek bloedarmoede te heb-
ben en bijna alle patiënten (97%) hadden een verlaagd albuminegehalte. Te 
hoge waarden van gamma-glutamyltransferase , alkalische fosfatase, aspartaat 
aminotransferase en calcium werden gevonden bij 60-75% van de patiënten. 
Afwijkende waarden van alanine aminotransferase, bilirubine, natrium en kalium 
werden gevonden bij 8,8-36,0% van de patiënten. Bij 60% van de patiënten 
184 CHAPTER 8
werd een slechte nierfunctie gevonden, die voordien onbekend was. Dertien 
patiënten (22%) met een regulier (vast) voorschrift van morfine en 1 patiënt die 
behandeld werd met een NSAID hadden een ernstig nierfalen. Vooral het lage 
albuminegehalte en een slechte lever- en nierfunctie zouden implicaties kunnen 
hebben voor de werking van de geneesmiddelen die patiënten aan het einde van 
het leven vaak krijgen. De geschikte geneesmiddelen en de doseringen daarvan 
kunnen het beste worden bepaald aan de hand van de geschatte nierfunctie 
(glomerulaire filtratiesnelheid, eGFR).
DE fArMACOkinEtiEk vAn MOrfinE
Hoofdstuk 6 betreft een studie naar de farmacokinetiek van morfine en de twee 
belangrijkste metabolieten (morfine-3-glucuronide en morfine-6-glucuoride) bij 
palliatieve patiënten. Voor deze studie werden 152 bloedmonsters van 47 pati-
enten gebruikt. Uit de analyse bleek dat de werking van morfine het best wordt 
beschreven aan de hand van een twee-compartimenten model en van de beide 
metabolieten aan de hand van één-compartiment modellen. De tijd tot overlijden 
en de nierfunctie in combinatie met het albuminegehalte werden als belangrijkste 
covarianten gevonden; hoe dichter de patiënt bij het overlijden is, hoe minder 
de klaring van morfine wordt.  Daarom verdient het aanbeveling de dosering 
van morfine aan te passen op basis van deze covarianten. Er is echter meer 
onderzoek nodig om dit in de vorm van een doseringsschema voor de dagelijkse 
klinische praktijk te kunnen gieten.
intErPrEtAtiE vAn DE bEvinDinGEn
In hoofdstuk 7 worden de bevindingen van de studies uit dit proefschrift geïnter-
preteerd en bediscussieerd met ook aanbevelingen voor toekomstig onderzoek, 
zoals naar de farmacokinetiek, -dynamiek en -genetica van palliatieve genees-
middelen, waaronder morfine, midazolam en haloperidol. Ook worden enkele 
cruciale strategieën genoemd  om de uitdagingen die men tegenkomt bij het doen 
van onderzoek in de palliatieve zorg het hoofd te bieden.
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ALAT/ALT Alanine aminotransferase
ALP Alkaline phosphatase
ASAT/AST Aspartate aminotransferase
ATC system Anatomical therapeutic chemical classification system; to categorize drugs
Bili Total bilirubin
BIS Bispectral index
BLQ Below the quantification limit
BSV Between-subject variability
Ca Calcium
Cacorr Calcium, corrected for albumin levels
CAM Confusion Assessment Methods
CI Confidence interval
Cl Clearance
CSPC Consciousness Scale for palliative care
CRP C-reactive protein
CWRES Conditional weighted residuals
DOS scale Delirium Observation Screening scale
DSM Diagnostic and Statistical Manual of Mental Disorders
DV Observed concentrations
EAPC European Association of Palliative Care
eGFR Estimated glomerular filtration rate
EMG Electromyography; a variable measured during BIS monitoring
F Bioavailability
Fm1 Fraction of morphine clearance responsible for M3G formation
Fm2 Fraction of morphine clearance responsible for M6G formation
FOCE+I First-order conditional estimation method with interaction
gGT/GGT Gamma-glutamyltransferase
Hb Haemoglobin
IPRED Individual prediction
IQR Interquartile range
K Potassium
KNMG Royal Dutch Medical Association
MDRD Modification of Diet in Renal Disease formula; used to calculate eGFR
MOPAT Multidimensional Objective Pain Assessment Tool
M3G Morphine-3-glucuronide 
M6G Morphine-6-glucuronide
Na Sodium
NRS Numeric Rating Scale
NPDE Normalised prediction distribution errors
NRS-observer NRS score assigned by the same person who performed the observation for the 
REPOS score
NRS-patient NRS score given by a patient himself
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NRS-proxy NRS score assigned by a caregiving nurse
NSAID Non-steroidal anti-inflammatory drug
NPDE Normalised prediction distribution errors
OFV Objective function value
PAINAD Pain Assessment in Advanced Dementia
PD Pharmacodynamics
PK Pharmacokinetics
PRED Population prediction
Q Intercompartmental clearance
RASS Richmond Agitation-Sedation Scale
REPOS Rotterdam Elderly Pain Observation Scale
RSE Relative standard error
SD Standard deviation
Ta Day of admission
Td Day of death
TTD Time to death
V1 Central compartment
V2 Peripheral compartment
Vd Volume of distribution
WHO World Health Organisation
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